The maxillofacial region, as a component of the stomatognathic system, is one of the links of a complex mechanism of postural control, and is closely related to other musculoskeletal and neural sensors, in particular the musculoskeletal system, under the control of the central nervous system. Electromyographic research is one of the leading diagnostic methods in dentistry, which allows to objectively assess muscle activity and, accordingly, the functional state of the maxillofacial region. The aim of the study was to determine the features of electromyographic activity of masticatory, mimic, sternocleidomastoid muscles in children with malocclusion and musculoskeletal disorders. The main group consisted of 26 children with malocclusion and musculoskeletal disorders. The average age was 9.5±1.8 years. There were 12 (46.2%) girls and 14 (53.8%) boys. The control group consisted of 20 children without malocclusion, musculoskeletal disorders and other somatic pathology, comparable in age and sex. The average age of the children was 9.2±1.6 years, there were 11 (55.0%) girls and 9 (45.5%) boys. All subjects of the main and control groups underwent surface electromyography of the temporal, masticatory, sternocleidomastoid, submental and orbicular muscle of mouth in the tests: maximum bilateral teeth clenching, swallowing, teeth clenching on the left side, teeth clenching on the right side. In children with malocclusion and mus­culoskeletal disorders, an imbalance of muscle work was established, both in tension tests (teeth clenching) and in swal­lowing functions. In the bilateral teeth clenching test, asymmetric, “cross” activity of the temporal, masticatory and sternocleidomastoid muscles on the left and right sides was diagnosed. In the test of the lateral teeth clenching in children of the main group, there was no significant difference between the electromyographic activity of the muscles of the working and balancing sides, which was observed in the control group and was accepted as physiologically normal activity in these tests. In the functional swallowing test of subjects of the main group, a significant increase in the electromyographic activity of the sternocleidomastoid, submental and orbicular muscle of the mouth was determined, which significantly exceeded the values of the control group (p>0.05). The electromyographic activity of the chewing muscles was low and asymmetric.  

Key words: electromyographic activity, malocclusion, musculoskeletal system, bite, masticatory muscles, facial muscles

1. Drok VО. [Prevalence of dental anomalies and periodontal diseases among adolescents]. Ukrainian Dental Almanac.2018;1:72-4.  doi: https://doi.org/10.31718/2409-0255.1.2018.17
2. Makhlynets NP, Ozhohan ZR, Pantus AV, Pla­viuk LIu, Neiko NV. [Myofunctional appliances and elimination of bad habits as necessary]. Actual Dentistry. 2023;6:61-9. doi: https://doi.org/10.33295/1992-576X-2023-6-61.6-61
3. Lombardo G, Vena F, Negri P, Pagano S, Bari­lotti C, Paglia L, et al. Worldwide prevalence of maloc­clusion in the different stages of dentition: A systematic review and meta-analysis. Eur J Paediatr Dent. 2020 Jun;21(2):115122. doi: https://doi.org/10.23804/ejpd.2020.21.02.05
4. Alhammadi MS, Halboub E, Fayed MS, Labib A, El-Saaidi C. Global distribution of malocclusion traits: A systematic review. Dental Press J Orthod. 2018 Nov-Dec;23(6):40.
   doi: https://doi.org/10.1590/2177-6709.23.6.40
5. Flis PS, Ivanova KV, Dakhno LO. [Prevalence of malocclusion in children aged 6-13 from Kyiv and Kyiv region]. Ukrainian Dental Almanac. 2021;4:42-7. Ukrainian. doi: https://doi.org/10.31718/2409-0255.4.2021.07
6. Jaiswal S, Sayed F, Kulkarni VV, Kulkarni P, Te­kale P, Fafat K. Comparative Evaluation of the Rela­tionship Between Airway Inadequacy, Head Posture, and Craniofacial Morphology in Mouth-Breathing and Nasal-Breathing Patients: A Cephalometric Observational Study. Cureus.2023 Oct 21;15(10):e47435. doi: https://doi.org/10.7759/cureus.47435
7. Wang H, Qiao X, Qi S, Zhang X, Li S. Effect of adenoid hypertrophy on the upper airway and cranio­maxillofacial region. Transl Pediatr. 2021;10:2563-72. doi: https://doi.org/10.21037/tp-21-437
8. Lin L, Zhao T, Qin D, Hua F, He H. The impact of mouth breathing on dentofacial development: A concise review. Front Public Health. 2022 Sep 8;10:929165. doi: https://doi.org/10.3389/fpubh.2022.929165
9. Znak O, Dudnik V, Zubarenko O, Koloskova O, Ovcharenko L, Sorokman T, et al. Status of child popu­lation health — the future of the country (part 1). Child`s health.2021 Sep 20;13(1):1-11. doi: https://doi.org/10.22141/2224-0551.13.1.2018.127059
10. Šedý J, Rocabado M, Olate LE, Vlna M, Žižka R. Neural Basis of Etiopathogenesis and Treatment of Cervi­cogenic Orofacial Pain. Medicina. 2022;58(10):1324. doi: https://doi.org/10.3390/medicina58101324
11. Smaglyuk L, Karasiunok A, Kulish N, et al. Optimization of the clinical diagnostic examination algorithm of patients with a cross bite complicated by cranio-mandibular dysfunction and postural disorder. Polski Merkuriusz Lekarski: Organ Polskiego To­warzystwa Lekarskiego. 2024;52(2):203-7. doi: https://doi.org/10.36740/merkur202402109
12. Lombardo G, Vena F, Negri P, Pagano S, Bari­lotti C, Paglia L, et al. Worldwide prevalence of maloc­clusion in the different stages of dentition: A systematic review and meta-analysis. Eur J Paediatr Dent. 2020 Jun;21(2):115-22. doi: https://doi.org/10.23804/ejpd.2020.21.02.05
13. Ramírez S, Díaz-Reissner C, Maldonado C, Jo­lay E, Ferreira-Gaona M, Fatecha A. [Rocabado-penning skull-cervical posture in orthodontic patients]. Rev Cient Odontol (Lima). 2024 Sep 17;12(3):e208. Spanish. doi: https://doi.org/10.21142/2523-2754-1203-2024-208
14. Smaglyuk LV, Liakhovska AV. EMG-characte­ristic of masticatory muscles in patients with class II malocclusion and temporomandibular disorders. Wiado­mosci 2019;72:1043-47. doi: https://doi.org/10.36740/WLek201905217
15. Sforza C, Tartaglia GM, Lovecchio N, Ugolini A, Monteverdi R, Giannì AB, et al. Mandibular movements at maximum mouth opening and EMG activity of masticatory and neck muscles in patients rehabilitated after a mandibular condyle fracture. J Craniomaxillofac Surg. 2009 Sep;37(6):327-33. doi: https://doi.org/10.1016/j.jcms.2009.01.002
16. Hoiko ОV. [Methodological approach to choosing a method of statistical data processing for medical and sociological research]. Medychna informatyka ta inzhe­neriia. 2015;2:52-8. Ukrainian. doi: https://doi.org/10.11603/mie.1996-1960.2015.2.4911
17. Choi KH, Kwon OS, Kim L, Lee SM, Jerng UM, Jung J. Electromyographic changes in masseter and sternocleidomastoid muscles can be applied to diagnose of temporomandibular disorders: An observational study. Integr Med Res. 2021 Dec;10(4):100732. doi: https://doi.org/10.1016/j.imr.2021.100732
18. Korol MD. [Functional activity of the masticatory muscles themselves in intact dentition, as well as in defects and deformations of the dentition]. Visnyk problem biolohii i medytsyny. 2017;2.3:189-92. Ukrainian.
19. Kostiuk TM. [Electromyographic study of the work of masticatory muscles in dysfunctional disorders of the temporomandibular joint]. Aktualni problemy su­chasnoi medytsyny. Visnyk Ukrainskoi medychnoi stoma­tolohichnoi akademii. 2018;8.3(63):212-9. Ukrainian.
20. Novikov VM, Pankevych AI, Gogol AM, Kolis­nyk IA, Rezvina KY, Korostashova MA. Correlation of temporomandibular joint changes in reproductive-age female patients according to the pathogenetic clas­sification. World of Medicineand  2024;3(89):137-41. doi: https://doi.org/10.267224/2079-8334-2024-3-89-137-141
21. Nogami Y, Saitoh I, Inada E. Prevalence of an in­competent lip seal during growth periods throughout Japan: a large-scale, survey-based, cross-sectional study. EnvironHealth Prev  2021;26(1):11. doi: https://doi.org/10.1186/s12199-021-00933-5
22. Shcherbyna TV, Lykhota KM. [Orofacial myo­func­tio­nal disorders in patients with dentofacial disorders (li­terature review)]. Fizychne zdorovia. 2024;1(15):77-85. Uk­rainian. doi: https://doi.org/10.32689/2663-0672-2024-1-14

Look through:

Smaglyuk L.V. Poltava State Medical University, Poltava, Ukraine
https://orcid.org/0000-0002-7030-8313

Liakhovska A.V. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-7268-9551

Smaglyuk L.V., Liakhovska A.V. Electromyographic characteristics of muscles in children with malocclusion and disorders of the musculoskeletal system in the period of mixed bite. Medicni perspektivi. 2025;30(3):4-13.
doi: https://doi.org/10.26641/2307-0404.2025.3.340532

Influence of substituted quinones on the excretory function of the rat kidney and evaluation of the prospects of their use as potential diuretics

The purpose of this work was to study the effect of fixed prosthetics with metal crowns on the antioxidant defense system of the body in periodontitis of bacterial-immune genesis. The experimental animals were divided into four groups: I – control (n=10); II – animals with periodontitis on the 30^th day of the study (n=8); III – animals with periodontitis on the 30^th day of the study with stamped crowns (n=8); IV – animals with periodontitis on the 30^th day of the study with solid-cast crowns (n=8). Stamped crowns were manufactured by stamping standard sleeves, and cast crowns were manufactured by casting from cobalt-chromium alloy. Experimental bacterial-immune periodontitis was modeled by injecting a suspension of microorganisms (Staphylococcus aureus and Streptococcus haemolyticus) in egg white into the periodontal tissues. To enhance the immune response, rats were additionally administered Freund's complete adjuvant. This procedure was repeated on the 14^th day. On the 30^th day, blood serum was collected. The activity of antioxidant protection was assessed by the level of superoxide dismutase, catalase, ceruloplasmin and the glutathione system, which were deter­mined by biochemical methods. On the 30^th day of periodontitis development, the level of superoxide dismutase decreased by 2.06 times (p<0.001), reduced glutathione by 3.39 times (p<0.001), and catalase and ceru­loplasmin increased by 2.70 times compared to the control (p<0.001); by 1.25 times (p<0.01), respectively. After fixation of the stamped crowns, the level of catalase and ceruloplasmin was higher, and superoxide dismutase and reduced glutathione were lower compared to the control. The use of cast structures led to similar changes, but with less severity. Determination of catalase and ceruloplasmin activity in cast crowns showed its decrease by 1.06 times (p<0.05) compared to stamped ones, and the indicators of superoxide dismutase and reduced glutathione were higher by 1.61 times (p<0.01) and by 1.46 times (p<0.001), respectively when using cast structures. Cast crowns showed less negative impact on the antioxidant system compared to stamped ones, which may indicate better biocompatibility of this type of prosthesis.

Key words: unremovable prosthesis, stamped crowns, cast crowns, periodontitis, periodontium, antioxidants, antioxidant protection, biocompatibility of materials

1. Bandrivsky YuL, Bilan VO. Investigation of im­munological indicators in the oral fluid of military personnel of the Ukrainian Armed Forces with chronic generalised periodontitis of the initial – II degree with consideration of their psycho-emotional state. Odesa Medical 2024;190(5):35-9. doi: https://doi.org/10.32782/2226-2008-2024-5-5
2. Demkovych A, Hasiuk P, Korobeinikova Y, Shcher­ba V, Korobeinikov L. Dynamics of changes of C-reactive protein level in blood serum in the development and course of experimental periodontitis and their cor­rection by flavonol. Wiadomosci 2022;75(2):451-5. doi: https://doi.org/10.36740/WLek20220212
3. Novytska IK, Drum MB, Nikolaeva AV, Schnai­der SA, Tretyakova OV. [Study of the moomiyo-con­tai­ning oral gel effect on the activity of the antioxidant defense system in experimental periodontitis]. World of Medicine and Biology. 2021;1(75):115-9. Ukrainian. doi: https://doi.org/10.26724/2079-8334-2021-1-75-115-119
4. Krynytska I, Khudan R, Svanishvili N, Dum­badze Z, Marushchak M, Korda M. Hydrogen sulfide metabolism and its role in the development of periodontal diseases. Romanian journal of diabetes, nutrition and metabolism. 2021;28(3):311-5. doi: https://doi.org/10.46389/rjd-2021-1047
5. Bandrivsky Y, Bandrivska O, Bandrivska N, Be­denyuk O, Kuchyrka L, Zmarko I. Medication correction of the main clinical symptoms of generalized periodontitis in patients with different blood groups. Pharmacia. 2023;70(3):499-507. doi: https://doi.org/10.3897/pharmacia.70.e102850
6. Solvar ZL, Pohoretska JO. [Changes in the nitric oxide system in the guinea pigs` lungs with experimental allergic alveolitis and experimental periodontitis at different periods of experiment simulation]. Journal of marine medicine. 2023;4:90-3. Ukrainian. doi: https://doi.org/10.5281/zenodo.10606742
7. Bolon B, Baze W, Shilling CJ, Keatley KL, Pat­rick DJ, Schafer KA. Good laboratory practice in the academic setting: Fundamental principles for nonclinical safety assessment and GLP-compliant pathology support when developing innovative biomedical products. ILAR Journal.2018;59:18-28. doi: https://doi.org/10.1093/ilar/ily008
8. Agrawal H. Stainless steel crown: A review article. Indian Journal of Forensic Medicine & Toxicology. 2020;14(4):9929-32. doi: https://doi.org/10.37506/ijfmt.v14i4.13169
9. Haraguchi M, Towithelertkul C, Ali IE, Han X, Su­mita YI. An indirect-direct technique with hot water for fab­ri­cating a cast metal crown under an existing removable partial denture. J Prosthet Dent. 2022;14:S0022-3913(22)00491-7. doi: https://doi.org/10.1016/j.prosdent.2022.08.007
10. Demkovych A, Shcherba V, Yaremchuk O, Stoi­kevych H, Machogan V, Luchynskyi V. Effects of flavonol quercetin on syndrome of endogenous intoxication in experimental periodontitis. Pharmacia. 2021;68(3):627-32. doi: https://doi.org/10.3897/pharmacia.68.e67341
11. European convention for the protection of verte­brate animal used for experimental and other scientific purposes [Internet]. Council of Europe, Strasbourg. 1986 [cited 2024 Feb 23]. 11 р. Available from: https://rm.coe.int/168007a67b
12. Berkalo LV, Bobovych OV, Bobrova NO, Hei­ko OO, Kaidashev IP, Kutsenko LO, et al. [Methods of clinical and experimental research in medicine]. 2nd ed. Kaidashev IP, editor. Poltava: Polimet; 2003. 320 p. Ukrainian. Available from: https://repository.pdmu.edu.ua/handle/123456789/18528
13. Zhu X. Sample size calculation for Mann-Whitney U test with five methods. Int J Clin Trials. 2021;8(3):184-95. doi: https://doi.org/10.18203/2349-3259.ijct20212840
14. Viglianisi G, Tartaglia GM, Santonocito S, Ama­to M, Polizzi A, Mascitti M, et al. The emerging role of salivary oxidative stress biomarkers as prognostic markers of periodontitis: New insights for a personalized approach in dentistry. J Pers Med. 2023 Jan 17;13(2):166. doi: https://doi.org/10.3390/jpm13020166
15. Saienko OS, Chemych MD. [Serum ceruloplasmin as a prognostic indicator of Long COVID]. Bulletin of prob­lems biology and medicine. 2024;31(174):173-9. Ukrainian. doi: https://doi.org/10.29254/2077-4214-2024-3-174-173-179
16. Paltov YeV, Masna ZZ, Horbova NO. [Normal indicators of oxidative stress and the dynamics of their changes at different terms of experimental opioid in­fluence]. Clinical Anatomy and Operative Surgery. 2022;21(3):22-8. Ukrainian. doi: https://doi.org/10.24061/1727-0847.21.3.2022.33
17. Veljovic T, Djuric M, Mirnic J, Gusic I, Ma­letin A, Ivic S, et al. Effect of nonsurgical periodontal treatment on salivary and plasma superoxide dismutase levels of patients suffering from periodontitis. J Clin Med. 2023;12(20):6688. doi: https://doi.org/10.3390/jcm12206688
18. Mohideen K, Chandrasekaran K, Veeraragha­van H, Faizee SH, Dhungel S, Ghosh S. Meta-analysis of assessment of total oxidative stress and total antioxidant capacity in patients with periodontitis. Dis Markers. 2023;2023:9949047. doi: https://doi.org/10.1155/2023/9949047
19. Sukhomeilo DO, Reizvikh OE. [Biochemical pa­rameters of rat gums in experimental modeling of perio­dontitis against the background of nutritional vitamin D deficiency]. Stomatological Bulletin. 2023;124(3):2-8. Uk­rainian. doi: https://doi.org/10.35220/2078-8916-2023-49-3.1
20. Demkovych A, Bondarenko Y, Hasiuk PA. Oxi­dative modification of proteins in the process of expe­rimental periodontitis development. Interv Med Appl Sci. 2017;9(4):218-21. doi: https://doi.org/10.1556/1646.9.2017.28
21. Biloklytska GF, Gutnyk OY, Novytska IK, Tretia­kova OV. The effect of the treatment and prevention complex on the activity of the antioxidant protection system in experimental periodontitis combined with stress. Wiad 2024;77(11):2296-302. doi: https://doi.org/10.36740/WLek/197116
22. uan W, Chen J, Sun J, Song C, Chen Z. Associa­tion between oxidative balance score and serum cobalt level in population with metal implants: a cross-sectional study from NHANES 2015-2020. Front Nutr. 2024;11:1485428. doi: https://doi.org/10.3389/fnut.2024.1485428
23. Nikonov A, Krynychko V, Bobrovska N, Bresla­vets N, Smirnova O, Muhin Z. A study of the impact of solid cast removable dentures with silver electroplating on the condition of patients. Acta Marisiensis – Seria Medica. 2023;69(1):30-6.
    doi: https://doi.org/10.2478/amma-2023-0002
24. Patil MB, Lavanya T, Kumari CM, Shetty SR, Gufran K, Viswanath V, et al. Serum ceruloplasmin as can­cer marker in oral pre-cancers and cancers. J Carcinog. 2021;20:15. doi: https://doi.org/10.4103/jcar.jcar_10_21
25. Balitska OY, Hasiuk PA, Piasetska LV, Dzet­siukh TI, Vorobets AB, Rosolovska SO. Functional state of the antioxidant defense system in the blood serum of patients with generalized periodontitis and type 2 diabetes mellitus. Clinical and Preventive Medicine. 2024;8:46-52. doi: https://doi.org/10.31612/2616-4868.8.2024.05
26. Fei Z, Gao W, Xu X, Sheng H, Qu S, Cui R. Se­rum superoxide dismutase activity: a sensitive, convenient, and economical indicator associated with the prevalence of chronic type 2 diabetic complications, especially in men. FreeRadic  2021;55(3):275-81. doi: https://doi.org/10.1080/10715762.2021.1937146
27. Perepelova T, Faustova M, Dvornyk V, Dobro­volskyi O, Koval Y, Loban G. The level of dysbiosis of the oral cavity depends on the type of dental prosthesis of the patient. Bratisl Lek Listy. 2023;124(8):599-603. doi: https://doi.org/10.4149/BLL_2023_093
28. Moradpoor H, Samavati M, Raissi S, Emami M, Habibkhodaei M, Shirani M. Clinical marginal and inter­nal adaptation of single metal-ceramic crowns fabricated with casting, milling, and milling/sintering methods. Int J Prosthodont.2023;36(5):581-7. doi: https://doi.org/10.11607/ijp.8024
29. Abdulhameed EA, Al-Rawi NH, Omar M, Khali­fa N, Samsudin ABR. Titanium dioxide dental implants surfaces related oxidative stress in bone remodeling: a systematic review. PeerJ. 2022;10:e12951. doi: https://doi.org/10.7717/peerj.12951

Look through:

Demkovych A.Ye. I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-9823-4283

Marfiian O.V. I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
https://orcid.org/0009-0007-7782-8278

Demkovych A.Ye., Marfiian O.V. Changes in the antioxidant defense system of the body in periodontitis of bacterial-immune genesis and against the background of using metal crowns. Medicni perspektivi. 2025;30(3):14-24.
doi: https://doi.org/10.26641/2307-0404.2025.3.340535

Analyses of electromagnetic effects as colors of the vision analyzer

An analysis of current scientific literature shows that device-based treatment methods play an important role in the comprehensive postoperative rehabilitation of patients after reconstructive and plastic surgery on the face. Despite the active introduction of radiofrequency, laser, ultrasound and light methods into clinical practice, the question of comparing their effectiveness remains open. This is particularly relevant in the treatment of the consequences of deep mechanical and thermal damage, which are accompanied by complex processes of skin restoration. Objective: to conduct an analysis, including a multidimensional comparative analysis, of device-based methods for facial skin restoration during rehabilitation after plastic and reconstructive surgery. The study involved 72 subjects (women and men, average age 40.5±8.1 years) who underwent plastic or reconstructive surgery on the face. Depending on the method of hardware exposure, patients were divided into four groups: radiofrequency, laser, ultrasound (HIFU) and light (LED/IPL) therapy. The control group (n=24) consisted of patients who received only traditional treatment without device-based methods. The Vancouver Scar Scale (VSS), biometric parameters (Cutometer^®, Corneometer^®), dermatoscopy and the visual analogue scale (VAS) were used to evaluate the results. A multidimensional comparative analysis was performed using the sum of squares method, which took into account five key characteristics: clinical effectiveness, duration of the procedure, number of sessions, interval between surgery and the start of therapy, and cost of treatment. LED light therapy received the highest rating (R=1), which was characterised by the shortest interval between surgery and the start of treatment (21 days), the lowest cost (6,000 UAH) and the shortest duration of the procedure (0.5 hours). Radiofrequency and non-ablative laser therapies received the same rating (R=2), indicating their high effectiveness but longer and more expensive therapy (1 hour and 9-15 thousand UAH, respectively). The ultrasound method ranked third (R=3) due to significant time (90 days) and financial (15,000 UAH) constraints, as well as the duration of the procedure (1.5 hours). The results of the study indicate the advisability of early inclusion of LED and radiofrequency therapy in standardised rehabilitation protocols to improve skin healing quality, reduce the risk of scarring and enhance the overall aesthetic effect after plastic and reconstructive surgery on the face.

Key words: device-based methods, reconstructive surgery, plastic surgery, rehabilitation, skin restoration, radiofrequency therapy, laser therapy, light therapy

1. Alam M, et al. Efficacy of HIFU in enhancing facelift results: A randomized study. Dermatol Surg. 2021;47(5):289-98. doi: https://doi.org/10.1097/DSS.0000000000002960
2. Jia X, Feng Y. Energy-based skin rejuvenation: A review of mechanisms and thermal effects. J Cosmet Dermatol.2025;24(2):e16657. doi: https://doi.org/10.1111/jocd.16657
3. Pan R, Gu D, Zhang Y, et al. Efficacy and safety of intense focused ultrasound for skin rejuvenation: A systematic review and meta-analysis. Arch Dermatol Res. 2024;316(3):513.
   doi: https://doi.org/10.1007/s00403-024-03263-y
4. Corduff N. Surgical or nonsurgical facial rejuvenation: The patients’ choice. Plast Reconstr Surg Glob Open. 2023;11(10):e5318. doi: https://doi.org/10.1097/GOX.0000000000005318
5. Shah SA, Alster TS. Anatomical approach to ra­diofrequency-assisted facial rejuvenation: A retrospective review. Aesthet Surg J. 2023;45(Suppl 1):S1-9. doi: https://doi.org/10.1093/asj/sjad001
6. Gold MH, et al. Radiofrequency microneedling in post-facelift skin rejuvenation. J Cosmet Dermatol. 2019;18(2):123-34. doi: https://doi.org/10.1111/jocd.12759
7. Kneiber D, Amin M, Nguyen TA, Gharavi NM. Review of radiofrequency microneedling: History, devices and uses. J Cosmet Laser Ther. 2023;25(5-8):59-64. doi: https://doi.org/10.1080/14764172.2023.2219851
8. Benítez-Roig V, Trelles MA. Procedure and re­sults on lower face and neck rejuvenation using a temperature-controlled bipolar fractional radiofrequency microneedling device. Lasers Surg Med. 2022;54(5):639-47. doi: https://doi.org/10.1002/lsm.23524
9. Chien AL, et al. Innovations in light-based the­rapies for aesthetic medicine. Int J Dermatol. 2023;62(5):615-22. doi: https://doi.org/10.1111/ijd.16584
10. Kent DE, Jacob CI. Energy-based devices: The mainstays of aesthetic practices. The Aesthetic Guide [Internet]. 2023 [cited 2025 Apr 30]. Available from: https://www.theaestheticguide.com/energy-based-devices-treatments/energy-based-devices-the-mainstays-of-aesthetic-practices
11. Marchell NL, MacGregor JL. Safety and efficacy of combining RF microneedling with LED phototherapy in skin rejuvenation. Lasers Surg Med. 2022;54(6):716-24. doi: https://doi.org/10.1002/lsm.23524
12. Nguyen L, Blessmann M, Schneider SW, et al. Radiofrequency microneedling for skin tightening of the lower face, jawline, and neck region. Dermatol Surg. 2022;48(11):1299-305. doi: https://doi.org/10.1097/DSS.0000000000003502
13. Kamal A, et al. Blue light therapy: A skin treat­ment mask using blue light to cure skin disorders. Sukkur IBA J Emerg Technol. 2024;7(2):20-8. doi: https://doi.org/10.30537/sjet.v7i2.1454
14. Nadarajan V, Thota B, Dogaroiu A, Kim L, Nik­sic A, Barillas J, et al. Lasers, light, and energy-based devices in plastic surgery: A 3-year review of a resident cosmetic clinic experience. Aesthet Surg J Open Forum. 2024 Nov 29;6:ojae094. doi: https://doi.org/10.1093/asjof/ojae094
15. Ryu HJ, et al. Ultrasound and radiofrequency sy­nergy for post-surgical facial contour maintenance. J CosmetLaser  2024;26(1):20-8. doi: https://doi.org/10.1080/14764172.2023.2219851
16. Shauly O, Marxen T, Menon A, Gould DJ, Mil­ler LB, Losken A. Radiofrequency microneedling: Tech­nology, devices, and indications in the modern plastic surgery practice. Aesthet Surg J Open Forum. 2023;5:ojad100. doi: https://doi.org/10.1093/asj/sjad100
17. Lin J, et al. Advancements in AI-driven energy-based rejuvenation therapies. J Aesthet Sci. 2023;22(1):98-112.
18. Zhang Y, et al. Combination energy-based thera­pies in facial rejuvenation: A meta-analysis. Aesthet Med J. 2022;15(4):215-29.
19. Sullivan T, Smith J, Kermode J, McIver E, Cour­temanche DJ. Rating the burn scar. J Burn Care Rehabil. 1990;11(3):256-60. doi:https://doi.org/10.1097/00004630-199005000-00014
20. Hayes MH, Patterson DG. Experimental develop­ment of the graphic rating method. Psychol Bull. 1921;18(1):98-9.
21. Romanenko IV, Hubarieva OA. [Methods of sta­tistical analysis in medical research]. Kharkiv: KhNMU; 2020. 168 p.
22. Rudenko VM. [Mathematical statistics]. Kyiv: Tsentr uchbovoi literatury; 2012. 304 p.

Look through:

Hutchenko K.S. Central Research Institute of the Armed Forces of Ukraine, Kyiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0008-6377-7745

Shevchuk O.S. Sultan Medical Center, Mangaf, Kuwait
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0002-0401-973X

Savitska A.O. "Genius" Clinic, Kyiv, Ukraine
https://orcid.org/0009-0006-8360-0512

Kozachuk V.L. Central Research Institute of the Armed Forces of Ukraine, Kyiv, Ukraine
https://orcid.org/0000-0002-0207-7461

Alotaibi S.R. Sultan Medical Center, Mangaf, Kuwait
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0000-8039-0181

Shevchuk S.V. Ukrainian Military Medical Academy, Kyiv, Ukraine
https://orcid.org/0009-0005-5414-9526

Hutchenko K.S., Shevchuk O.S., Savitska A.O., Kozachuk V.L., Alotaibi S.R., Shevchuk S.V. Device-based methods in facial skin restoration during rehabilitation after plastic and reconstructive surgeries. Medicni perspektivi. 2025;30(3):25-30. 
doi: https://doi.org/10.26641/2307-0404.2025.3.340536

Characteristics of base materials and acrylates used in removable prosthetics in dental practice (review)

The current level of national defense security requires enhanced standards for the health and professional reliability of military personnel. In this context, oral health is considered a key factor influencing the performance of official duties, well-being, and quality of life. It can be asserted that optimizing the treatment of periodontal pathology in military personnel is not only an element of maintaining general health but also a part of the strategic orientation of any country. However, therapeutic approaches to generalized periodontitis often demonstrate low effectiveness, with only a temporary stabilizing effect on disease progression. The aim of this study is to evaluate the effectiveness of available local treatment options in controlling chronic periodontitis, with or without concurrent mechanical debridement by scaling. A total of 77 English- and Ukrainian-language scientific sources published between 2006 and 2025 were analyzed, selected based on relevance, presence of empirical data, and methodological quality. The literature search was conducted using the electronic catalog of the National Scientific Medical Library of Ukraine and databases such as Google Scholar, PubMed, and Scopus. The analysis focused on the effectiveness of various groups of local drug formulations, with special attention to gels exhibiting antibacterial, anti-inflammatory, antioxidant, and mucoadhesive properties. Mucogingival gels were found to ensure stable delivery of active components without systemic load, reduce periodontal pocket depth, bleeding, swelling, and promote tissue regeneration. The highest clinical efficacy was demonstrated by gels containing chlorhexidine, metronidazole, doxycycline, statins, and phytocomponents. Their use is recommended at all stages of treatment, including supportive therapy. The results of the literature review confirm the potential of mucogingival gel in the comprehensive treatment of generalized periodontitis, substantiating its application for military personnel and veterans.

Key words: military personnel, periodontitis, anti-bacterial agents, gels

1. Anderson Q. Military dentistry themed issue. Br Dent J. 2021 Apr;230(7):383. doi: https://doi.org/10.1038/s41415-021-2843-0
2. Combes J, Pepper T, Bryce G, MacBeth N. Dental care provision to UK military personnel serving on Operation Herrick in Afghanistan. Part 1: access to dental care. Br Dent J. 2018 Dec 21;225(12):1068-72. doi: https://doi.org/10.1038/sj.bdj.2018.1037
3. Kaniura OA, Badiuk MI, Vlasenko OM. [Organi­zation of dental care for the population of Ukraine and dental support for conscripts and military reserve personnel of the Armed Forces of Ukraine]. Problemy viisk okhorony zdorovia. 2012;31:425-33. Ukrainian.
4. Ahad A, Bey A, Khan S, Ahmad MS. Periodontal status associated with dual habits of smoking and smokeless tobacco use: A cross-sectional study in young adults. J Adv Periodontol Implant Dent. 2021 Jul 13;13(2):69-75. doi: https://doi.org/10.34172/japid.2021.010
5. Lavigne SE, Forrest JL. An umbrella review of systematic reviews examining the relationship between type 2 diabetes and periodontitis: Position paper fromthe  Canadian Dental Hygienists Association. Can J  Dent    2021 Feb 15;55(1):57-67. Available from: https://files.cdha.ca/profession/journal/2730.pdf
6. D'Ambrosio F, Caggiano M, Schiavo L, Sava­rese G, Carpinelli L, et al. Chronic stress and depression in periodontitis and peri-implantitis: A narrative review on neurobiological, neurobehavioral and immune-micro­biome interplays and clinical management implications. Dent J (Basel). 2022 Mar 18;10(3):49. doi: https://doi.org/10.3390/dj10030049
7. Osuh ME, Oke GA, Lilford RJ, Owoaje E, Har­ris B, Taiwo OJ, et al. Prevalence and determinants of oral health conditions and treatment needs among slum and non-slum urban residents: Evidence from Nigeria. PLOS Glob Public Health. 2022 Apr 22;2(4):e0000297. doi: https://doi.org/10.1371/journal.pgph.0000297
8. Tiwari T, Franstve-Hawley J. Addressing oral health of low-income populations-a call to action. JAMA Netw Open. 2021 Sep 1;4(9):e2125263. doi: https://doi.org/10.1001/jamanetworkopen.2021.25263
9. Relvas M, Regueira-Iglesias A, Balsa-Castro C, Salazar F, Pacheco JJ, Cabral C, et al. Relationship bet­ween dental and periodontal health status and the salivary microbiome: bacterial diversity, co-occurrence networks and predictive models. Sci Rep. 2021 Jan 13;11(1):929. doi: https://doi.org/10.1038/s41598-020-79875-x
10. Tagger-Green N, Nemcovsky C, Fridenberg N, Green O, Chaushu L, Kolerman R. Oral and dental con­siderations of combat-induced post traumatic stress disorder (PTSD)-A Cross-Sectional Study. J Clin Med. 2022 Jun 6;11(11):3249. doi: https://doi.org/10.3390/jcm11113249
11. Schindler DK, Lopez Mitnik GV, Soliván-Or­tiz AM, Irwin SP, Boroumand S, Dye BA. Oral health status among adults with and without prior active duty service in the U.S. Armed Forces, NHANES 2011-2014. Mil Med. 2021 Jan 30;186(1-2):e149-e159. doi: https://doi.org/10.1093/milmed/usaa355
12. Corridore D, Saccucci M, Zumbo G, Fontana E, Lamazza L, Stamegna C, et al. Impact of Stress on Periodontal Health: Literature Revision. Healthcare (Basel). 2023 May 22;11(10):1516. doi: https://doi.org/10.3390/healthcare11101516
13. Seizer L, Schubert C. On the role of psycho­neuroimmunology in oral medicine. Int Dent J. 2022 Dec;72(6):765-72. doi: https://doi.org/10.1016/j.identj.2022.07.002
14. Decker A, Askar H, Tattan M, Taichman R, Wang HL. The assessment of stress, depression, and in­flammation as a collective risk factor for periodontal diseases: a systematic review. Clin Oral Investig. 2020 Jan;24(1):1-12. doi: https://doi.org/10.1007/s00784-019-03089-3
15. Hilgert JB, Hugo FN, Bandeira DR, Bozzetti MC. Stress, cortisol, and periodontitis in a population aged 50 years and over. J Dent Res. 2006 Apr;85(4):324-8. doi: https://doi.org/10.1177/154405910608500408
16. Ishisaka A, Ansai T, Soh I, Inenaga K, Awano S, Yoshida A, et al. Association of cortisol and dehy­dro­epiandrosterone sulphate levels in serum with periodontal status in older Japanese adults. J Clin Periodontol. 2008 Oct;35(10):853-61. doi: https://doi.org/10.1111/j.1600-051X.2008.01309.x
17. Ribeiro FV, Mehta JJ, Monteiro MF, Moore J, Ca­sati MZ, Nibali L. Minimal invasiveness in nonsurgical periodontal therapy. Periodontol 2000. 2023 Feb;91(1):7-19. doi: https://doi.org/10.1111/prd.12476
18. Haas AN, Furlaneto F, Gaio EJ, Gomes SC, Pa­lioto DB, Castilho RM, et al. New tendencies in non-surgi­cal periodontal therapy. Braz Oral Res. 2021;35(Supp 2):e095. doi: https://doi.org/10.1590/1807-3107bor-2021.vol35.0095
19. Vinel A, Al Halabi A, Roumi S, Le Neindre H, Millavet P, Simon M, et al. Non-surgical periodontal treat­ment: SRP and Innovative therapeutic approaches. Adv Exp Med Biol. 2022;1373:303-27. doi: https://doi.org/10.1007/978-3-030-96881-6_16
20. Sanz M, Herrera D, Kebschull M, Chapple I, Jep­sen S, Beglundh T, et al. Treatment of stage I-III periodo­ntitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47(Suppl 22):4-60. doi: https://doi.org/10.1111/jcpe.13290
21. Ren J, Fok MR, Zhang Y, Han B, Lin Y. The role of non-steroidal anti-inflammatory drugs as adjuncts to periodontal treatment and in periodontal regeneration. J Transl 2023 Feb 25;21(1):149. doi: https://doi.org/10.1186/s12967-023-03990-2 
22. Sgolastra F, Petrucci A, Ciarrocchi I, Masci C, Sp­adaro A. Adjunctive systemic antimicrobials in the treatment of chronic periodontitis: A systematic review and network meta-analysis. J Periodontal Res. 2021 Apr;56(2):236-48. doi: https://doi.org/10.1111/jre.12821
23. Hammami C, Nasri W. Antibiotics in the treatment of periodontitis: A systematic review of the literature. Int J Dent.2021 Nov 8;2021:6846074. doi: https://doi.org/10.1155/2021/6846074 
24. Herrera D, Van Winkelhoff AJ, Matesanz P, Lau­wens K, Teughels W. Europe's contribution to the eva­luation of the use of systemic antimicrobials in the treat­ment of periodontitis. Periodontol 2000. 2023 Jun 14. doi: https://doi.org/10.1111/prd.12492.
25. Zubair S. Targeted use of antimicrobials in pe­riodontal therapy. Cureus. 2025 Mar 1;17(3):e79874. doi: https://doi.org/10.7759/cureus.79874
26. Sholapurkar A, Sharma D, Glass B, Miller C, Nimmo A, Jennings E. Professionally delivered local anti­microbials in the treatment of patients with periodontitis-A narrative review. Dent J (Basel). 2020 Dec 22;9(1):2. doi: https://doi.org/10.3390/dj9010002
27. Dhamecha D, Jagwani S, Rao M, Jadhav K, Shaikh S, Puzhankara L, et al. Local drug delivery systems in the management of periodontitis: A scientific review. J Control 2019 Aug 10;307:393-409. doi: https://doi.org/10.1016/j.jconrel.2019.06.038 
28. Amato M, Santonocito S, Polizzi A, Tartag­lia GM, Ronsivalle V, Viglianisi G, et al. Local delivery and controlled release drugs systems: A new approach for the clinical treatment of periodontitis therapy. Pharma­ceutics.2023 Apr 21;15(4):1312. doi: 10.3390/pharmaceutics15041312. 
29. Santos MS, Carvalho MS, Silva JC. Recent ad­vances on electrospun nanofibers for periodontal regenera­tion. Nanomaterials (Basel). 2023 Apr 7;13(8):1307. doi: https://doi.org/10.3390/nano13081307
30. Ashique S, Hussain A, Khan T, Pal S, Rihan M, et Insights into intra periodontal pocket patho­genesis, treatment, in vitro-in vivo models, products and patents, Challenges and  Opportunity. AAPS PharmSciTech. 2024;25(5):121. doi: https://doi.org/10.1208/s12249-024-02842-6
31. Azaripour A, Dittrich S, Van Noorden CJF, Wil­lershausen B. Efficacy of photodynamic therapy as adjunct treatment of chronic periodontitis: a systematic review and meta-analysis. Lasers Med Sci. 2018 Feb;33(2):407-23. doi: https://doi.org/10.1007/s10103-017-2383-7
32. Rosa CDDRD, Gomes JML, Moraes SLD, Le­mos CAA, Da Fonte TP, Limirio JPJO, et al. Use of chlor­hexidine chip after scaling and root planning on perio­dontal disease: A systematic review and meta-analysis. SaudiDent  2021 Jan;33(1):1-10. doi: https://doi.org/10.1016/j.sdentj.2020.11.002 
33. Ma L, Diao X. Effect of chlorhexidine chip as an adjunct in non-surgical management of periodontal pockets: a meta-analysis. BMC Oral Health. 2020 Sep 21;20(1):262. doi: https://doi.org/10.1186/s12903-020-01247-8
34. Annisa ZU, SulijayaB, Tadjoedin ESS, Huto­mo DI, Masulili  Effectiveness of chlorhexidine gels and chips in Periodontitis Patients after Scaling and Root Planing: a systematic review and Meta-analysis. BMC Oral Health. 2023 Oct 29;23(1):819. doi: https://doi.org/10.1186/s12903-023-03241-2 
35. ZhengH, Zhou Y, Zheng Y, Liu  Advances in hydrogels for the treatment of periodontitis. J Mater Chem B. 2023 Aug 9;11(31):7321-33. doi: https://doi.org/10.1039/d3tb00835e
36. MicuIC, Muntean A, Roman A, Stratul ȘI, Pall E, Ciurea A, et  A local desiccant antimicrobial agent as an alternative to adjunctive antibiotics in the treatment of periodontitis: A Narrative Review. Antibiotics (Basel). 2023 Feb 24;12(3):456. doi: https://doi.org/10.3390/antibiotics12030456
37. Figuero E, Serrano J, Arweiler NB, Auschill TM, Gürkan A, Emingil G. Supra and subgingival application of antiseptics or antibiotics during periodontal therapy. Periodontol 2023 Sep 28. doi: https://doi.org/10.1111/prd.12511
38. Castro MML, Duarte NN, Nascimento PC, Mag­no MB, Fagundes NCF, Flores-Mir C, et al. Antioxidants as Adjuvants in Periodontitis Treatment: A Systematic Review and Meta-Analysis. Oxid Med Cell Longev. 2019 Jul 22;2019:9187978. doi: https://doi.org/10.1155/2019/9187978
39. Moro MG, De Carvalho VF, Godoy-Miranda BA, Kassa CT, Horliana ACRT, Prates RA. Efficacy of anti­microbial photodynamic therapy (aPDT) for nonsurgical treatment of periodontal disease: a systematic review. LasersMed  2021 Oct;36(8):1573-90. doi: https://doi.org/10.1007/s10103-020-03238-1
40. Graziani F, Izzetti R, Perić M, Marhl U, Nisi M, Gennai S. Early periodontal wound healing after chlor­hexidine rinsing: a randomized clinical trial. Clin Oral Investig.2024 Jun 4;28(6):354. doi: https://doi.org/10.1007/s00784-024-05643-0 
41. Zhao H, Hu J, Zhao L. Adjunctive subgingival application of Chlorhexidine gel in nonsurgical periodontal treatment for chronic periodontitis: a systematic review and meta-analysis. BMC Oral Health. 2020 Jan 31;20(1):34. doi: https://doi.org/10.1186/s12903-020-1021-0
42. Matesanz-Pérez P, García-Gargallo M, Figuero E, Bascones-Martínez A, Sanz M, Herrera D. A systematic review on the effects of local antimicrobials as adjuncts to subgingival debridement, compared with subgingival debridement alone, in the treatment of chronic perio­dontitis. J Clin Periodontol. 2013 Mar;40(3):227-41. doi: https://doi.org/10.1111/jcpe.12026
43. Balta MG, Papathanasiou E, Blix IJ, Van Dy­ke TE. Host modulation and treatment of periodontal disease.J Dent  2021 Jul;100(8):798-809. doi: https://doi.org/10.1177/0022034521995157 
44. Hajishengallis G, Chavakis T, Lambris JD. Cur­rent understanding of periodontal disease pathogenesis and targets for host-modulation therapy. Periodontol 2000. 2020 Oct;84(1):14-34. doi: https://doi.org/10.1111/prd.12331
45. Zhang Y, Ding Y, Guo Q. Probiotic species in the management of periodontal diseases: An overview. Front CellInfect  2022 Mar 25;12:806463. doi: https://doi.org/10.3389/fcimb.2022.806463 
46. Gheisary Z, Mahmood R, Harri Shivanantham A, Liu J, Lieffers JRL, Papagerakis P, et al. The clinical, microbiological, and immunological effects of probiotic supplementation on prevention and treatment of perio­dontal diseases: A systematic review and meta-analysis. Nutrients.2022 Feb 28;14(5):1036. doi: https://doi.org/10.3390/nu14051036 
47. Ranjith A, Nazimudeen NB, Baiju KV. Probiotic mouthwash as an adjunct to mechanical therapy in the treatment of stage II periodontitis: A randomized controlled clinical trial. Int J Dent Hyg. 2022 May;20(2):415-21. doi: https://doi.org/10.1111/idh.12589
48. Ma S, Lu X, Yu X, Du Y, Xu S, et al. An in­jectable multifunctional thermo-sensitive chitosan-based hyd­rogel for periodontitis therapy. Biomater Adv. 2022;142:213158. doi: https://doi.org/10.1016/j.bioadv.2022.213158
49. Donos N, Calciolari E, Brusselaers N, Goldoni M, BostanciN, Belibasakis GN. The adjunctive use of host modulators in non-surgical periodontal therapy. A syste­matic review of randomized, placebo-controlled clinical studies. J Clin Periodontol. 2020 Jul;47(Suppl 22):199-238. doi: https://doi.org/10.1111/jcpe.13232
50. Aminu N, Chan SY, Yam MF, Toh SM. A dual-action chitosan-based nanogel system of triclosan and flurbiprofen for localised treatment of periodontitis. Int J Pharm.2019 Oct 30;570:118659. doi: https://doi.org/10.1016/j.ijpharm.2019.118659 
51. Batool F, Agossa K, Lizambard M, Petit C, Bu­gueno IM, Delcourt-Debruyne E, et al. In-situ forming implants loaded with chlorhexidine and ibuprofen for periodontal treatment: Proof of concept study in vivo. Int J Pharm.2019 Oct 5;569:118564. doi: https://doi.org/10.1016/j.ijpharm.2019.118564 
52. Budală DG, Luchian I, Tatarciuc M, Butnaru O, Armencia AO, Virvescu DI, et al. Are local drug delivery systems a challenge in clinical periodontology? J Clin Med.2023 Jun 19;12(12):4137. doi: https://doi.org/10.3390/jcm12124137
53. Fratila DN, Virvescu DI, Luchian I, Hancianu M, Baciu ER, Butnaru O, et al. Advances and functional in­tegration of hydrogel composites as drug delivery systems in contemporary dentistry. Gels. 2024 Oct 16;10(10):661. doi: https://doi.org/10.3390/gels10100661
54. Wei Y, Deng Y, Ma S, Ran M, Jia Y, Meng J, et al. Local drug delivery systems as therapeutic strategies against periodontitis: A systematic review. J Control Release.2021 May 10;333:269-82. doi: https://doi.org/10.1016/j.jconrel.2021.03.041
55. Verma N, Saimbi CS, Gupta S, Kumar A, Tri­pathi AK. Compare the efficacy of chlosite gel as an adjunctive therapy after scaling and root planing. Contemp Clin 2022 Apr-Jun;13(2):108-12. doi: https://doi.org/10.4103/ccd.ccd_121_20 
56. Gegout PY, Stutz C, Huck O. Gels as adjuvant to non-surgical periodontal therapy: A systematic review and meta-analysis. 2023 Jul 1;9(7):e17789. doi: https://doi.org/10.1016/j.heliyon.2023.e17789
57. Dhamecha D, Jagwani S, Rao M, Jadhav K, Shaikh S, Puzhankara L, et al. Local drug delivery systems in the management of periodontitis: A scientific review. J Control 2019 Aug 10;307:393-409. doi: https://doi.org/10.1016/j.jconrel.2019.06.038 
58. Sun H, Chen S, Yang C, Kuang H, Huang Y, He X, et al. Advances in the use of chlorhexidine for periodontitis treatment in diabetic patients: A review. Medicine (Baltimore). 2024 Sep 6;103(36):e39627. doi: https://doi.org/10.1097/MD.0000000000039627
59. Chandra C, Chandra S. Effect of chlosite (xanthan gel with chlorhexidine) on clinical & microbiological parameters in smokers-A case series. Indian Journal of Forensic Medicine & Toxicology. 2010;4(2):39-41. Available from: https://scispace.com/papers/effect-of-chlosite-xanthan-gel-with-chlorhexidine-on-1bjf1rl8gv
60. Liu S, Zheng W, Wang L, Zhang Y, Feng K, Zhang Y, et Bioinspired hydrogel for sustained mino­cycline release: A superior periodontitis solution. Mater Today Bio. 2025 Mar 12;32:101638. doi: https://doi.org/10.1016/j.mtbio.2025.101638
61. Ranch KM, Maulvi FA, Koli AR, Desai DT, Pa­rikh RK, Shah DO. Tailored doxycycline hyclate loaded in situ gel for the treatment of periodontitis: optimization, in vitro characterization, and antimicrobial studies. AAPS PharmSciTech.2021 Feb 17;22(3):77. doi: https://doi.org/10.1208/s12249-021-01950-x
62. Levine JB, Goncalves J, Nguyen D, Nguyen O, Hasturk H. Efficacy of a novel post-foaming dental gel on gingival inflammation: A randomized controlled clinical trial.J  2020 Dec;91(12):1569-83. doi: https://doi.org/10.1002/JPER.19-0594 
63. Butera A, GalloS, Pascadopoli M, Taccardi D, Scribante A. Home oral care of periodontal patients using antimicrobial gel with postbiotics, lactoferrin, and aloe barbadensis leaf juice powder vs. conventional chlorhexidine gel: A split-mouth randomized clinical trial. Antibiotics (Basel). 2022 Jan 17;11(1):118. doi: https://doi.org/10.3390/antibiotics11010118 
64. Scribante A, Gallo S, Pascadopoli M, Frani M, Bute­ra A. Ozonized gels vs chlorhexidine in non-surgical perio­dontal treatment: A randomized clinical trial. Oral Dis. 2024;30(6):3993-4000. doi: https://doi.org/10.1111/odi.14829
65. Akncbay H, Senel S, Ay ZY. Application of chi­tosan gel in the treatment of chronic periodontitis. J Biomed Mater Res B Appl Biomater. 2007 Feb;80(2):290-6. doi: https://doi.org/10.1002/jbm.b.30596
66. Kumaar NR, Nair SC. Nanomaterials: an intra-periodontal pocket drug-delivery system for periodontitis. Ther 2023 Mar;14(3):227-49. doi: https://doi.org/10.4155/tde-2023-0001
67. Rani N, Singla RK, Narwal S, Kumar N, Rah­man MM. Medicinal plants used as an alternative to treat gingivitis and periodontitis. Evid Based Complement Alternat 2022 Sep 6;2022:2327641. doi: https://doi.org/10.1155/2022/2327641 
68. Pasupuleti MK, Nagate RR, Alqahtani SM, Pen­metsa GS, Gottumukkala SNVS, Ramesh KSV. Role of medicinal herbs in periodontal therapy: A systematic review. J Int Soc Prev Community Dent. 2023 Feb 27;13(1):9-16. doi: https://doi.org/10.4103/jispcd.JISPCD_210_22
69. Malcangi G, Inchingolo AM, Casamassima L, Trilli I, Ferrante L, Inchingolo F, et al. Effectiveness of herbal medicines with anti-inflammatory, antimicrobial, and antioxidant properties in improving oral health and treating gingivitis and periodontitis: A systematic review. Nutrients.2025 Feb 21;17(5):762. doi: https://doi.org/10.3390/nu17050762  
70. Laleman I, Teughels W. Novel natural product-based oral topical rinses and toothpastes to prevent periodontal diseases. Periodontol 2000. 2020 Oct;84(1):102-23. doi: https://doi.org/10.1111/prd.12339
71. Janakiram C, Venkitachalam R, Fontelo P, Iafol­la TJ, Dye BA. Effectiveness of herbal oral care products in reducing dental plaque & gingivitis – a systematic review and meta-analysis. BMC Complement Med Ther. 2020 Feb 11;20(1):43. doi: https://doi.org/10.1186/s12906-020-2812-1
72. Anwar MA, Sayed GA, Hal DM, Hafeez MSAE, Shatat AS, Salman A, et al. Herbal remedies for oral and dental health: a comprehensive review of their multifaceted mechanisms including antimicrobial, anti-inflammatory, and antioxidant pathways. Inflammopharmacology. 2025 Mar;33(3):1085-160. doi: https://doi.org/10.1007/s10787-024-01631-8
73. Xin X, Xiang X, Xin Y, Li Q, Ma H, Liu X, et al. Global trends in research on oxidative stress associated with periodontitis from 1987 to 2022: A bibliometric analysis. Front Immunol. 2022 Sep 8;13:979675. doi: https://doi.org/10.3389/fimmu.2022.979675
74. Sun J, Zhang Y, Zheng Z, Ding X, Sun M, Ding G. Potential mechanism of ginseng in the treat­ment of periodontitis based on network pharmacology and molecular docking. 2024 Apr 1;42(2):181-91. doi: https://doi.org/10.7518/hxkq.2024.2023285
75. López-Valverde N, López-Valverde A, Montero J, Rodríguez C, Macedo de Sousa B, Aragoneses JM. Antio­xidant, anti-inflammatory and antimicrobial activity of natural products in periodontal disease: a comprehensive review. FrontBioeng  2023 Aug 3;11:1226907. doi: https://doi.org/10.3389/fbioe.2023.1226907
76. Aljuboori IW, Mahmood MS, Al-Rihaymee SA. Clinical effectiveness of Salvia officinalis in periodontitis: A Split-mouth randomized controlled trial. Cureus. 2024;16(4):e58582. doi: https://doi.org/10.7759/cureus.58582
77. Sindhusha VB, Rajasekar A. Formulation of Neem and Echinacea gel for oral health along with the evaluation of antimicrobial, cytotoxic, anti-inflammatory, and free radical scavenging activity: An in vitro study. Cureus. 2024 Jul 1;16(7):e63631. doi: https://doi.org/10.7759/cureus.63631

Look through:

Kopchak O.V. Private Higher Educational Institution "Kyiv Medical University", Kyiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-3244-2041

Berehovyi O.O. Private Higher Educational Institution "Kyiv Medical University", Kyiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0009-8328-5446

Asharenkova O.V. Private Higher Educational Institution "Kyiv Medical University", Kyiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-9200-1200

Obolonska H.O. Private Higher Educational Institution "Kyiv Medical University", Kyiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0008-7084-7289

Yanishevskyi K.A. Private Higher Educational Institution "Kyiv Medical University", Kyiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0000-6394-615X

Kopchak O.V., Berehovyi O.O., Asharenkova O.V., Obolonska H.O., Yanishevskyi K.A. Scientific rationale for the use of a mucogingival gel in the comprehensive treatment of generalized periodontitis in military personnel and veterans (literature review). Medicni perspektivi. 2025;30(3):31-40. 
doi: https://doi.org/10.26641/2307-0404.2025.3.340537

Characteristics of base materials and acrylates used in removable prosthetics in dental practice (review)

The goal of this study was to test the reliability and validity of the Albanian version of the 23-item effort-rewardimbalance (ERI) questionnaire and to analyze its association with job dissatisfaction in a sample of Albanian healthcare professionals working in Regional Hospital in Shkodra.A cross-sectional study on a representative sample was carried out. Descriptive statistics was performed. Cronbach’s alpha coefficient was calculated to estimate the internal consistency reliability. Significant differences were calculated using ANOVA. A total of 270 study participants were involved in the study, and the response rate was 81% (219/270). Women and those with master degree predominated. The consistencies of the three scales: effort, reward, and overcommitment were obtained. Mean ratio effort-reward was all the time higher than 1 for all cases in the study. Results show a significant difference for effort and overcommitment based on gender and department in which a person is working.This study is the first one supporting psychometric properties of the Albanian version of the ERI model. Based on the results of this study the Albanian version of the ERI questionnaire is considered a reliable and valid instrument for measuring psychosocial stress at work. Our suggestion is that it is applicable to Albanians working in healthcare sector.

Key words: effort-reward imbalance (ERI) questionnaire, Albanian version, healthcare workers, psychometric properties

1. Siegrist J, Starke D, Chandola T, Godin I, Mar­mot M, Niedhammer I, et al. The measurement of effort-reward imbalance at work: European comparisons. Soc Sci Med. 2004 Apr;58(8):1483-99. doi: https://doi.org/10.1016/S0277-9536(03)00351-4
2. Darin-Mattsson A, Fors S, Kåreholt I. Different indicators of socioeconomic status and their relative importance as determinants of health in old age. Int J Equity Health. 2017;16(1):173. doi: https://doi.org/10.1186/s12939-017-0670-3
3. Gëdeshi I, King R. New trends in potential migration from Albania [Internet]. Tiranë, Albania; 2018 [cited 2025 Apr 25]. p. 1-87. Available from: https://www.researchgate.net/publication/331571437_New_Trends_in_Potential_Migration_from_Albania
4. [The Assembly of the Republic of Albania, on regulated professions in the Republic of Albania In support of articles 78 and 83 point 1 of the Constitution, upon the proposal of the Council of Ministers]. [Internet]. 2009 [cited 2025 Apr 25]. Albanian. Available from: https://www.drejtesia.gov.al/wp-content/uploads/2017/11/Law_10_193_03.12.2009_ON_JURISDICTIONAL_RELATIONS_WITH_FOREIGN_AUTHORITIES.pdf
5. Karasek R., Theorell T. Healthy work: Stress, pro­du­ctivity and the reconstruction of working life. [Internet]. Basic Books; 1992 [cited 2025 Apr 25]. 398 р. Available from: http://archive.org/details/healthyworkstres0000kara/mode/2up
6. Siegrist JJ. A theory of occupational stress. In: Dunham J, editor. Stress in the workplace: Past, present and future. Whurr Publishers; 2001. p. 52-66. Available from: https://www.researchgate.net/publication/232531019_A_theory_of_occupational_stress
7. Msaouel PP, Keramaris NC, Apostolopoulos AP, Syrmos N, Kappos T, Tasoulis A, et al. The effort-reward imbalance questionnaire in Greek: translation, validation and psychometric properties in health professionals. J Occup Health. 2012;54(2):119-30. doi: https://doi.org/10.1539/joh.11-0197-oa
8. Derycke H, Vlerick P, Burnay N, Decleire C, D'Hoore W, Hasselhorn H-M, et al. Impact of the effort–reward imbalance model on intent to leave among Belgian health care workers: A prospective study. J Occup Organ Psychol. 2010;83(4):879-93. doi: https://doi.org/10.1348/096317909X477594
9. Li J, Yang W, Cheng Y, Siegrist J, Cho SI. Effort-reward imbalance at work and job dissatisfaction in Chinese healthcare workers: a validation study. Int Arch Occup Environ Health. 2005 Apr;78(3):198-204. doi: https://doi.org/10.1007/s00420-004-0581-7
10. Tzeng DS, Chung WC, Lin CH, Yang CY. Effort-reward imbalance and quality of life of healthcare workers in military hospitals: a cross-sectional study. BMC Health Serv Res. 2012 Sep 8;12:309. doi: https://doi.org/10.1186/1472-6963-12-309
11. Yesuf SM, Derseh BT, Girma D, Dejene TM. Work-related stress and associated factors among health professionals in zone 1, Afar region, Ethiopia. Heliyon. 2022 Dec 10;8(12):e12167. doi: https://doi.org/10.1016/j.heliyon.2022.e12167
12. Chor D, Werneck GL, Faerstein E, de M Al­ves MG, Rotenberg L. The Brazilian version of the effort-reward imbalance questionnaire to assess job stress. Cad Saude Publica. 2008;24(1):219-24. doi: https://doi.org/10.1590/S0102-311X2008000100022
13. Kivimäki M, Virtanen M, Elovainio M, Kou­vonen A, Väänänen A, Vahtera J. Work stress in the etiology of coronary heart disease--a meta-analysis. Scand J Work Environ Health. 2006 Dec;32(6):431-42. doi: https://doi.org/10.5271/sjweh.1049
14. Siegrist J. Effort-reward imbalance at work and cardiovascular diseases. Int J Occup Med Environ Health. 2010;23(3):279-85.
    doi: https://doi.org/10.2478/v10001-010-0013-8
15. Wright BJ. Effort-reward imbalance is as­sociated with salivary immunoglobulin a and cortisol secretion in disa­bility workers. J Occup Environ Med. 2011 Mar;53(3):308-12. doi: https://doi.org/10.1097/JOM.0b013e31820c90b7
16. The population of Albania by counties, total and by gender. INSTAT [Internet]. 2023 [cited 2025 Apr 25]. Available from: https://www.instat.gov.al/en/themes/demography-and-social-indicators/population/publication/2023/population-of-albania-on-1st-january-2023/
17. Regional Hospital of Shkodra. Data for hospital visits [Internet]. 2023 [cited 2025 Apr 25]. Available from: https://www.architekturstudio-mezey.de/en/portfolio/regional-hospital-shkodra-albania/
18. Weinberg A, Creed F. Stress and psychiatric disorder in healthcare professionals and hospital staff. Lancet. 2000 Feb 12;355(9203):533-7. doi: https://doi.org/10.1016/S0140-6736(99)07366-3
19. Pisljar T, van der Lippe T, den Dulk L. Health among hospital employees in Europe: a cross-national study of the impact of work stress and work control. Soc Sci Med. 2011 Mar;72(6):899-906. doi: https://doi.org/10.1016/j.socscimed.2010.12.017
20. Martinez MC, Latorre MDRDO, Fischer FM. Factors associated with work ability and intention to leave nursing profession: a nested case-control study. Ind Health. 2022 Feb 8;60(1):29-39. doi: https://doi.org/10.2486/indhealth.2021-0085
21. Kroczek M. Analyzing nurses' decisions to leave their profession-a duration analysis. Eur J Health Econ. 2024 Apr;25(3):471-96. doi: https://doi.org/10.1007/s10198-023-01600-y
22. Siegrist J. Psychometric properties of the effort-reward imbalance questionnaire. Department of Medical Sociology, Faculty of Medicine, Duesseldorf University, Germany; 2014. Available from: https://www.semanticscholar.org/paper/Psychometric-properties-of-the-E%EF%AC%80ort-Reward-Siegrist-Li/a7f1cb357063e76969fe9ca7301cfd978b1f6842#related-papers
23. Siegrist J, Wege N, Pühlhofer F, Wahrendorf M. A short generic measure of work stress in the era of globalization: effort-reward imbalance. Int Arch Occup Environ Health. 2009 Aug;82(8):1005-13. doi: https://doi.org/10.1007/s00420-008-0384-3
24. Iacobucci D, Duhachek А. Advancing Alpha: Measuring Reliability With Confidence. Journal of Consumer Psychology. 2003;13(4):478-87. doi: https://doi.org/10.1207/S15327663JCP1304_14
25. Siegrist J. Adverse health effects of high-ef­fort/low-reward conditions. J Occup Health Psychol. 1996 Jan;1(1):27-41.
    doi: https://doi.org/10.1037//1076-8998.1.1.27
26. Niedhammer I, Siegrist J, Landre MF, Gold­berg M, Leclerc A. [Study of the psychometric qualities of the French version of the effort/reward imbalance model]. Rev Epidemiol Sante Publique. 2000;48(5):419-38. French. Available from: https://pubmed.ncbi.nlm.nih.gov/11084523/
27. Tsutsumi A, Ishitake T, Peter R, Siegrist J, Mato­ba T. The Japanese version of the Effort-Reward Im­balance Questionnaire: A study in dental technicians. Work Stress. 2001;15(1):86-96. doi: https://doi.org/10.1080/02678370118173
28. Macías Robles MD, Fernández-López JA, Hernán­dez-Mejía R, Cueto-Espinar A, Rancaño I, Sieg­rist J. [Asses­sment of work-related stress in workers at a Spanish public hospital. Study of the psychometric pro­perties of the Spanish version of the "Effort-Reward Imbalance" model]. Med Clin (Barc). 2003;120(17):652-7. Spanish. doi: https://doi.org/10.1016/S0025-7753(03)73799-3
29. Hanson EK, Schaufeli W, Vrijkotte T, Plomp NH, Godaert GL. The validity and reliability of the Dutch Effort-Reward Imbalance Questionnaire. J Occup Health Psychol. 2000 Jan;5(1):142-55. doi: https://doi.org/10.1037//1076-8998.5.1.142
30. Tsutsumi A, Iwata N, Wakita T, Kumagai R, No­guchi H, Kawakami N. Improving the measurement accuracy of the effort-reward imbalance scales. Int J Behav Med. 2008;15(2):109-19. doi: https://doi.org/10.1080/10705500801929718
31. Pikhart H, Bobak M, Pajak A, Malyutina S, Ku­binova R, Topor R, et al. Psychosocial factors at work and depression in three countries of Central and Eastern Europe. Soc Sci Med. 2004 Apr;58(8):1475-82. doi: https://doi.org/10.1016/S0277-9536(03)00350-2
32. Li J, Yang W, Cho SI. Gender differences in job strain, effort-reward imbalance, and health functioning among Chinese physicians. Soc Sci Med. 2006 Mar;62(5):1066-77. doi: https://doi.org/10.1016/j.socscimed.2005.07.011
33. Buddeberg-Fischer B, Klaghofer R, Stamm M, Sieg­rist J, Buddeberg C. Work stress and reduced health in young physicians: prospective evidence from Swiss resi­dents. Int Arch Occup Environ Health. 2008 Oct;82(1):31-8. doi: https://doi.org/10.1007/s00420-008-0303-7

Look through:

Pjetri Emiljano University of Shkodra “Luigj Gurakuqi”, Faculty of Natural Sciences, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0004-7299-0346

Shabani Zamira University of Shkodra “Luigj Gurakuqi”, Faculty of Natural Sciences, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-8021-5391

Shala Irena University of Shkodra “Luigj Gurakuqi”, Faculty of Natural Sciences, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-3726-6115

Bekteshi Adem University of Shkodra “Luigj Gurakuqi”, Faculty of Natural Sciences, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0000-5701-8082

Pjetri Emiljano, ShabaniZamira, Shala Irena, Bekteshi Adem Psychometric properties of the Albanian version of the effort-reward imbalance model in a sample of healthcare workers in Shkodra, Albania hospital. Medicni perspektivi. 2025;30(3):41-49.
doi: https://doi.org/10.26641/2307-0404.2025.3.340583

Deletion of cyclin dependent kinase inhibitor 2a gene as a marker of oropharyngeal carcinomas non-associated with human papillomavirus and its prognostic value

Cerebral small vessel disease has been considered to worsen short-term stroke outcome in upcoming 90 days, whereas few research have evaluated the role of cerebral small vessel disease in long-term prognosis (for instance, beyond a year). The aim of the research is to investigate the association between cerebral small vessel disease burden and long-term post-stroke survival in patients with acute stroke. It was a prospective single-center cohort study. 294 consecutive patients with acute stroke were recruited. All participants underwent magnetic resonance imaging and computed tomography assessment for cerebral small vessel disease markers as well as clinical-neurological testing.. To determine the associations of small vessel disease with mortality in patients after stroke, we used multivariate survival analysis using Cox regression with Kaplan-Meier survival curves for 5 years of follow-up after discharge. In multivariable Cox regression proportional hazards model, cerebral small vessel disease presence was associated with long-term all-cause post-stroke mortality (hazard ratio =3.8; 95% confidence interval 1.9-7.9, p<0.001). In the same model, cerebral small vessel disease severity grade 1 (hazard ratio =2.4; 95% confidence interval 1.1-5.4, p=0.033), cerebral small vessel disease severity grade 2 (hazard ratio =6.9; 95% confidence interval 3.2-15.0, p<0.001) were associated with poor survival. We also found significant association between presence of lacunes and mortality: (adjusted hazard ratio =6.2; 95% confidence interval 3.3-11.5, p<0.001); as well as severe white matter hyperintensity and mortality: (adjusted hazard ratio =2.1; 95% confidence interval 1.1-4.1, p=0.019). Cerebral vessel disease is significantly associated with mortality in patients after stroke during 5 years of follow-up. It may be useful in determining patient prognosis and future patient selection for preventive strategies.

Key words: cerebral small vessel disease, stroke, survival analysis, lacunes, white matter hyperintensity, magnetic resonance imaging, computed tomography, vascular pathology

1. Verhoeven JI, Allach Y, Vaartjes ICH, Klijn CJM, de Leeuw FE. Ambient air pollution and the risk of ischaemic and haemorrhagic stroke. Lancet Planet Health. 2021;5(8):e542-e552.
   doi: https://doi.org/10.1016/S2542-5196(21)00145-5
2. Zozulya IS, Volosovets AO, Zozulya AI, Volo­sovets OP. [Modern approaches to diagnosis, treatment and prevention of cerebral stroke]. Medytsyna nevid­kladnykh staniv. 2022;18(7):39-45. Ukrainian. doi: https://doi.org/10.22141/2224-0586.18.7.2022.1530
3. Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022 [published correction appears in: Int J Stroke. 2022 Apr;17(4):478. doi: https://doi.org/10.1177/17474930221080343 ]. Int J Stroke.2022;17(1):18-29. doi: https://doi.org/10.1177/17474930211065917 
4. Markus HS, de Leeuw FE. Cerebral small vessel disease: Recent advances and future directions. Int J Stroke.2023;18(1):4-14. doi: https://doi.org/10.1177/17474930221144911  
5. Ryu WS, Jeong SW, Kim DE. Total small vessel disease burden and functional outcome in patients with ischemic stroke. PLoS One. 2020;15(11):e0242319. doi: https://doi.org/10.1371/journal.pone.0242319
6. Yasnii OM, Lebedynets DV, Trishchynska MA. [Features of the course of acute cerebral stroke in patients with type 2 diabetes]. Mizhnarodnyi nevrolohichnyi zhurnal.2024;19(8):273-77.  doi: https://doi.org/10.22141/2224-0713.19.8.2023.1033
7. Ren Y, Meng K, Sun Y, Wu M, Li S, Zhao W, et al. Effects of white matter lesion grading on the cognitive function of patients with chronic alcohol dependence. Am J Transl Res. 2023;15(2):1129-39. PMID: 36915744; PMCID: PMC10006824.
8. Wardlaw JM, Smith EE, Biessels GJ, Cordon­nier C, Fazekas F, Frayne R, et al. Neuroimaging standards for re­search into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-38. doi: https://doi.org/10.1016/S1474-4422(13)70124-8
9. Qiu W, Hu W, Ge Y, Liu P, Zhao M, Lu H, et al. Total burden of cerebral small vessel disease predict subjective cognitive decline in patients with Parkinson's disease. Front Aging Neurosci. 2024;16:1476701. doi: https://doi.org/10.3389/fnagi.2024.1476701
10. Asaithambi G, Martins SL. Validation of a neuro­vascular comorbidity index for risk adjustment of comor­bid conditions among ischemic stroke patients receiving reperfusion treatment. J Stroke Cerebrovasc Dis. 2023;32(8):107189. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107189
11. Zhuo Y, Qu Y, Wu J, Huang X, Yuan W, Lee J, et al. Estimation of stroke severity with National Institutes of Health Stroke Scale grading and retinal features: A cross-sectional study. Medicine (Baltimore). 2021;100(31):e26846. doi: https://doi.org/10.1097/MD.0000000000026846
12. Nobels-Janssen E, Postma EN, Abma IL, van Dijk JMC, Haeren R, Schenck H, et al. Inter-method reliability of the modified Rankin Scale in patients with subarachnoid hemorrhage. J Neurol. 2022;269(5):2734-42. doi: https://doi.org/10.1007/s00415-021-10880-4
13. Bodien YG, Barra A, Temkin NR, Barber J, Fore­man B, Vassar M, et Diagnosing Level of Con­sciousness: The Limits of the Glasgow Coma Scale Total Score. J Neurotrauma. 2021;38(23):3295-305. doi: https://doi.org/10.1089/neu.2021.0199 
14. Gallegos M, Morgan ML, Cervigni M, Martino P, Murray J, Calandra M, et al. 45 Years of the mini-mental state examination (MMSE): A perspective from ibero-america. Dement Neuropsychol. 2022;16(4):384-7. doi: https://doi.org/10.1590/1980-5764-DN-2021-0097
15. Rathburn CM, Mun KT, Sharma LK, Saver JL. TOAST stroke subtype classification in clinical practice: implications for the Get With The Guidelines-Stroke nationwide registry. Front Neurol. 2024;15:1375547. doi: https://doi.org/10.3389/fneur.2024.1375547
16. Dey T, Lipsitz SR, Cooper Z, Trinh QD, Krzy­winski M, Altman N. Survival analysis-time-to-event data and censoring. Nat Methods. 2022;19(8):906-8. doi: https://doi.org/10.1038/s41592-022-01563-7
17. Bensken WP, Ho VP, Pieracci FM. Basic In­troduction to Statistics in Medicine, Part 2: Comparing Data. Surg Infect (Larchmt). 2021;22(6):597-603. doi: https://doi.org/10.1089/sur.2020.430
18. Yi F, Jacob MA, Verhoeven JI, Cai M, Due­ring M, Tuladhar AM, et al. Baseline and Longitudinal MRI Markers Associated With 16-Year Mortality in Patients With Cerebral Small Vessel Disease. Neurology. 2024;103(6):e209701. doi: https://doi.org/10.1212/WNL.0000000000209701
19. Yang Q, Wei X, Deng B, Chang Z, Jin D, Huang Y, et al. Cerebral small vessel disease alters neuro­vascular unit regulation of microcirculation integrity involved in vascular cognitive impairment. Neurobiol Dis. 2022;170:105750. doi: https://doi.org/10.1016/j.nbd.2022.105750
20. Kitagawa K, Toi S, Hosoya M, Seki M, Yama­gishi S, Hoshino T, et al. Small vessel disease burden predicts incident stroke and all-cause death, but not acute coronary event. Hypertens Res. 2024 Nov;47(11):3001-9. doi: https://doi.org/10.1038/s41440-024-01797-2
21. Hakim A, Gallucci L, Sperber C, Rezny-Kas­przak B, Jäger E, Meinel T, et al. The analysis of asso­ciation between single features of small vessel disease and stroke outcome shows the independent impact of the number of microbleeds and presence of lacunes. Sci Rep. 2024 Feb 10;14(1):3402. doi: https://doi.org/10.1038/s41598-024-53500-7
22. Melkas S, Putaala J, Oksala NK, Pohjasvaara T, Oksala A, Kaste M, et al. Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neuro­logy.2011 Feb 22;76(8):734-9. doi: https://doi.org/10.1212/WNL.0b013e31820db666
23. Kissela B, Lindsell CJ, Kleindorfer D, Al­well K, Moomaw CJ, Woo D, et Clinical prediction of func­tional outcome after ischemic stroke: the surprising importance of periventricular white matter  disease and race. Stroke. 2009 Feb;40(2):530-6. doi: https://doi.org/10.1161/STROKEAHA.108.521906 
24. Leonards CO, Ipsen N, Malzahn U, Fiebach JB, Endres M, Ebinger M. White matter lesion severity in mild acute ischemic stroke patients and functional outcome after 1 Stroke. 2012 Nov;43(11):3046-51. doi: https://doi.org/10.1161/STROKEAHA.111.646554
25. Xu M, Li B, Zhong D, Cheng Y, Wu Q, Zhang S, et al. Cerebral Small Vessel Disease Load Predicts Functional Outcome and Stroke Recurrence After Intracerebral Hemorrhage: A median follow-up of 5 years. FrontAging  2021 Feb 19;13:628271. doi: https://doi.org/10.3389/fnagi.2021.628271
26. Ghaznawi R, Geerlings MI, Jaarsma-Coes M, He­ndrikse J, de Bresser J, UCC-Smart Study Group. As­sociation of White Matter Hyperintensity Markers on MRI and Long-term Risk of Mortality and Ischemic Stroke: The SMART-MR Study. Neurology. 2021;96(17):e2172-e2183. doi: https://doi.org/10.1212/WNL.0000000000011827
27. Arba F, Palumbo V, Boulanger JM, Pracucci G, Inzitari D, Buchan AM, et al. Leukoaraiosis and lacunes are associated with poor clinical outcomes in ischemic stroke patients treated with intravenous thrombolysis. Int J Stroke.2016;11(1):62-7. doi: https://doi.org/10.1177/1747493015607517
28. Crouch EE, Bhaduri A, Andrews MG, Cebrian-Silla A, Diafos LN, Birrueta JO, et al. Ensembles of endothelial and mural cells promote angiogenesis inprenatal human brain. Cell. 2022;185(20):3753-3769.e18.
    doi: https://doi.org/10.1016/j.cell.2022.09.004
29. Jiang S, Wu S, Zhang S, Wu B. Advances in Understanding the Pathogenesis of Lacunar Stroke: From Pathology and Pathophysiology to Neuroimaging. Cereb­rovasc Dis. 2021;50(5):588-96. doi: https://doi.org/10.1159/000516052 

Look through:

Bartiuk R.S. Vinnytsia National Pirogov Memorial Medical University, Vinnytsia, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-8698-3014

Smolko D.G. Vinnytsia National Pirogov Memorial Medical University, Vinnytsia, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-3040-3639

Marunkevych Ya.Yu. Vinnytsia National Pirogov Memorial Medical University, Vinnytsia, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-6871-4347

Smotrytska T.V. Vinnytsia National Pirogov Memorial Medical University, Vinnytsia, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0008-3805-5564

Moskovko S.P. Vinnytsia National Pirogov Memorial Medical University, Vinnytsia, Ukraine
This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-3910-2672

Bartiuk R.S., Smolko D.G., Marunkevych Ya.Yu., Smotrytska T.V., Moskovko S.P. Survival analysis in stroke patients with cerebral small vessel disease. Medicni perspektivi. 2025;30(3):49-59.
doi: https://doi.org/10.26641/2307-0404.2025.3.340543

Pathomorphology of severe Grade 3-4 hepatic encephalopathy in decompensated cirrhosis patients with acute-on-chronic liver failure

The COVID-19 pandemic has become one of the most serious challenges for the global healthcare system, causing high mortality and a significant burden on medical institutions. Despite the development of medicine in many countries, none of them was fully prepared for the pandemic. Comorbid conditions that complicate the course of coronavirus disease and affect the effectiveness of treatment have become one of the key risk factors for severe disease and death. Identification of the most important laboratory markers and their correlation with the clinical course of COVID-19 will allow us to improve the prediction of disease outcomes and develop more effective treatment strategies. The article examines the impact of COVID-19 on the overall mortality structure in Ukraine, the features of its course, and prognostic markers of disease severity in patients with comorbid conditions. The aim of our work was to study specific changes in hemostasis indicators as markers of disease severity and prognosis for health status in patients with COVID-19 and comorbid conditions. A retrospective analysis of 399 hospitalizations and 296 deaths in the Chernivtsi Regional Clinical Hospital in 2021 was conducted. The changes we identified showed that a severe course of COVID-19 was significantly more common (p<0.05) in older patients and mainly in men, which may indicate that age and gender are one of the causes of the severity of COVID-19. This pattern is explained by the fact that with age (>65 years), patients are more likely to suffer from cardiovascular diseases and metabolic diseases (diabetes mellitus (DM)), which significantly reduces immunological resistance to SARS-CoV-2 infection. Laboratory indicators that can serve as prognostic markers of a severe course of the disease were analyzed: thrombocytopenia, increased levels of D-dimer, procalcitonin, C-reactive protein, and IL-6. Low body temperature at admission and decreased saturation levels were found to be predictors of poor prognosis. The results may improve monitoring and treatment strategies for COVID-19.

Key words: COVID-19, hemostasis indicators, acute phase indicators of inflammation, comorbidity, mortality

1. Trykhlib VI. [Complications in COVID-19 pa­tients]. Infectious Diseases. 2020;1:99. Ukrainian. doi: https://doi.org/10.11603/1681-2727.2020.1.11097
2. Belova IV, Dyakonova II, Taranuk LM, Demi­khov OI. Analysis of factors influencing mortality caused by COVID-19. Bulletin of Sumy State University. Economics series. 2020;3:164-72. doi: https://doi.org/10.21272/1817-9215.2020.3-18
3. Fedorova OA, Nedlinska TY. [Analysis of mor­tality among COVID-19 patients in the first quarter of 2020]. Ukrainian scientific medical youth journal. 2020;3(118):71-2. Ukrainian. Available from: http://ir.librarynmu.com/handle/123456789/2467
4. Muromtseva Yu. [Excess mortality and its measu­rement in Ukraine during the COVID-19 pandemic]. In: Scientific Bulletin. Materials of the IV All-Ukrainian Scientific and Practical Internet Conference «Geography and tourism» (2021 Feb 26, Kharkiv). 2021. р. 140-53. Ukrainian. Available from: https://www.researchgate.net/publication/350072865_Nadsmertnist_ta_ii_vimiruvanna_v_Ukraini_v_umovah_pandemii_COVID-19
5. Ferencova N, Visnovcova Z, Ondrejka I, Ton­hajze­rova I. COVID-19 pandemic as a huge stressor of the 21st century. Bratislavske lekarske listy. 2024;125(11):677-84. doi: https://doi.org/10.4149/BLL_2024_103
6. Hruzieva TS, Lekhan VM, Ohniev VA, Haliien­ko LI, Kriachkova LV, Palamar BI, et al. [Biostatistics]. Vin­nytsia: New Book; 2020. 384 p. Ukrainian. Available from: https://library.pdpu.edu.ua/images/2021/medbook/36.pdf
7. Sereda SO, Dubrov SO, Denysiuk MV, et al. [Ret­rospective analysis of mortality causes in patients with severe COVID-19]. Pain, Anesthesia, and Intensive Care. 2021;4(97):62-8. Ukrainian. doi: https://doi.org/10.25284/2519-2078.4(97).2021.248401
8. Zhang JJ, Dong X, Liu GH, Gao YD. Risk and Pro­tective Factors for COVID-19 Morbidity, Severity, and Mortality. Clinical reviews in allergy & im­munology. 2023;64(1):90-107. doi: https://doi.org/10.1007/s12016-022-08921-5
9. Salazar M, Barochiner J, Espeche W, Ennis I. [COVID-19 and its relationship with hypertension and cardiovascular disease]. Hipertension y riesgo vascular. 2020;37(4):176-80. Spanish. doi: https://doi.org/10.1016/j.hipert.2020.06.003
10. Tashchuk V, Nesterovska R, Kalarash V. [Rela­tionship between hospital mortality and inflammatory markers in patients with COVID-19 and coronary heart disease]. Bukovinian Medical Bulletin. 2021;25(3):118-23. Ukrainian.
    doi: https://doi.org/10.24061/2413-0737.XXV.3.99.2021.18
11. Aras Júnior R, Durães A, Roever L, Macedo C, Aras MG, Nascimento L, et al. The Impact of COVID-19 on the Cardiovascular System. Revista da Associacao Medica Brasileira. 2021;67(Supp l):163-7. doi: https://doi.org/10.1590/1806-9282.67.Suppl1.20201063
12. Hryzhak I, Pryshliak O, Kobryn T, et al. Clinical and echocardiographic findings in patients with COVID-19 across different severity levels. Journal of Medicine and Life. 2023;16(11):1692-700. doi: https://doi.org/10.25122/jml-2023-0206
13. Singh AK, Khunti K. COVID-19 and Diabetes. Annual reviewof  2022;73:129-47. doi: https://doi.org/10.1146/annurev-med-042220-011857
14. Bondar MV, Pilipenko MM, Ovsiienko TV, Los­kutov OA. Pathogenetic therapy of COVID-19: focus on glucocorticoids. Emergency medicine. 2022;18(2):6-12. doi: https://doi.org/10.22141/2224-0586.18.2.2022.1466
15. Tylishchak Z, Pryshlyak O, Skrypnyk N, et al. COVID-19 in patients with type 2 diabetes: Clinical and laboratory characteristics. Romanian Journal of Diabetes, Nutrition, and Metabolic Diseases. 2023;30(1):9-15. doi: https://doi.org/10.46389/rjd-2023-1224
16. Bondarenko AM, Kopcha VS. [Reflections on therapeutic and preventive options for COVID-19]. Infec­tious 2020;2:100. Ukrainian. doi: https://doi.org/10.11603/1681-2727.2020.2.11286
17. Heidari-Beni F, Vahedian-Azimi A, Shojaei S, Rahimi-Bashar F, Shahriary A, Johnston TP, et al. The Level of Procalcitonin in Severe COVID-19 Patients: A Systematic Review and Meta-Analysis. Advances in experimental medicine and biology. 2021;1321:277-86. doi: https://doi.org/10.1007/978-3-030-59261-5_25
18. Keski H. Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19. Indian J Hematol Blood Transfus. 2021;37:534-42. doi: https://doi.org/10.1007/s12288-021-01407-y
19. Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe COVID-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436. doi: https://doi.org/10.1136/bmj.n436
20. Ivanytska TA, Petrov YE, Burmak YG, Iva­nyts­kyi IV, Trybrat TA. [Changes in thrombotic and inflam­matory markers as indicators of disease severity and prognosis in COVID-19 patients with comorbid essential hypertension]. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2022;7(3):127-33. Ukrainian. Available from: https://repository.pdmu.edu.ua/server/api/core/bitstreams/8564bf79-512b-42c6-8964-e6268e8b5549/content
21. Tazerji SS, Shahabinejad F, Tokasi M, Rad MA, Khan MS, Safdar M, et al. Global data analysis and risk factors associated with morbidity and mortality of COVID-19. Gene Rep. 2022 Mar;26:101505. doi: https://doi.org/10.1016/j.genrep.2022.101505

Look through:

Moskaliuk V.D. Bukovyna State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0001-6206-1210

Pudyak Kh.I. Bukovyna State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0002-0157-1433

Balaniuk I.V. Bukovyna State Medical University, Chernivtsi, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-1146-4065

Dubik L.V. Bukovyna State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0001-8307-1733

Chernetskaya N.V. Bukovyna State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0002-5156-1313

Melenko S.R. Bukovyna State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0003-4920-5843

Moskaliuk V.D., Pudyak Kh.I., Balaniuk I.V., Dubik L.V., Chernetskaya N.V., Melenko S.R. Changes in some indicators of hemostasis and inflammatory markers in patients with COVID-19. Medicni perspektivi. 2025;30(3):59-67.
doi: https://doi.org/10.26641/2307-0404.2025.3.340589

Conections between platelets amino acids profile and known cardiometabolic risk factors in patients with coronary artery disease and atrial fibrillation

More and more preclinical and clinical studies indicate the crucial role of oxidative stress in the pathogenesis of skin diseases. This became the basis for the analysis of current literature data on oxidative stress and antioxidant protection in the skin in the norm and dermatological diseases, as well as on the antioxidants use to manage this pathology.The aim of the study was to review the current literature on oxidative stress and antioxidant protection in the skin and to analyze the possibilities of using antioxidants in skin diseases. The search for literature sources for 2005-2025 was carried out in the biometric search engine PubMed using the terms: “oxidative stress”, “antioxidant”, “skin”, “skin disease”, “topical treatment”, “α-toco­pherol”, “ascorbic acid”, “polyphenol”, “quercetin”, “coenzyme Q10”, “resveratrol”, “N-acetylcysteine”, as well as word combinations based on them. The inclusion criteria were: a document in English; publication in the period 2005-2025; compliance with search queries; availability of the article full text. The exclusion criteria were: a case from practice; conference proceedings; a publication that does not meet the purpose of the review; lack of full text, reflection of skin manifestations of a systemic disease or infection. The maximum number of literature sources was found for the query “oxidative stress – antioxidant – skin” (n=3076). After systematizing the selected documents using bibliographic and analytical methods, 115 of the most relevant sources remained. It was shown that the suppliers of reactive oxygen species (ROS) in the skin are processes that occur in keratinocytes, fibroblasts, and hematogenous cells. Many antioxidants eliminate ROS in the skin, they act together with superoxide dismutase, catalase, glutathione peroxidase and non-enzymatic antioxidants. Disruption of the balance between ROS and the power of antioxidant protection, i.e. oxidative stress, accompanies contact dermatitis, urticaria, atopic dermatitis, psoriasis, malignant skin tumors, photoaging, and vitiligo. The contribution of key natural antioxidants (ascorbic acid, α-tocopherol, retinoids, coenzyme Q10, resveratrol, selenium, and polyphenols) to skin care has been described, but there was only a small number of evidence-based studies that would justify the dosage and indications for their use in dermatology. Synthetic antioxidants are represented by almost one N-acetylcysteine in the treatment of toxic epidermal necrolysis, drug hypersensitivity syndrome, ichthyosis, contact and atopic dermatitis and some other diseases. The topical use of antioxidants is complicated by the search for an adequate dosage form, in which the stabilization of a substance with antioxidant properties is crucial, as well as its absorption, the ability to reach the target tissue in an active form and remain there for a long enough time, which is solved by the use of new methods of drug delivery, in particular based on nanotechnology. Thus, changes in the redox balance are widely represented in dermatoses, and the use of antioxidants can be of great importance if they are prescribed rationally. Obviously, it is advisable to combine antioxidants with each other and to introduce synthetic antioxidants more widely into practice..

Key words: oxidative stress, antioxidant, skin, disease, treatment

1. KhanAQ, Agha MV, Sheikhan KSAM, Younis SM, Tamimi MA, Alam M, et  Targeting deregulated oxidative stress in skin inflammatory diseases: An update on clinical importance. Biomed Pharmacother. 2022 Oct;154:113601. doi: https://doi.org/10.1016/j.biopha.2022.113601
2. MartemucciG, Portincasa P, Centonze V, Maria­no M, Khalil M, D'Alessandro  Prevention of Oxi­dative Stress and Diseases by Antioxidant Supplemen­tation. Med Chem. 2023;19(6):509-37. doi: https://doi.org/10.2174/1573406419666221130162512 
3. KrukJ, Duchnik  Oxidative stress and skin diseases: possible role of physical activity. Asian Pac J Cancer Prev. 2014;15(2):561-8. doi: https://doi.org/10.7314/apjcp.2014.15.2.561
4. Addor Antioxidants in dermatology. An Bras Dermatol. 2017 May-Jun;92(3):356-62. doi: https://doi.org/10.1590/abd1806-4841.20175697
5. PaiVV, Shukla P, Kikkeri  Antioxidants in der­matology. Indian Dermatol Online J. 2014 Apr;5(2):210-4. doi: https://doi.org/10.4103/2229-5178.131127
6. ChenJ, Liu Y, Zhao Z, Qiu  Oxidative stress in the skin: Impact and related protection. Int J Cosmet Sci. 2021 Oct;43(5):495-509. doi: https://doi.org/10.1111/ics.12728
7. FeniniG, Contassot E, French  Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treat­ment of Inflammatory Skin Diseases. Front Phar­macol. 2017 May 22;8:278. doi: https://doi.org/10.3389/fphar.2017.00278
8. Md Jaffri Reactive Oxygen Species and Antioxidant System in Selected Skin Disorders. Malays J Med Sci. 2023 Feb;30(1):7-20. doi: https://doi.org/10.21315/mjms2023.30.1.2
9. White PubMed 2.0. Medical Reference Services Quarterly. 2020;39(4):382-7. doi: https://doi.org/10.1080/02763869.2020.1826228
10. NakaiK, Tsuruta  What Are Reactive Oxygen Species, Free Radicals, and Oxidative Stress in Skin Diseases? Int J Mol Sci. 2021 Oct 6;22(19):10799. doi: https://doi.org/10.3390/ijms221910799
11. BelambriSA, Rolas L, Raad H, Hurtado-Ne­delec M, Dang PM, El-Benna  NADPH oxidase acti­vation in neutrophils: Role of the phosphorylation of its subunits. Eur J Clin Invest. 2018;48(Suppl 2):e12951. doi: https://doi.org/10.1111/eci.12951
12. MoghadamZM, Henneke P, Kolter  From Flies to Men: ROS and the NADPH Oxidase in Phagocytes. Front Cell Dev Biol. 2021;9:628991. doi: https://doi.org/10.3389/fcell.2021.628991
13. Manea NADPH oxidase-derived reactive oxygen species: Involvement in vascular physiology and pathology. Cell Tissue Res. 2010;342:325-39. doi: https://doi.org/10.1007/s00441-010-1060-y
14. SteinbrennerH, Ramos MC, Stuhlmann D, Mi­tic D, Sies H, Brenneisen  Tumor promoter TPA stimulates MMP-9 secretion from human keratinocytes by activation of superoxide-producing NADPH oxidase. Free Radic Res. 2005;39:245-53. doi: https://doi.org/10.1080/10715760500053487
15. PapparellaI, Ceolotto G, Lenzini L, Mazzoni M, Franco L, Sartori M, et al. Angiotensin II-induced over-activation of p47phox in fibroblasts from hypertensives: Which role in the enhanced ERK1/2 responsiveness to angiotensin II? J  2005;23:793-800. doi: https://doi.org/10.1097/01.hjh.0000163148.97459.9d
16. RudolfJ, Raad H, Taieb A, Rezvani  NADPH Oxidases and Their Roles in Skin Homeostasis and Carcinogenesis. Antioxid Redox Signal. 2018;28:1238-61. doi: https://doi.org/10.1089/ars.2017.7282
17. NakaiK, Yoneda K, Moriue T, Igarashi J, Ko­saka H, Kubota  HB-EGF-induced VEGF production and eNOS activation depend on both PI3 kinase and MAP kinase in HaCaT cells. J Dermatol Sci. 2009;55:170-8. doi: https://doi.org/10.1016/j.jdermsci.2009.06.002
18. NakaiK, Karita S, Igarashi J, Tsukamoto I, Hi­rano K, Kubota  CoA-Cl prevented TGF-β1-induced CTGF expression by Akt dephosphorylation in normal human dermal fibroblasts, and it attenuated skin fibrosis in mice models of systemic sclerosis. J Dermatol Sci. 2019;94:205-12. doi: https://doi.org/10.1016/j.jdermsci.2019.02.003
19. NandiA, Yan LJ, Jana CK, Das  Role of Cata­lase in Oxidative Stress- and Age-Associated Degenerative Diseases. Oxid Med Cell Longev. 2019;2019:9613090. doi: https://doi.org/10.1155/2019/9613090
20. ZhengM, Liu Y, Zhang G, Yang Z, Xu W, Chen  The Applications and Mechanisms of Superoxide Dismutase in Medicine, Food, and Cosmetics. Anti­oxidants (Basel). 2023 Aug 27;12(9):1675. doi: https://doi.org/10.3390/antiox12091675
21. Case A. On the origin of superoxide dismutase: an evolutionary perspective of superoxide-mediated redox signaling. Antioxidants.2017;6(4):82. doi: https://doi.org/10.3390/antiox6040082
22. Nocchi S, Björklund S, Svensson B, Engblom J, Ruzgas T. Electrochemical monitoring of native catalase activity in skin using skin covered oxygen electrode. Biosens 2017;93:9-13. doi: https://doi.org/10.1016/j.bios.2017.01.001
23. Sharma G, Shin E-J, Sharma N, Nah S-Y, Mai HN, Nguyen BT, et al. Glutathione peroxidase-1 and neuromodulation: novel potentials of an old enzyme. Food Chem 2021;148:111945. doi: https://doi.org/10.1016/j.fct.2020.111945
24. Al-Roujayee AS. Naringenin improves the healing process of thermally-induced skin damage in rats. J Int Med 2017;45(2):570-82. doi: https://doi.org/10.1177/0300060517692483
25. Sandmann G. Antioxidant protection from UV- and light-stress related to carotenoid structures. Anti­oxidants.2019;8:219. doi: https://doi.org/10.3390/antiox8070219
26. Coetzee V, Perrett DI. Effect of beta-carotene supplementation on African skin. J Biomed Opt. 2014;19(2):025004. doi: https://doi.org/10.1117/1.jbo.19.2.025004
27. Shafe MO, Gumede NM, Nyakudya TT, Chivan­di E. Lycopene: A Potent Antioxidant with Multiple Health Benefits. JNutr  2024 Jun 8;2024:6252426. doi: https://doi.org/10.1155/2024/6252426 
28. Obana A, Gohto Y, Nakazawa R, Moriyama T, Gellermann W, Bernstein PS. Effect of an antioxidant supplement containing high dose lutein and zeaxanthin on macular pigment and skin carotenoid levels. Sci Rep. 2020;10:10262.
    doi: https://doi.org/10.1038/s41598-020-66962-2
29. Pullar JM, Carr AC, Vissers MCM. The roles of vitamin C in skin health. Nutrients. 2017;9:866. doi: https://doi.org/10.3390/nu9080866
30. Wang K, Jiang H, Li W, Qiang M, Dong T, Li H. Role of vitamin C in skin diseases. Front Physiol. 2018;9:819. doi: https://doi.org/10.3389/fphys.2018.00819
31. Traber MG, Stevens JF. Vitamins C and E: bene­ficial effects from a mechanistic perspective. Free Radic Biol Med. 2011;51(5):1000-13. doi: https://doi.org/10.1016/j.freeradbiomed.2011.05.017
32. Mehling R, Schwenck J, Lemberg C, Traut­wein C, Zizmare L, Kramer D, et al. Immunomodulatory role of reactive oxygen species and nitrogen species during T cell-driven neutrophil-enriched acute and chronic cutaneous delayed-type hypersensitivity reactions. Theranostics. 2021;11:470-90. doi: https://doi.org/10.7150/thno.51462
33. Esser PR, Wölfle U, Dürr C, von Loewenich FD, Schempp CM, Freudenberg MA, et al. Contact sensitizers induce skin inflammation via ROS production and hyaluronic acid degradation. PloS One. 2012;7(7):e41340. doi: https://doi.org/10.1371/journal.pone.0041340
34. Cannavò SP, Riso G, Di Salvo E, Casciaro M, Giuffrida R, Minciullo PL, et al. Oxidative stress involve­ment in urticaria. J Biol Regul Homeost Agents. 2020 Mar-Apr;34(2):675-8. doi: https://doi.org/10.23812/19-483-12-L
35. Kalkan G, Seçkin HY, Duygu F, Akbaş A, Ozyurt H, Sahin M. Oxidative stress status in patients with acute urticaria. Cutan Ocul Toxicol. 2014 Jun;33(2):109-14. doi: https://doi.org/10.3109/15569527.2013.808658
36. Kasperska-Zajac A, Brzoza Z, Polaniak R, Roga­la B, Birkner E. Markers of antioxidant defence system and lipid peroxidation in peripheral blood of female patients with chronic idiopathic urticaria. Arch Dermatol Res. 2007;298:499-503.
    doi: https://doi.org/10.1007/s00403-006-0724-7
37. Nettis E, Distaso M, Saitta S, Casciaro M, Cris­tani M, Saija A, et al. Involvement of new oxidative stress markers in chronic spontaneous urticaria. Postepy Dermatol Alergol. 2017 Oct;34(5):448-52. doi: https://doi.org/10.5114/ada.2017.71110
38. Nakai K, Yoneda K, Maeda R, Munehiro A, Fujita N, Yokoi I, et al. Urinary biomarker of oxidative stress in patients with psoriasis vulgaris and atopic dermatitis. J Eur Acad Dermatol Venereol. 2009;23:1405-8. doi: https://doi.org/10.1111/j.1468-3083.2009.03327.x
39. Sivaranjani N, Rao SV, Rajeev G. Role of reactive oxygen species and antioxidants in atopic dermatitis. J Clin Diagn Res. 2013 Dec;7(12):2683-5. doi: https://doi.org/10.7860/JCDR/2013/6635.3732
40. Nakai K, Yoneda K, Murakami Y, Koura A, Maeda R, Tamai A, et al. Effects of Topical N-Ace­tylcysteine on Skin Hydration/Transepidermal Water Loss in Healthy Volunteers and Atopic Dermatitis Patients. Ann Dermatol. 2015;27:450-1. doi: https://doi.org/10.5021/ad.2015.27.4.450
41. Bertino L, Guarneri F, Cannavò SP, Casciaro M, Pioggia G, Gangemi S. Oxidative Stress and Atopic Der­matitis. Antioxidants. 2020;9(3):196. doi: https://doi.org/10.3390/antiox9030196
42. Dobrică EC, Cozma MA, Găman MA, Voicu­lescu VM, Găman AM. The Involvement of Oxidative Stress in Psoriasis: A Systematic Review. Antioxidants (Basel). 2022 Jan 29;11(2):282. doi: https://doi.org/10.3390/antiox11020282
43. Pleńkowska J, Gabig-Cimińska M, Mozolewski P. Oxidative Stress as an Important Contributor to the Patho­genesis of Psoriasis. Int J Mol Sci. 2020 Aug 27;21(17):6206. doi: https://doi.org/10.3390/ijms21176206
44. Wroński A, Wójcik P. Impact of ROS-Dependent Lipid Metabolism on Psoriasis Pathophysiology. Int J Mol Sci. 2022 Oct 12;23(20):12137. doi: https://doi.org/10.3390/ijms232012137
45. Xian D, Lai R, Song J, Xiong X, Zhong J. Emer­ging Perspective: Role of Increased ROS and Redox Imbalance in Skin Carcinogenesis. Oxid Med Cell Longev. 2019 Sep 16;2019:8127362. doi: https://doi.org/10.1155/2019/8127362
46. Azzimonti B, Ballacchino C, Zanetta P, Cuc­ci MA, Monge C, Grattarola M, et al. Microbiota, Oxida­tive Stress, and Skin Cancer: An Unexpected Triangle. Antioxidants (Basel). 2023 Feb 21;12(3):546. doi: https://doi.org/10.3390/antiox12030546
47. Emanuelli M, Sartini D, Molinelli E, Campag­na R, Pozzi V, Salvolini E, et al. The Double-Edged Sword of Oxidative Stress in Skin Damage and Melanoma: From Physiopathology to Therapeutical Approaches. Antioxi­dants (Basel). 2022 Mar 23;11(4):612. doi: https://doi.org/10.3390/antiox11040612
48. Lingappan K. NF-κB in oxidative stress. Current opinion in toxicology. 2018;7:81-6. doi: https://doi.org/10.1016/j.cotox.2017.11.002
49. Farias CF, Massaoka MH, Girola N, et al. Ben­zofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo. BMC Cancer.2015;15(1):807. doi: https://doi.org/10.1186/s12885-015-1835-3
50. Papaccio F, Arino DA, Caputo S, Bellei B. Focus on the Contribution of Oxidative Stress in Skin Aging. Antioxidants(Basel). 2022 Jun 6;11(6):1121. doi: https://doi.org/10.3390/antiox11061121
51. Shin SH, Lee YH, Rho NK, Park KY. Skin aging from mechanisms to interventions: focusing on dermal  aging. Front Physiol. 2023 May 10;14:1195272. doi: https://doi.org/10.3389/fphys.2023.1195272
52. Shin MH, Rhie GE, Kim YK, Park CH, Cho KH, Kim KH, et al. H₂O₂ accumulation by catalase reduction changes MAP kinase signaling in aged human skin in vivo. J Investig Dermatol. 2005;125:221-9. doi: https://doi.org/10.1111/j.0022-202X.2005.23823.x
53. Rinnerthaler M, Bischof J, Streubel MK, Trost A, Richter K. Oxidative stress in aging human skin. Bio­molecules.2015 Apr 21;5(2):545-89. doi: https://doi.org/10.3390/biom5020545
54. MohaniaD, Chandel S, Kumar P, Verma V, Dig­vijay K, Tripathi D, et  Ultraviolet Radiations: Skin Defen­se-Damage Mechanism. Adv Exp Med Biol. 2017;996:71-87. doi: https://doi.org/10.1007/978-3-319-56017-5_7
55. Gromkowska-Kępka KJ, Puścion-Jakubik A, Mar­kiewicz-Żukowska R, Socha K. The impact of ultraviolet radiation on skin photoaging – review of in vitro studies. J Cosmet Dermatol. 2021 Nov;20(11):3427-31. doi: https://doi.org/10.1111/jocd.14033
56. de Jager TL, Cockrell AE, Du Plessis SS. Ultra­violet Light Induced Generation of Reactive Oxygen Species. Adv Exp Med Biol. 2017;996:15-23. doi: https://doi.org/10.1007/978-3-319-56017-5_2
57. Bang E, Kim DH, Chung HY. Protease-activated receptor 2 induces ROS-mediated inflammation through Akt-mediated NF-kappaB and FoxO6 modulation during skin photoaging. Redox Biol. 2021;44:102022. doi: https://doi.org/10.1016/j.redox.2021.102022
58. Solano F. Photoprotection and Skin Pigmen­tation: Melanin-Related Molecules and Some Other New Agents Obtained from Natural Sources. Molecules. 2020 Mar 27;25(7):1537. doi: https://doi.org/10.3390/molecules25071537
59. Xuan Y, Yang Y, Xiang L, Zhang C. The Role of Oxidative Stress in the Pathogenesis of Vitiligo: A Culprit for Melanocyte Death. Oxid Med Cell Longev. 2022 Jan 22;2022:8498472. doi: https://doi.org/10.1155/2022/8498472
60. Shah AA, Sinha AA. Oxidative stress and autoim­mune skin disease. Eur J Dermatol. 2013 Jan-Feb;23(1):5-13. doi: https://doi.org/10.1684/ejd.2012.1884
61. Motor S, Ozturk S, Ozcan O, Gurpinar AB, Can Y, Yuksel R, et al. Evaluation of total antioxidant status, total oxidant status and oxidative stress index in patients with alopecia areata. Int J ClinExp Med. 2014;7:1089-93. PMCID: PMC4057866. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4057866/
62. Acharya P, Mathur MC. Oxidative stress in alopecia areata: A systematic review and meta-analysis. Int J 2020;59:434-40. doi: https://doi.org/10.1111/ijd.14753 
63. Alzolibani Preferential recognition of hyd­roxyl radical-modified superoxide dismutase by circulating autoantibodies in patients with alopecia areata. Ann Dermatol. 2014;26:576-83. doi: https://doi.org/10.5021/ad.2014.26.5.576 
64. SorgH, Tilkorn DJ, Hager S, Hauser J, Mirast­schijski  Skin Wound Healing: An Update on the Current Knowledge and Concepts. Eur Surg Res. 2017;58(1-2):81-94. doi: https://doi.org/10.1159/000454919 
65. KolimiP, Narala S, Nyavanandi D, Yous­sef AAA, Dudhipala  Innovative treatment strategies to accelerate wound healing: trajectory and recent advan­cements. Cells. 2022 Aug 6;11(15):2439. doi: https://doi.org/10.3390/cells11152439
66. TottoliEM, Dorati R, Genta I, Chiesa E, Pisani S, Conti  Skin wound healing process and new emerging technologies for skin wound care and regeneration. Pharmaceutics. 2020 Aug 5;12(8):735. doi: https://doi.org/10.3390/pharmaceutics12080735
67. Bowers S, Franco E. Chronic Wounds: Evaluation and Management. Am Fam Physician. 2020 Feb 1;101(3):159-66. PMID: 32003952.Available from: https://pubmed.ncbi.nlm.nih.gov/32003952/
68. BilgenF, Ural A, Kurutas EB, Bekerecioglu  The effect of oxidative stress and Raftlin levels on wound healing. Int Wound J. 2019 Oct;16(5):1178-84. doi: https://doi.org/10.1111/iwj.13177
69. KampferH, Pfeilschifter J, Frank  Expression and activity of arginase isoenzymes during normal and diabetes-impaired skin repair. J Investig Dermatol. 2003;121:1544-51. doi: https://doi.org/10.1046/j.1523-1747.2003.12610.x
70. PaprockiJ, Pawłowska M, Sutkowy P, Pie­chocki J, Woźniak  Evaluation of Oxidative Stress in Patients with Difficult-to-Heal Skin Wounds Treated with Hyperbaric Oxygen. Oxid Med Cell Longev. 2020 Jul 31;2020:1835352. doi: https://doi.org/10.1155/2020/1835352
71. GeorgescuSR, Mitran CI, Mitran MI, Nicolae I, Matei C, Ene CD, et  Oxidative Stress in Cutaneous Lichen Planus-A Narrative Review. J Clin Med. 2021;10:2692. doi: https://doi.org/10.3390/jcm10122692
72. Sredoja TismaV, Bulimbasic S, Galesic Ljuba­novic D, Galesic K, Morovic-Vergles J, Mitrovic J, et  The Onset of Systemic Oxidative Stress Associated with the Accumulation of Lipid Peroxidation Product Acrolein in the Skin of Patients with Small-Vessel Vasculitis. Molecules. 2021;26:2344. doi: https://doi.org/10.3390/molecules26082344
73. BergqvistC, Safi R, El Hasbani G, Abbas O, Kibbi A, Nassar  Neutrophil Extracellular Traps are Present in Immune-complex-mediated Cutaneous Small Vessel Vasculitis and Correlate with the Production of Reactive Oxygen Species and the Severity of Vessel Damage. Acta Derm Venereol. 2020;100:adv00281. doi: https://doi.org/10.2340/00015555-3363
74. EmreS, Metin A, Demirseren DD, Akoglu G, Oz­tekin A, Neselioglu S, et  The association of oxidative stress and disease activity in seborrheic dermatitis. Arch Dermatol Res. 2012;304:683-7. doi: https://doi.org/10.1007/s00403-012-1254-0
75. SeçkinHY, Kalkan G, Bas Y, Akbas A, Önder Y, Özyurt H, et  Oxidative stress status in patients with melasma. Cutan Ocul Toxicol. 2014;33:212-7.doi: https://doi.org/10.3109/15569527.2013.834496
76. Hughes MCB, Williams GM, Pageon H, Four­tanier A, Green AC. Dietary Antioxidant Capacity and Skin Photoaging: A 15-Year Longitudinal Study. J Invest Dermatol. 2021 Apr;141(4S):1111-8.e2. doi: https://doi.org/10.1016/j.jid.2020.06.026
77. Kumar V, Tanwar N, Goel M, Khan M, Kumar D, Singh G, et al. Antioxidants for Skin Health. Recent Adv Food Nutr Agric. 2024 Aug 6. Epub ahead of print. doi: https://doi.org/10.2174/012772574X311177240710100118
78. Boo YC. Ascorbic Acid (Vitamin C) as a Cos­meceutical to Increase Dermal Collagen for Skin Antiaging Purposes: Emerging Combination Therapies. Antioxidants (Basel). 2022 Aug 26;11(9):1663. doi: https://doi.org/10.3390/antiox11091663
79. Keen MA, Hassan I. Vitamin E in dermatology. Indian Dermatol Online J. 2016 Jul-Aug;7(4):311-5. doi: https://doi.org/10.4103/2229-5178.185494
80. Pincemail J, Meziane S. On the Potential Role of the Antioxidant Couple Vitamin E/Selenium Taken by the Oral Route in Skin and Hair Health. Antioxidants. 2022;11(11):2270. doi: https://doi.org/10.3390/antiox11112270
81. Teo CWL, Tay SHY, Tey HL, Ung YW, Yap WN. Vitamin E in Atopic Dermatitis: From Preclinical to Clinical Studies. Dermatology. 2021;237(4):553-64. doi: https://doi.org/10.1159/000510653
82. Lain ET, Agrawal N, Ruvolo E, Weise JM, Cal­lender VD. The Role of Coenzyme Q10 in Skin Aging and Opportunities for Topical Intervention: A Review. J Clin Aesthet Dermatol. 2024 Aug;17(8):50-5. PMCID: PMC11324190. Available from: https://pubmed.ncbi.nlm.nih.gov/39148958/
83. Knott A, Achterberg V, Smuda C, Mielke H, Sper­ling G, Dunckelmann K, et al. Topical treatment with coenzyme Q10-containing formulas improves skin's Q10 level and provides antioxidative effects. Biofactors. 2015 Nov-Dec;41(6):383-90. doi: https://doi.org/10.1002/biof.1239
84. Žmitek K, Žmitek J, Rogl Butina M, Pogačnik T. Effects of a Combination of Water-Soluble Coenzyme Q10 and Collagen on Skin Parameters and Condition: Results of a Randomised, Placebo-Controlled, Double-Blind Study. Nutrients. 2020 Feb 27;12(3):618. doi: https://doi.org/10.3390/nu12030618
85. Tessema EN, Bosse K, Wohlrab J, Mrestani Y, Neubert RHH. Investigation of ex vivo Skin Penetration of Coenzyme Q10 from Microemulsions and Hydrophilic Cream. Skin Pharmacol Physiol. 2020;33(6):293-9. doi: https://doi.org/10.1159/000511443
86. Ayunin Q, Miatmoko A, Soeratri W, Erawati T, Susanto J, Legowo D. Improving the anti-ageing activity of coenzyme Q10 through protransfersome-loaded emul­gel. Sci Rep. 2022 Jan 18;12(1):906. doi: https://doi.org/10.1038/s41598-021-04708-4
87. Ma EZ, Khachemoune A. Flavonoids and their therapeutic applications in skin diseases. Arch Dermatol Res. 2023Apr;315(3):321-31. doi: https://doi.org/10.1007/s00403-022-02395-3
88. Kostenko V, Akimov O, Gutnik O, Kostenko H, Romantseva T, et al. Modulation of redox-sensitive trans­cription factors with polyphenols as pathogenetically grounded approach in therapy of systemic inflammatory response. Heliyon. 2023 Apr 16;9(5):e15551. doi: https://doi.org/10.1016/j.heliyon.2023.e15551
89. Sun M, Deng Y, Cao X, Xiao L, Ding Q, Luo F, et al. Effects of Natural Polyphenols on Skin and Hair Health: A Review. Molecules. 2022 Nov 14;27(22):7832. doi: https://doi.org/10.3390/molecules27227832
90. Tuong W, Walker L, Sivamani RK. Polyphenols as novel treatment options for dermatological diseases: A systematic review of clinical trials. J Dermatolog Treat. 2015;26(4):381-8. doi: https://doi.org/10.3109/09546634.2014.991675
91. Di Salvo E, Gangemi S, Genovese C, Cicero N, Cas­ciaro M. Polyphenols from Mediterranean Plants: Biological Activities for Skin Photoprotection in Atopic Dermatitis, Psoriasis, and Chronic Urticaria. Plants (Basel). 2023 Oct 15;12(20):3579. doi: https://doi.org/10.3390/plants12203579
92. Duarte MS, Fuhro VM, de Souza Nogueira J, Romana-Souza B. Polyphenol hydroxytyrosol present olive oil improves skin wound healing of diabetic mice. Wound Repair Regen. 2024 Nov-Dec;32(6):904-15. doi: https://doi.org/10.1111/wrr.13217
93. Zhang Y, Heinemann N, Rademacher F, Dar­vin ME, Raab C, Keck CM, et al. Skin Care Product Rich in Antioxidants and Anti-Inflammatory Natural Com­pounds Reduces Itching and Inflammation in the Skin of Atopic Dermatitis Patients. Antioxidants (Basel). 2022 May 28;11(6):1071. doi: https://doi.org/10.3390/antiox11061071
94. Yavtushenko IV, Nazarenko SM, Katrushov OV, Kostenko VO. Quercetin limits the progression of oxi­dative and nitrosative stress in the rats' tissues after experimental traumatic brain injury. Wiad Lek. 2020;73(10):2127-32. doi: https://doi.org/10.36740/WLek202010104
95. Zaborowski MK, Długosz A, Błaszak B, Szulc J, Leis K. The Role of Quercetin as a Plant-Derived Bioactive Agent in Preventive Medicine and Treatment in Skin Disorders. Molecules. 2024 Jul 5;29(13):3206. doi: https://doi.org/10.3390/molecules2933206
96. Beken B, Serttas R, Yazicioglu M, Turkekul K, Erdogan S. Quercetin Improves Inflammation, Oxidative Stress, and Impaired Wound Healing in Atopic Dermatitis Model of Human Keratinocytes. Pediatr Allergy Immunol Pulmonol. 2020 Jun;33(2):69-79. doi: https://doi.org/10.1089/ped.2019.1137
97. Shin EJ, Lee JS, Hong S, Lim TG, Byun S. Quer­cetin Directly Targets JAK2 and PKCδ and Prevents UV-Induced Photoaging in Human Skin. Int J Mol Sci. 2019 Oct 23;20(21):5262. doi: https://doi.org/10.3390/ijms20215262
98. Lim HJ, Kang SH, Song YJ, Jeon YD, Jin JS. Inhibitory Effect of Quercetin on Propionibacterium acnes-induced Skin Inflammation. Int Immunopharmacol. 2021 Jul;96:107557. doi: https://doi.org/10.1016/j.intimp.2021.107557
99. Hatahet T, Morille M, Hommoss A, Devois­selle JM, Müller RH, Bégu S. Quercetin topical appli­cation, from conventional dosage forms to nanodosage forms. Eur J Pharm Biopharm. 2016 Nov;108:41-53. doi: https://doi.org/10.1016/j.ejpb.2016.08.011
100. Chekalina NI, Kazakov YM, Mamontova TV, Ves­nina LE, Kaidashev IP. Resveratrol more effectively than quercetin reduces endothelium degeneration and level of necrosis factor α in patients with coronary artery disease. Wiad Lek. 2016;69(3 pt 2):475-9. PMID: 28478409. Available from: https://pubmed.ncbi.nlm.nih.gov/28478409/
101. Frenkel Y, Cherno V, Kostenko H, Chopra H, Gautam RK, Kostenko V. Dietary Supplementation with Resveratrol Attenuates Serum Melatonin Level, Pro-Inflammatory Response and Metabolic Disorder in Rats Fed High-Fructose High-Lipid Diet under Round-the-Clock Lighting. Pathophysiology. 2023 Feb 19;30(1):37-47. doi: https://doi.org/10.3390/pathophysiology30010005
102. de Brito Oliveira AL, Monteiro VVS, Navegantes-Lima KC, Reis JF, de Souza Gomes R, Rodrigues DVS, et al. Resveratrol role in autoimmune disease – A mini-review. Nutrients. 2017;9:1306. doi: https://doi.org/10.3390/nu9121306
103. Lin MH, Hung CF, Sung HC, Yang SC, Yu HP, Fang JY. The bioactivities of resveratrol and its naturally occurring derivatives on skin. J Food Drug Anal. 2021;29:15-38. doi: https://doi.org/10.38212/2224-6614.1151
104. Marko M, Pawliczak R. Resveratrol and Its Deri­vatives in Inflammatory Skin Disorders-Atopic Derma­titis and Psoriasis: A Review. Antioxidants (Basel). 2023 Nov 2;12(11):1954. doi: https://doi.org/10.3390/antiox12111954
105. Adil M, Amin SS, Mohtashim M. N-acetylcys­teine in dermatology. Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):652-9. doi: https://doi.org/10.4103/ijdvl.IJDVL_33_18
106. Janeczek M, Moy L, Riopelle A, Vetter O, Reser­va J, Tung R, et al. The Potential Uses of N-acetylcysteine in Dermatology: A Review. J Clin Aesthet Dermatol. 2019 May;12(5):20-6. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6561714/
107. Stachura A, Sobczak M, Kędra K, Kopka M, Kop­ka K, Włodarski PK. The Influence of N-Acetylcysteine-Enriched Hydrogels on Wound Healing in a Murine Model of Type II Diabetes Mellitus. Int J Mol Sci. 2024 Sep 16;25(18):9986. doi: https://doi.org/10.3390/ijms25189986
108. Padalhin A, Abueva C, Ryu HS, Yoo SH, SeoHH, ParkSY, et  Impact of Thermo-Responsive N-Acety­lcysteine Hydrogel on Dermal Wound Healing and Oral Ulcer Regeneration. Int J Mol Sci. 2024 Apr 29;25(9):4835. doi: https://doi.org/10.3390/ijms25094835
109. JędrejkoK, CatlinO, Stewart T, Muszyńska  Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes and consideration of their potential as performance enhancing drugs. Drug Test Anal. 2024 Dec;16(12):1436-67. doi: https://doi.org/10.1002/dta.3655
110. GuptaDS, Bagwe ParabS, Kaur  Promising effects of emoxypine and its succinate derivative in the management of various diseases – with insights on recent patent applications. Curr Res Pharmacol Drug Discov. 2022 Aug 1;3:100121. doi: https://doi.org/10.1016/j.crphar.2022.100121
111. LokesK, Kiptilyi A, Skikevych M, Steblovskyi D, Lychman V, Bilokon S, et al. Microbiological substan­tiation of the effectiveness of quercitin and its combination with ethylmethylhydroxypyridine succinate in the complex treatment of odontogenic phlegmon and maxillofacial abscesses. Front Oral Health. 2024 Jan 19;5:1338258. doi: https://doi.org/10.3389/froh.2024.1338258
112. Vazhnichaya E, Baliuk O, Sydorenko A. Systemic Effect of the Antioxidant Gel in Experimental Derma­tologic Pathology. EC Pharmacology and Toxicology. 2024;12(12):01-09. Available from: https://ecronicon.net/assets/ecpt/pdf/ECPT-12-00863.pdf
113. Ji H, Li XK. Oxidative Stress in Atopic Dermatitis. Oxid Med Cell Longev. 2016;2016:2721469. doi: https://doi.org/10.1155/2016/2721469
114. LinX, Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res. 2016 Jun;50(6):585-95. doi: https://doi.org/10.3109/10715762.2016.1162301
115. Guarneri F, Bertino L, Pioggia G, Casciaro M, Gan­gemi S. Therapies with Antioxidant Potential in Psoriasis, Viti­ligo, and Lichen Planus. Antioxidants (Basel). 2021;10(7):1087. doi: https://doi.org/10.3390/antiox10071087

Look through:

Vazhnichaya E.M. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-2515-7963

Baliuk O.Ye. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-3260-6317

Deviatkina N.M. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-0137-2124

Vlasenko N.O. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-2159-5229

Kovalev S.V. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-3529-0146

Bobrova N.O. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-1071-5697

Vazhnichaya E.M., Baliuk O.Ye., Deviatkina N.M., Vlasenko N.O., Kovalev S.V., Bobrova N.O. Oxidative stress in skin diseases and the role of antioxidants in their treatment. Medicni perspektivi. 2025;30(3):68-81.
doi: https://doi.org/10.26641/2307-0404.2025.3.340594

Association between glycosylated hemoglobin and newly diagnosed hypertension in a non-diabetic kosovar population: a cross-sectional analysis

Currently, chronic obstructive pulmonary disease (COPD) is considered a systemic disease with multiple extrapulmonary effects, which is caused by systemic manifestations of the inflammatory process. On the other hand, obesity, oxidative stress, chronic hyperglycemia, and insulin resistance, inherent in type 2 diabetes mellitus (DM), are key factors for enhancing the body's inflammatory response. Our study aimed to review the existing scientific literature to determine the patterns, relationships, and pathogenetic relationships between type 2 diabetes mellitus and chronic obstructive pulmonary disease. The empirical research method of modern English-language medical literature was used in depth from 2003 to 2024, using search engines on the PubMed and Google Scholar platforms and the Scopus and Web of Science abstract scientific literature databases, and the Cochrane scientific library. Based on the search results, 59 information sources were selected and processed.The analysis used system-structural, formal-logical, bibliographic, and informal (traditional) methods. The authors designed their own figures to visually present information using the infographic methods based on the Miro web resource (miro.com). It has been shown that patients with type 2 diabetes mellitus have an increased risk of developing COPD due to active systemic inflammation, obesity, insulin resistance, and oxidative stress. In addition, hyperglycemia contributes to decreased lung functional parameters and airway remodeling. Adipose tissue plays a vital role in the pathogenesis of COPD and type 2 diabetes mellitus by producing adipokines, such as leptin, resistin, adiponectin, and omentin. An imbalance between pro- and anti-inflammatory adipokines contributes to chronic inflammation, leading to lung function deterioration. Oxidative stress caused by chronic hyperglycemia is an essential factor in the pathogenesis of COPD. Reactive oxygen species (ROS) activate signaling pathways that lead to chronic inflammation and damage to lung tissue. Chronic hyperglycemia affects the function of bronchial smooth muscles, causing its hyperreactivity and excessive proliferation, which can worsen the course of COPD. Thus, COPD and type 2 diabetes are closely interconnected at the level of pathogenetic mechanisms, and the presence of one of these diseases may contribute to the development and progression of the other. Further studies of these relationships may contribute to developing more effective approaches to diagnosing, treating, and prevention of given pathologies.

Key words: chronic obstructive pulmonary disease, type 2 diabetes, obesity, pathogenesis, immune homeostasis

1. Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Resp Crit Care Med. 2022;206(11):1317-25. doi: https://doi.org/10.1164/rccm.202204-0671PP
2. Di Stefano A, Gnemmi I, Dossena F, Ricciar­dolo FL, Maniscalco M, Lo Bello F, et al. Pathogenesis of COPD at the cellular and molecular level. Minerva Medica. 2022 Jun;113(3):405-23. doi: https://doi.org/10.23736/S0026-4806.22.07927-7
3. MacNee W. ABC of chronic obstructive pulmo­nary disease. Pathology, pathogenesis, and pathophy­siology. BMJ. 2006;332:1202-4. doi: https://doi.org/10.1136/bmj.332.7551.1202
4. Lange P, Ahmed E, Lahmar ZM, Martinez FJ, Bourdin A. Natural history and mechanisms of COPD. Respirology. 2021;26:298-321. doi: https://doi.org/10.1111/resp.14007
5. Chen X-R, Wang D-X. Serum MCP-1 and NGAL are important in the acute inflammatory event of chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2021;18:425-31. doi: https://doi.org/10.1080/15412555.2021.1954151
6. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. Journal of Clinical Investigation.2008;118:3546-56. doi: https://doi.org/10.1172/jci36130
7. Cornwell W, Kim V, Song C, Rogers T. Patho­genesis of inflammation and repair in advanced COPD. Seminars in Respiratory and Critical Care Medicine. 2010;31:257-66.
   doi: https://doi.org/10.1055/s-0030-1254066
8. Xu J, Zeng Q, Li S, Su Q, Fan H. Inflammation mechanism and research progress of COPD. Frontiers in Immunology.2024 Aug 9;15:1404615. doi: https://doi.org/10.3389/fimmu.2024.1404615
9. Agustí AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic ob­structive pulmonary disease. European Respiratory Journal.2003;21:347-60. doi: https://doi.org/10.1183/09031936.03.00405703
10. Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: a chronic low-grade inflammation and its markers. Cureus. 2022 Feb 28;14(2):e22711. doi: https://doi.org/10.7759/cureus.22711
11. González P, Lozano P, Ros G, Solano F. Hyper­glycemia and oxidative stress: an integral, updated and critical overview of their metabolic interconnections. International Journal of Molecular Sciences. 2023;24(11):9352. doi: https://doi.org/10.3390/ijms24119352
12. Liu J, Han X, Zhang T, Tian K, Li Z, Luo F. Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy. Journal of Hematology & Oncology. 2023 Nov 30;16(1):116. doi: https://doi.org/10.1186/s13045-023-01512-7
13. Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus – an overview. International Journal of Molecular Sciences. 2024;25:1882. doi: https://doi.org/10.3390/ijms25031882
14. Antomonov MY. [Mathematical processing and analysis of medical and biological data]. Kyiv; 2018. 579 p. Ukrainian.
15. Damania D, Hameed S, Eng A, Douen A, Kha­nijao S, Sajawal Q, et al. Role of diabetes in exacerbation of COPD. Chest. 2021;160:A1888. doi: https://doi.org/10.1016/j.chest.2021.07.1678
16. SuJ, Li M, Wan X, Yu H, Wan Y, Hang D, et  Associations of diabetes, prediabetes and diabetes duration with the risk of chronic obstructive pulmonary disease: a prospective UK Biobank study. Diabetes, Obesity and Metabolism. 2023;25:2575-85. doi: https://doi.org/10.1111/dom.15142
17. ChiuHT, Li TC, Li CI, Liu CS, Lin WY, Lin  Visit-to-visit glycemic variability is a strong predictor of chronic obstructive pulmonary disease in patients with type 2 diabetes mellitus: competing risk analysis using a national cohort from the Taiwan diabetes study. PLOS ONE. 2017;12:e0177184. doi: https://doi.org/10.1371/journal.pone.0177184
18. ChenG, Lin Q, Zhuo D, Cui  Elevated blood glucose is associated with severe exacerbation of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2022;17:2453-59. doi: https://doi.org/10.2147/copd.s378259
19. AgarwalA, Grover A, Agarwal  Pulmonary function test in patients of type 2 diabetes mellitus. International Journal of Research in Medical Sciences. 2019;7:2240.
    doi: https://doi.org/10.18203/2320-6012.ijrms20192505
20. SharmaA, Sharma A, Chauhan  Spirometric lung functions in type 2 diabetes mellitus: a hospital-based study. Cureus. 2023 May 12;15(5):e38919. doi: https://doi.org/10.7759/cureus.38919
21. VaishnavBT, Gangani SK, Anand S, Ruchitha P, Mondkar  Comparative study of spirometry parameters in chronic smokers with and without type 2 diabetes mellitus (T2DM). Journal of Family Medicine and Primary Care. 2024;13:2921-26. doi: https://doi.org/10.4103/jfmpc.jfmpc_1770_23
22. Chernetska [Features of the combined course of chronic obstructive pulmonary disease and type 2 diabetes mellitus]. Klinichna ta eksperymentalna patolohiia. 2020;19:138-43. doi: https://doi.org/10.24061/1727-4338. XІX.3.73.2020.19
23. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Martín-Rodríguez A, Martínez-Guardado I, Navarro-Jiménez E, et al. The role of adipokines in health and disease. Biomedicines. 2023;11:1290. doi: https://doi.org/10.3390/biomedicines11051290
24. Taylor The complex role of adipokines in obesity, inflammation, and autoimmunity. Clinical Science. 2021;135(6):731-52. doi: https://doi.org/10.1042/CS20200895
25. ZhangJ, Lu E, Deng L, Zhu Y, Lu X, Li X, et  Immunological roles for resistin and related adipokines in obesity-associated tumors. International Immunopharma­cology. 2024;142:112911. doi: https://doi.org/10.1016/j.intimp.2024.112911
26. IacobazziD, Convertini P, Todisco S, Santar­siero A, Iacobazzi V, Infantino  New insights into NF-κB signaling in innate immunity: focus on immuno­metabolic crosstalks. Biology. 2023;12:776. doi: https://doi.org/10.3390/biology12060776
27. ChoiHM, Doss HM, Kim KS. Multifaceted phy­siological roles of adiponectin in inflammation and diseases. International Journal of Molecular Sciences. 2020;21:1219. doi: https://doi.org/10.3390/ijms21041219
28. Ramos-Ramírez P, Malmhäll C, Tliba O, Rådin­ger M, Bossios A. Adiponectin/AdipoR1 axis promotes IL-10 release by human regulatory T cells. Frontiers in Immunology.2021 May 18;12:677550. doi: https://doi.org/10.3389/fimmu.2021.677550
29. Salvator H, Grassin-Delyle S, Brollo M, Cou­derc L-J, Abrial C, Victoni T, et al. Adiponectin inhibits the production of TNF-α, IL-6 and chemokines by human lung macrophages. Frontiers in Pharmacology. 2021;12:718929. doi: https://doi.org/10.3389/fphar.2021.718929
30. Sena CM. Omentin: a key player in glucose homeostasis, atheroprotection, and anti-inflammatory potential for cardiovascular health in obesity and diabetes. Biomedicines.2024;12:284. doi: https://doi.org/10.3390/biomedicines12020284
31. Kocot J, Dziemidok P, Kiełczykowska M, Hor­dyjewska A, Szcześniak G, Musik I. Adipokine profile in patients with type 2 diabetes depends on degree of obesity. Medical Science Monitor. 2017;23:4995-5004. doi: https://doi.org/10.12659/msm.904318
32. Abudalo R, Alqudah A, Qnais E, Athamneh RY, Oqal M, Alnajjar R. Interplay of adiponectin and resistin in type 2 diabetes: Implications for insulin resistance and atherosclerosis. Pharmacia/Farmaciâ. 2024;71:1-8. doi: https://doi.org/10.3897/pharmacia.71.e114863
33. Cheung KKT, Luk AOY, So WY, Ma RCW, Kong APS, Chow FCC, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. Journal of Diabetes Investigation.2014;6:112-23. doi: https://doi.org/10.1111/jdi.12288
34. Laghari M, Murtaza S, Talpur Z, Memon KA, Tehzeen A, Hamid M. Serum testosterone level in type 2 diabetes mellitus. Journal of Pharmaceutical Research International. 2021;33:517-22. doi: https://doi.org/10.9734/jpri/2021/v33i44b32703
35. Gangwar SK, Verma SK, Modi S. Frequency and correlates of hypogonadism in adult males with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism. 2021;25:320-5. doi: https://doi.org/10.4103/ijem.ijem_239_21
36. Khalil SHA, Dandona P, Osman NA, Assaad RS, Zaitoon BTA, Almas AA, et al. Diabetes surpasses obesity as a risk factor for low serum testosterone level. Diabetol Metab  2024 Jun 28;16(1):143. doi: https://doi.org/10.1186/s13098-024-01373-1
37. Wang X, Huang L, Jiang S, Cheng K, Wang D, Luo Q, et al. Testosterone attenuates pulmonary epithelial inflammation in male rats of COPD model through preventing NRF1-derived NF-κB signaling. Journal of Molecular Cell Biology. 2021;13:128-40. doi: https://doi.org/10.1093/jmcb/mjaa079
38. Traish A, Bolanos J, Nair S, Saad F, Morgen­taler A. Do androgens modulate the pathophysiological pathways of inflammation? Appraising the contemporary evidence. Journal of Clinical Medicine. 2018;7:549. doi: https://doi.org/10.3390/jcm7120549
39. Grandys M, Majerczak J, Zapart-Bukowska J, Duda K, Kulpa JK, Zoladz JA. Lowered serum testos­terone concentration is associated with enhanced inflam­mation and worsened lipid profile in men. Frontiers in Endocrinology.2021 Sep 9;12:735638. doi: https://doi.org/10.3389/fendo.2021.735638
40. Barnes PJ. Oxidative stress in chronic obstructive pulmonary disease. Antioxidants.2022;11:965. doi: https://doi.org/10.3390/antiox11050965
41. Aschner Y, Downey GP. Transforming growth factor-β: master regulator of the respiratory system in health and disease. American Journal of Respiratory Cell and Molecular Biology. 2016;54:647-55. doi: https://doi.org/10.1165/rcmb.2015-0391tr
42. Kraik K, Tota M, Laska J, Łacwik J, Paździerz Ł, Sędek Ł, et al. The role of transforming growth factor-β (TGF-β) in asthma and chronic obstructive pulmonary disease (COPD). Cells. 2024;13:1271. doi: https://doi.org/10.3390/cells13151271
43. Chung J, Huda MN, Shin Y, Han S, Akter S, Kang I, et al. Correlation between oxidative stress and transforming growth factor-beta in cancers. International Journal of Molecular Sciences. 2021;22:13181. doi: https://doi.org/10.3390/ijms222413181
44. Cazzola M, Calzetta L, Rogliani P, Lauro D, No­velli L, Page CP, et al. High glucose enhances respon­siveness of human airways smooth muscle via the Rho/ROCK pathway. American Journal of Respiratory Cell and Molecular Biology. 2012;47:509-16. doi: https://doi.org/10.1165/rcmb.2011-0449oc
45. Dekkers BGJ, Saad SI, van Spelde LJ, Bur­gess JK. Basement membranes in obstructive pulmonary diseases. Matrix Biology Plus. 2021;12:100092. doi: https://doi.org/10.1016/j.mbplus.2021.100092
46. Cao Z, Liu Y, Wang Y, Leng P. Research progress on the role of PDGF/PDGFR in type 2 diabetes. Biomedicine & Pharmacotherapy. 2023;164:114983. doi: https://doi.org/10.1016/j.biopha.2023.114983
47. Kardas G, Daszyńska-Kardas A, Marynowski M, Brząkalska O, Kuna P, Panek M. Role of platelet-derived growth factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharma­cological target. Frontiers in Pharmacology. 2020;11:47. doi: https://doi.org/10.3389/fphar.2020.00047
48. Mao QY, He SY, Hu QY, Lu Y, Niu YX, Li XY, et al. Advanced Glycation End Products (AGEs) Inhibit Macrophage Efferocytosis of Apoptotic β Cells through Binding to the Receptor for AGEs. J Immunol. 2022 Mar 1;208(5):1204-13. doi: https://doi.org/10.4049/jimmunol.2100695
49. Kapellos TS, Conlon TM, Yildirim AÖ, Leh­mann M. The impact of the immune system on lung injury and regeneration in COPD. Eur Respir J. 2023;62(4):2300589. doi: https://doi.org/10.1183/13993003.00589-2023
50. Pertseva NO, Chub DI. [Endothelial function factors as markers of progression of diabetic kidney disease]. Medychni perspektyvy. 2018;23(2, part 1):110. Ukrainian.
51. Poto R, Loffredo S, Palestra F, Marone G, Pa­tella V, Varricchi G. Angiogenesis, lymphangiogenesis, and inflammation in chronic obstructive pulmonary disease (COPD): few certainties and many outstanding questions. Cells.2022;11:1720. doi: https://doi.org/10.3390/cells11101720
52. Sun X, Zhang H, Liu J, Wang G. Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus. Journal of International Medical Research. 2019;47:5584-92. doi: https://doi.org/10.1177/0300060519872033
53. Kurniawan LB, Rika Andriany, Yuyun Wida­ningsih, Esa T, Uleng Bahrun, Adnan E, et al. Glycemic control as the main determinant factor of serum VEGF levels in type 2 diabetes mellitus patients. Romanian Journal of Internal Medicine. 2023;61:135-40. doi: https://doi.org/10.2478/rjim-2023-0009
54. Lourenço JD, Ito JT, Martins MA, Tibério IFLC, Lopes FDTQDS. Th17/Treg imbalance in chronic obstructive pulmonary disease: clinical and experimen­tal evidence. Front Immunol. 2021 Dec 9;12:804919. doi: https://doi.org/10.3389/fimmu.2021.804919
55. Ostedgaard LS, et al. Gel-forming mucins form distinct morphologic structures in airways. Proc Natl Acad Sci USA. 2017 Jun 27;114(26):6842-7. doi: https://doi.org/10.1073/pnas.1703228114
56. Li J, Ye Z. The Potential Role and Regulatory Me­chanisms of MUC5AC in Chronic Obstructive Pulmonary Disease. Molecules.2020;25:4437. doi: https://doi.org/10.3390/molecules25194437
57. Song JS, Kang CM, Yoo MB, Kim SJ, Yoon HK, Kim YK, et al. Nitric oxide induces MUC5AC mucin in respiratory epithelial cells through PKC and ERK dependent pathways. Respir Res. 2007 Mar 29;8(1):28. doi: https://doi.org/10.1186/1465-9921-8-28
58. WangC, Wang H, Dai L, Zhang J, Fang L, Liu L, et al. T-Helper 17 cell/regulatory T-Cell imbalance in COPD combined with T2DM patients. International Journal of Chronic Obstructive Pulmonary Disease. 2021;16:1425-35. doi: https://doi.org/10.2147/copd.s306406
59. Zhang S, Gang X, Yang S, Cui M, Sun L, Li Z, et al. The alterations in and the role of the Th17/Treg balance in metabolic diseases. Front Immunol. 2021 Jul 12;12:678355. doi: https://doi.org/10.3389/fimmu.2021.678355

Look through:

Sanina N.A. Dnipro State Medical University, Dnipro, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-6603-0219

Sutyrin D.O. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0009-0009-1058-5237

Turlyun T.S. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0001-5208-9121

Sanina N.A., Sutyrin D.O., Turlyun T.S. Current understanding of the pathogenetic relationships between chronic obstructive pulmonary disease and type 2 diabetes mellitus: an integrative review. Medicni perspektivi. 2025;30(3):81-91.
doi: https://doi.org/10.26641/2307-0404.2025.3.340743

Predicting the dynamics of heart rate variability in patients with type 1 diabetes against improving glycemic control

Hereditary motor-sensory neuropathies (HMSN) are a large group of genetically heterogeneous diseases of the peripheral nerves, characterized by symptoms of progressive polyneuropathy with a predominant lesion of the muscles of the distal parts of extremities. The progressive course of the disease and the lack of effective etiological therapy lead to early disability of patients and significantly reduce the level of their quality of life due to significant limitations in gait and self-care. The study of the relationship between neurophysiological indicators, anamnestic data and clinical and neurological characteristics of patients with HMSN type 1A is important for understanding the pathophysiology of clinical polymorphism, as well as factors affecting the severity and rate of progression of the disease. The aim of the work was to determine clinical and instrumental criteria for predicting the severity of HMSN type 1A. The study included 153 patients with HMSN type 1A. During the study, a comprehensive approach was applied using clinical and anamnestic, clinical and neurological, clinical and genealogical, and electroneuromyographic methods. Conducting a comprehensive assessment of testing data using the following diagnostic scales and questionnaire: "Neuropathy Impairment Score (NIS)", "Neuropathy Disability Score (NDS)", "Medical Research Council Weakness Scale Sum Score (MRC-SS)", "Overall Disability Sum Score (ODSS)", "Bartel's Daily Activity Scale (Bartel Index)", and the "Functional Walking Categories" test allowed us to objectify the criteria for determining the severity of HMSN type 1A and improve the quality of diagnosis of functional disorders due to this pathology. The majority of the examined patients, namely 41.2%, were aged from 36 to 60 years at the time of examination. Early clinical debut of the disease (up to 20 years) in the examined was observed in 65.4% of cases; the average age of clinical debut of the disease was 19.3 years. In the vast majority of patients, namely 43.8%, the duration of the period of clinical manifestation of the disease was more than 10 years. The electroneurophysiological pattern in the vast majority of the examined patients was characteristic of diffuse demyelination and axonal loss of varying degrees; a gross decrease in the SPI was determined in the motor nerves, mainly of the lower extremities. According to the Spearman rank correlation coefficient, a correlation between the amplitude of the M-response and the age of the disease debut, as well as between the amplitude of the M-response and the age at the time of examination; and was absent a high degree of negative correlation between the amplitude of the M-response and the duration of the period of clinical manifestation of the disease was determined. Analysis of the obtained research results allowed us to determine the following clinical, anamnestic and instrumental criteria for the prognosis of the course of HMSN type 1A: 1) low M-response amplitudes from the beginning of clinical debut are a prognostic criterion for an unfavorable prognosis with a severe clinical course and a rapid rate of progression; 2) late clinical debut (after 20 years) is a prognostic criterion for a rapid rate of disease progression; 3) a decrease in M-response amplitudes is a prognostic criterion for the progression of the pathological process and indicates an aggravation of the severity of the disease before the appearance of clinical signs.

Key words: hereditary motor-sensory neuropathy type 1A, clinical and anamnestic characteristics, electroneuromyographic examination, severity of the disease, prognosis criteria

1. Dohrn MF, Saporta M. Hereditary motor neuro­pathies. Current opinion in neurology. 2020;33(5):568-74. doi:https://doi.org/10.1097/WCO.0000000000000848
2. Ma M, Li Y, Dai S, Chu M, Sun L, Liu L, et al. A meta-analysis on the preva lence of Charcot–Marie–Tooth disease and related inherited peripheral neuropathies. J Neurol.2023;270(5):2468-82. doi: https://doi.org/10.1007/ s00415-023-11559-8
3. Finsterer J, Löscher WN, Wanschitz J, Iglseder S. Orphan peripheral neu ropathies. J Neuromuscul Dis. 2021;8(1):1-23. doi: https://doi.org/10.3233/ JND-200518
4. Cortese A, Wilcox JE, Polke JM, et al. Targeted next‐generation sequencing panels in the diagnosis of Char­cot‐Marie‐Tooth disease. Neurology. 2020;94(1):e51‐e61. doi: https://doi.org/10.1212/WNL.0000000000008672
5. Ionasescu VV. Charcot-Marie-Tooth neuro­pa­thies: from clinical description to molecular genetics. Muscle 1995;18:267-75. doi: https://doi.org/10.1002/mus.880180302
6. Higuchi Y, Takashima H. Clinical genetics of Char­cot–Marie–Tooth disease. J Hum Genet. 2023;68(3):199-214. doi: https://doi.org/10.1038/ s10038-022-01031-2
7. Masingue M, Fernández-Eulate G, Debs R, Tard C, Labeyrie C, Leonard-Louis S, et al. Strategy for genetic analysis in hereditary neuropathy. Rev Neurol. 2023;179(1-2):10-29. doi: https://doi.org/10.1016/j.neurol.2022.11.007
8. Visser HJ, Wolfe J, Kouri R, Aviles R. Neurologic conditions associated with cavus foot deformity. Clin PodiatrMed  2021;38(3):323-42. doi: https://doi.org/10.1016/j.cpm.2021.03.001
9. Al-Khlaiwi T, Meo I, Butt MA, Khan A. Electro­physiological and radiological diagnosis of hereditary motor and sensory polyneuropathy. J Family Med Prim Care.2024 Jun;13(6):2511-5. doi: https://doi.org/10.4103/jfmpc.jfmpc_1513_23
10. Hovbakh IO. [Analysis of electroneuro­myogra­phic indicators in patients with hereditary motor-sensory neuropathy type 1A]. Zdobutky klinichnoi ekspery­mentalnoi medytsyny. 2023;1:83-9. Ukrainian. doi: https://doi.org/10.11603/1811-2471.2023.v.i1.13652
11. Lehmann HC, Wunderlich G, Fink GR, Som­mer C. Diagnosis of peripheral neuropathy. Neurological researchand  2020;2:20. doi: https://doi.org/10.1186/s42466-020-00064-2
12. Lupo V, Sancho P, Espinós C. Factors affecting Neurodevelopment. In: Hereditary motor neuropathies and overlapping Elsevier; 2021. p. 3-14. doi: https://doi.org/10.1016/B978-0-12-817986-4.00001-8
13. Sokolova LI, Cherenko TM, Illiash TI, Dovbo­nos TA, Melnyk VS. [Methods of examining a neuro­logical patient: a training manual]. Kyiv: VSV «Medy­tsyna»; 144 p. Ukrainian. Available from: http://ir.librarynmu.com/handle/123456789/13659
14. Sidelkovskyi OL, Ovsiannikov OA, Marusi­chen­ko VV, Savchuk MM. [Diagnostic scales and tests in neurology, neurosurgery and neurorehabilitation]. Kyiv: Pablish Pro; 2022. 294 p. Ukrainian.
15. Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: clinical-electrophysiologic-ul­trasound correlation. Philadelphia, PA: Elsevier; 2020. 780 p. ISBN: 9780323661805
16. Yusevych YuS. [Essays on clinical electro­myo­graphy]. Moskva: Medytsyna; 1972. Russian.
17. Ryzhov OA, Penkin YuM. [Statistical methods for analyzing the results of medical and biological research: an initial methodological guide]. Lviv: Mahnoliia 2006; 2022. 160 р. Ukrainian.
18. Hovbakh IO. [Clinical and neurological cha­rac­teristics of spasmodic sensorimotor neuropathy type 1A]. Psychiatry, Neurology and Medical Psychology. 2020;14:40-50. doi: https://doi.org/10.26565/2312-5675-2020-14-05
19. Martin PB, Hicks AN, Holbrook SE, Cox GA. Overlapping spectrums: the clini cogenetic com­mo­nalities between Charcot-Marie-Tooth and other neuro­de generative diseases. Brain Res. 2020;1727:146532. doi: https://doi.org/10.1016/j. brainres.2019.146532
20. Cavallaro T, Tagliapietra M, Fabrizi GM, Bai Y, Shy ME, Vallat JM. Hereditary neuropathies: a patholo­gical perspective. J Peripher Nerv Syst. 2021 Nov;26(Suppl 2):S42-S60. doi: https://doi.org/10.1111/jns.12467

Look through:

Govbakh I.O. Kharkiv National Medical University, Kharkiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-5951-9806

Grechanina O.Ya. Kharkiv National Medical University; Municipal non-profit enterprise of the Kharkiv Regional Council «Interregional Specialized Medical and Genetic Center – Center for Rare (Orphan) Diseases», Kharkiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-8196-1617

Tsogoeva L.M. Kharkiv National Medical University, Kharkiv, Ukraine
https://orcid.org/0009-0002-0513-2718

Molodan L.V. Kharkiv National Medical University; Municipal non-profit enterprise of the Kharkiv Regional Council «Interregional Specialized Medical and Genetic Center – Center for Rare (Orphan) Diseases», Kharkiv, Ukraine
https://orcid.org/0000-0002-0564-090X

Govbakh I.O., Grechanina O.Ya., Tsogoeva L.M., Molodan L.V. Clinical and instrumental criteria for the prognosis of the course of hereditary motor-sensory neuropathy type 1A. Medicni perspektivi. 2025;30(3):92-104.
doi: https://doi.org/10.26641/2307-0404.2025.3.340747

Side effects and hypersensitivity reactions to corticosteroids

The purpose of the study is a historical analysis of the Dnipro School of Dermatove­nereology through the prism of the philosophy of science, identification of key periods of its formation and development, main achievements, and the role of leaders in the formation of the scientific school for further improvement of teaching methodology and scientific research. Materials and methods of the study – general scientific, special and interdisciplinary methods based on the principles of historicism, scientificity and objectivity in the coverage of events which formed the methodological basis of the study. General scientific methods such as synthesis, analysis, induction and deduction were used to define the object and subject, the purpose, and conclusions were formulated. Descriptive statistics allowed us to process the data to ensure accuracy and relevance to the problem under study. The article highlights the “life path” of the Department of Skin and Venereal Diseases of Dnipro State Medical University from the moment of creation and formation of the scientific school to the “modern life of the department”. The authors try to strictly adhere to the principle of historicism, events and facts are considered in chronological order, taking into account the peculiarities of the circumstances and the flow of historical time for the development of education and science. The methodological basis of the study is based on the following: scientific and objective approach to the sequence of historical events and their impact on the present, using a set of general scientific methods with an interdisciplinary approach. The authors draw attention to the formation of medical science as a complex process and the importance of the discipline “History of Medicine” in covering the events of this process, the impact on medical students and the transformation in the field of medical research. In the historical development of the department, four periods were identified, which were compared with the areas of art, given that the word “Medicine” (Latin medicina) comes from the phrase “ars medicina” – the art of treatment, healing: The period of “medical ‘abstractionism’; The period of ‘medical modernism’; The period of ‘medical revival’; The period of ‘medical constructivism’. It was found that the historical development of the department follows the philosophical laws of the development of science by T. Kuhn and I. Lakatos. For the first time, the department was defined in terms of philosophy and its driving force in both formal and informal terms. The criteria and conditions for the creation of scientific schools are proved, and it is also proved that the life cycle of a department is longer than that of scientific schools. The importance of a leader in the life of a department and a scientific school is emphasized. It is emphasized that the main components of a leader are: charisma, strategic thinking, the desire for self-development, active scientific activity, and that these components contribute to the formation of medical science, improvement of methodological work in the educational activities of scientists and, as a result, the formation of the scientific and medical elite of the state.

Key words: history of medicine, history of science, leader,department of skin and venereal diseases, personality, Dnipro State Medical University

1. Toinbi A. Dzh. [Studies in History. Vol. 1]. Kyiv: Osnovy; 1995. 614 p. Ukrainian. Available from: https://b.eruditor.link/file/1289820/
2. Myres JL. History – Karl Jaspers: Vom Ursprung und Ziel der Geschichte. Zürich: Artemis-Verlag; 1949. 360 p. Cloth. Class Rev [Internet]. 1951 [cited 2025 Jan 4];1(2):104-5. doi: https://doi.org/10.1017/s0009840x00174645
3. Kyselov M. [History and historical memory: sphe­res of intersection]. Мultiversum. Philosophical almanac. 2020;2(1):44-63. doi: https://doi.org/10.35423/2078-8142.2020.2.1.03
4. Gorodnia N. Global history, world history and glo­balization. Eur Hist Stud. 2019;14:58-72. doi: https://doi.org/10.17721/2524-048x.2019.14.58-72
5. Krupskyi OP, Stasiuk YM. Storytelling as a tool for forming and supporting organisational culture in medical institutions. Commun Commun Technol. 2023 Oct17;23:134-44. doi: https://doi.org/10.15421/292321
6. Alkov VA. [Methodological perspectives of the history of everyday life in Ukrainian historical and medical local history]. Stud Hist Philos Sci Technol. 2021;29(1):73-80. doi: https://doi.org/10.15421/272009
7. Robak І, Alkov V, Demochko H. History of medi­cal everyday as a projectional direction of historical and medical studies. Shidnoevropejskij zurnal vnutrisnoi ta simejnoi med. 2023;2023(1):23-7. doi: https://doi.org/10.15407/internalmed2023.01.023
8. Hudoshnyk O, Krupskyi OP. Science and comics: from popularization to the discipline of Comics Studies. HistSci  2022 Dec 16;12(2):210-30. doi: https://doi.org/10.32703/2415-7422-2022-12-2-210-230
9. Duma D, Wong L, O’Neill D, Kelly BD. Taking histories: joint working of disciplines in medical history scholarship. Ir J Med Sci. 2021 Nov;190(4):1533-5. doi: https://doi.org/10.1007/s11845-021-02511-8
10. Schicktanz S, Michl S, Stoff H. Bioethics and the argumentative legacy of atrocities in medical history: reflections on a complex relationship. Bio­ethics.2021 Jul;35(6):499-507. doi: https://doi.org/10.1111/bioe.12841
11. da Silva N, Augustin M, Langenbruch A, Mro­wietz U, Reich K, Thaçi D, et al. Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. Eur J Dermatol. 2020;30(3):267-78. doi: https://doi.org/10.1684/ejd.2020.3768
12. Leluțiu-Weinberger C, Filimon ML, Hoover D, Lixandru M, Hanu L, Dogaru B, et al. An mHealth Inter­vention for Gay and Bisexual Men’s Mental, Behavioral, and Sexual Health in a High-Stigma, Low-Resource Con­text (Project Comunică): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2024;13:e52853. doi: https://doi.org/10.2196/52853
13. Balachandran A. Documents, Digitisation and History. South Asia. 2022;45(2):339-49. doi: https://doi.org/10.1080/00856401.2022.2037301
14. Balachandran A. Documents, Digitisation and History. South Asia. 2022;45(2):339-49. doi: https://doi.org/10.1080/00856401.2022.2037301
15. Piret J, Boivin G. Pandemics Throughout History. Front Microbiol. 2021 Jan 15;11:631736. doi: https://doi.org/10.3389/fmicb.2020.631736
16. Martin CMB. Observations from the Korean War for Modern Military Medicine. Korean J Med Hist. 2023;32(3):787-828. doi: https://doi.org/10.13081/kjmh.2023.32.787
17. Vasiliyev KK. Story of the history of medicine in Ukraine: pre-Soviet, Soviet and post- Soviet periods (XIX – early XXI centuries). Shidnoevropejskij zurnal vnutrisnoi ta simejnoi med. 2019;2019(1):29-35. doi: https://doi.org/10.15407/internalmed2019.01.029
18. Deforzh H. The contribution of functional mor­phologists to the development of medicine (the end of the XIX – the beginning of the XX centuries). Hist Sci Technol.2018;7(11):161-8. doi: https://doi.org/10.32703/2415-7422-2017-7-11-161-168 
19. Shadrina O. Scientific works P.I. Gavsevich (1883-1920) and the state research on the culture of medicinal plants. Hist Sci Technol. 2018;8(1, 12):244-56. doi: https://doi.org/10.32703/2415-7422-2018-8-1(12)-244-256
20. Gamaliia V. Natalia Osadcha-Yanata (1891-1982): Pages of Biography. Hist Sci Technol. 2018;8(2, 13):436-45.
    doi: https://doi.org/10.32703/2415-7422-2018-8-2(13)-436-445
21. Wulff E. Army Forces and epidemic diseases: A travel through the XIXth century International Sanitary Conferences. Hist Sci Technol. 2020;10(1, 16):138-50. doi: https://doi.org/10.32703/2415-7422-2020-10-1(16)-138-150
22. Eramo S, Barraco G, Zampetti P. The forgotten contribution of J.E. Purkyně to dentistry. Hist Sci Technol. 2020;10(2):281-92.
    doi: https://doi.org/10.32703/2415-7422-2020-10-2-281-292
23. Sakkas H, Spyropoulou P. The legacy of Saint Luke (Valentin Felixovich Voyno-Yasenetsky) to medical sciences. HistSci  2021;11(1):68-83. doi: https://doi.org/10.32703/2415-7422-2021-11-1-68-83 
24. Petrushko M, Piniaiev V, Yurchuk T. The history of assisted reproductive technologies: from prohibition to recognition. Hist Sci Technol. 2021;11(2):315-28. doi: https://doi.org/10.32703/2415-7422-2021-11-2-315-328
25. Adu-Gyamfi S, Gyasi RM, Darkwa BD. Historici­zing medical drones in Africa: a focus on Ghana. Hist Sci Technol.2021;11(1):103-25. doi: https://doi.org/10.32703/2415-7422-2021-11-1-103-125 
26. Duplenko YK. Oleksandr Bogomolets and the activities of the Academy of Sciences of Ukraine in times of his presidency (1930-1946). Nauka ta naukoznavstvo. 2019;3:94-105. doi: https://doi.org/10.15407/sofs2019.03.094
27. Zerbino DD, Chaikovskyi YB, Chernii VI, Svia­tenko TV, Volos LI, Svystunov IV, et al. Professor V.G. Shlopov – an outstanding representative of domestic pathological anatomy (to the 80th birthday). Medicni perspektivi.2021;26(3):228-9. doi: https://doi.org/10.26641/2307-0404.2021.3.242346  
28. Bohomolets O. [Selected Works: Vol. 3]. Kyiv: AN URSR; 1958. 369 р. Ukrainian.
29. Dovidonytė R. Implementation of Open Science in Lithuania. Nord Perspect Open Sci. 2019;4:1-12. doi: https://doi.org/10.7557/11.4828
30. Schacht A. Fractures overseen: soviet medical ex­perts splitting from the international epistemic community during the interwar period. Eur Rev Hist. 2024;31(1):75-98. doi: https://doi.org/10.1080/13507486.2023.2296138 
31. Florensa C, Nieto-Galan A. Introduction: Science popularization, dictatorships, and democracies. Hist Sci. 2022;60(3):329-47. doi: https://doi.org/10.1177/00732753221091029
32. Dziak H, Pertseva T, Vasylieva T, Khamaziuk T. [The origins and traditions of the art of healing in the puzzles of world history: from antiquity to the Middle Ages.]. Dnipro: Herda; 2022. Ukrainian. Available from: https://repo.dma.dp.ua/7703/
33. Bezpalko B. The Formation of the Image of the “Eenemy” in Soviet School Textbooks of the Hu­manities Block (1930s): Based on the Materials of Kyiv Publications. Kyiv Hist Stud. 2023;17(2):120-6. doi: https://doi.org/10.28925/2524-0757.2023.215
34. Hrusheva T, Mozghova O. [Between social and socialist realism: the aesthetics of photography in the context of soviet propaganda (on the example of the photo club «Zaporizhya»)]. Zaporizhzhia historical review [In­ternet]. 2020 [cited 2025 Mar 27];2(54). Ukrainian. doi: https://doi.org/10.26661/zhv-2020-2-54-32
35. Sukhoruchko VV. [Soviet punitive psychiatry as a tool to fight the Ukrainian dissident movement (1960s-1970s)]. Sci Notes Taurida Natl V.I. Vernadsky Univ Ser Hist Sci. 2023;2:78-82. Ukrainian. doi: https://doi.org/10.32782/2663-5984/2023/2.12
36. Martyniv MA. [Ideological component of educa­tional activities of the Ternopil institute for improvement of teachers’ qualifications 1945-1950]. Sci Notes Taurida Natl V.I. Vernadsky Univ. Ser: Hist sci. 2023;2:63-70. Ukrainian.
    doi: https://doi.org/10.32782/2663-5984/2023/210
37. Stukan TM. [Youth policy: essence, basic prin­ciples and state of implementation in Ukraine]. Tavriiskyi nauko­vyi visnyk. Ser.: Ekonomika. 2020;4:125-31. Ukrainian. doi: https://doi.org/10.32851/2708-0366/2020.4.15
38. Lantukh I, Lantukh A. On the question of bu­siness entities personal reliability concept as a psycho­logical definition. Pedagog Innov. 2020;2:152-60. doi: https://doi.org/10.32405/2413-4139-2020-2(25)-152-160
39. Vorobiova O, Prokopenko V. Implementation of the technology of individual training as a condition of high-quality medical education. MOD Pedagog. 2023;1(4):70-5. doi: https://doi.org/10.33272/2522-9729-2023-4(211)-70-75
40. Striukov VV, Hromtseva OV. State regulation of health education: present, problems and solutions. Econ Horiz.2022;(4, 22):100-12. doi: https://doi.org/10.31499/2616-5236.4(22).2022.267023
41. Borysiuk I, Yaremkevych R, Sviatenko T, Striu­kov V, Krupskу O. El impacto de la pandemia de COVID-19 en la educación de los estudiantes de medicina. Apunt Univ.2023;13(1):164-89. doi: https://doi.org/10.17162/au.v13i1.1322
42. Zakharov SV, Rusakova OO, Smolianova OV. [Motivational and emotional aspects of choosing a doctor's profession by applicants to a medical institution of higher education]. Med osvita. 2023;1:35-41. Ukrainian. doi: https://doi.org/10.11603/m.2414-5998.2023.1.13564
43. Kryshinska TY, Sharun AV, Zakharov SV, Ste­panskyi DA. Enghlish-language educational models in medical university. Medicni perspektivi. 2022;27(3):50-5. doi: https://doi.org/10.26641/2307-0404.2022.3.265850
44. Ziehfreund S, Wecker H, Mittag S, Weis J, Ti­zek L, Verkhoturova V, et al. Happiness across the borders – A cross‐sectional study among patients with pso­riasis and atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2025 Mar;39(3):529-42. doi: https://doi.org/10.1111/jdv.20288   
45. Striukov VV, Grynko TV, Krupskyi OP, Va­zov RG. Current state and strategic directions of development of state management of nursing education in Ukraine. Medicni perspektivi. 2022;27(1):174-83. doi: https://doi.org/10.26641/2307-0404.2022.1.254469
46. Pincus JD. Leadership as a determinant of need fulfillment: implications for meta-theory, methods, and practice. Front Psychol. 2024 Jun 25;15:1427072. doi: https://doi.org/10.3389/fpsyg.2024.1427072
47. Ahmedov HH. Some Comments About the Cul­tural-Historical Scientific School. TPJ. 2022;4:32-6. http://com/index.php/tpj/article/view/45
48. Yotka V. [To the essence of the concept of "Scientific School"]. Res Notes. 2023;1:7-13. Ukrainian. doi: https://doi.org/10.31654/2663-4902-2023-pp-1-7-13

Look through:

Sviatenko T.V. Dnipro State Medical University, Dnipro, Ukraine
е-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-4303-2937

Zakharov V.K. Dnipro State Medical University, Dnipro, Ukraine

Zakharov S.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0002-2278-5692

Striukov V.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0002-5463-3124

Bashmakov D.H. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0002-0803-0920

Gorbuntsov V.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0001-7752-0993

Pohrebniak L.A. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0003-3458-9995

Akymova V.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0009-0001-6166-8464

Sviatenko T.V., Zakharov V.K., Zakharov S.V., Striukov V.V., Bashmakov D.H., Gorbuntsov V.V., Pohrebniak L.A., Akymova V.V. Evolution of professional identity: the Dnipro School of Dermatovenereology in the XX-XXI centuries. Medicni perspektivi. 2025;30(3):105-120.
doi: https://doi.org/10.26641/2307-0404.2025.3.340748

Microbiological profile and antimicrobial susceptibility of bacteria associated with urinary tract infections in Ukrainian adults

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is commonly used to manage type 2 diabetes mellitus (T2DM). Although generally considered safe, recent studies suggest a potential role of DPP-4 inhibitors in modulating immune responses, potentially leading to autoimmune conditions, including thyroid dysfunction. This case report aims to investigate the potential association between sitagliptin use and hyperthyroidism, emphasizing the significance of regular thyroid function monitoring in patients treated with DPP-4 inhibitors. A 54-year-old man with a history of hypertension and a family history of diabetes and hypothyroidism was initiated on sitagliptin and metformin for diabetes (HbA1c=8.1%) with normal thyroid function. Three months after initiating treatment, the patient noted weight loss and other initial symptoms of hyperthyroidism; however, nine months later, the patient developed full symptoms of hyperthyroidism, including significant weight loss, palpitations, tremors, and fatigue. Laboratory findings confirmed elevated total T3 (260 ng/dL) and total T4 (20 µg/dL) levels, suppressed TSH (<0.05 µIU/mL) levels, and increased anti-thyroid peroxidase (anti-TPO) antibodies (548 IU/mL). Although thyroid-stimulating hormone receptor antibody (TRAb) testing, ultrasonography, and scintigraphy were not performed, the temporal relationship between sitagliptin initiation and symptom onset, followed by resolution upon drug discontinuation, strongly suggests a probable association. Sitagliptin was discontinued, and Carbimazole was initiated, resulting in clinical and biochemical im­provement. The patient’s thyroid function normalized within six months, further supporting the association between sitagliptin and hyperthyroidism. Carbimazole was continued for 15-months resulting in Hb1Ac (6.6%), total T3 (140 ng/dL), total T4 (8.85 µg/dL), and TSH (1.81 µIU/mL) levels. Five months after discontinuation of Carbimazole, laboratory investigations revealed HbA1c (6.6%), fasting blood glucose (112.33 mg/dL), vitamin D (29.7 ng/mL), vitamin B12 (231 pg/mL), total T3 (151 ng/dL), total T4 (9.84 µg/dL), and TSH (1.18 µIU/mL) levels. In conclusion, this case suggests a potential association between sitagliptin and hyperthyroidism, possibly via immunomodulation. While routine thyroid function monitoring in patients on DPP-4 inhibitors may be considered, larger studies are needed to confirm this association.

Key words: sitagliptin, diabetes mellitus, hyperthyroidism, autoimmune thyroid disease, carbimazole

1. Mathew P, Kaur J, Rawla P. Hyperthyroidism. In: StatPearls. Treasure Island (FL): StatPearls Publishing [Internet]. 2023 [cited 2025 Feb 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537053/
2. Gallwitz B. Clinical Use of DPP-4 Inhibitors. Frontiers in Endocrinolog. 2019;10:389. doi: https://doi.org/10.3389/fendo.2019.00389
3. Ye J, Xu J, Wen W, Huang B. Effect of Lirag­lutide on Serum TSH Levels in Patients with NAFLD and its Under­lying Mechanisms. Int J Clin Pract. 2022;2022:1786559. doi: https://doi.org/10.1155/2022/1786559
4. Hu X, Wang X, Xue X. Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases. Molecules.2022 Jul 14;27(14):4498. doi: https://doi.org/10.3390/molecules27144498
5. Padron S, Rogers E, Demory Beckler M, Kessel­man M. DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. BMJ Case Rep. 2019;12(8):e228981. doi: https://doi.org/10.1136/bcr-2018-228981. Corrected and republished in: Drug Ther Bull. 2020 Jan;58(1):12-15. doi: https://doi.org/10.1136/dtb.2019.228981rep
6. Kridin K, Amber K, Khamaisi M, Comaneshter D, Batat E, Cohen AD. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study. Immunol Res. 2018;66(3):425-30. doi: https://doi.org/10.1007/s12026-018-9005-8
7. Uehara R, Okada J, Yamada E, Ozawa A, Na­kajima Y, Okada S, et al. Painless thyroiditis induced by the cessation of a dipeptidyl peptidase-4 inhibitor. Annals of 2018;3:31. doi: https://doi.org/10.21037/aot.2018.10.06
8. Cui X, Wang F, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy. Front 2023;14:1062045. doi: https://doi.org/10.3389/fimmu.2023.1062045
9. Sekizaki T, Kameda H, Nomoto H, Cho KY, Na­kamura A, Takahashi K, et al. Dipeptidyl peptidase‐4 inhi­bitor might exacerbate Graves’ disease: A multicenter observational case–control study. J Diabetes Investig. 2021;12(11):1978-82. doi: https://doi.org/10.1111/jdi.13578
10. Abrahami D, Douros A, Yin H, Yu OHY, Re­noux C, Bitton A, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population-based cohort study. BMJ.2018;360:k872. doi: https://doi.org/10.1136/bmj.k872
11. Apollo Pharmacy, India [Internet]. [cited 2025 Feb 12]. Available from: https://www.apollophar­macy.in/medicine/sitagliptin-m-50-mg-500-mg-tablet-15-s

Look through:

Almarshad Feras M. Shaqra University, College of Medicine, Shaqra, Saudi Arabia
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-9468-1489

Jamal Yusuf I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-8155-179X

Ram Dushad Shaqra University, College of Medicine, Shaqra, Saudi Arabia
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-4908-5407

Arif Jamal Shaqra University, College of Medicine, Shaqra, Saudi Arabia
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-9491-3390

Usman Kauser King George Medical University, Lucknow, Uttar Pradesh, India 
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-4989-9120

Almarshad Feras M., Jamal Yusuf, Ram Dushad, Arif Jamal, Usman Kauser Sitagliptin-induced hyperthyroidism: a case report. Medicni perspektivi. 2025;30(3):121-126.
doi: https://doi.org/10.26641/2307-0404.2025.3.340749

Results of surgical treatment of patients with acute destructive diverticulitis of the colon using minimally invasive technologies

Adverse events associated with the use of various diagnostic and therapeutic agents are becoming an increasingly urgent and social problem. Anaphylaxis during anesthesia is a rare but life-threatening complication. The incidence of anaphylaxis to cephalosporins according to US researchers was 8 cases per 487,630 cases of parenteral administration of drugs, while cefazolin was the most common cause of perioperative anaphylaxis. Antibiotic prophylaxis is widely used before surgery, but can lead to severe anaphylactic reactions, including anaphylactic shock. The aim of this article was to present a clinical case of anaphylaxis during anesthesia with a description of the symptoms, differential diagnosis and algorithm for providing emergency care, which will allow to deepen the awareness of practicing anesthesiologists about this rare but potentially fatal complication. We present a clinical case of a 32-year-old patient who was scheduled for arthroscopic knee surgery under spinal anesthesia. Upon admission to the operating room, the patient's condition was assessed as satisfactory. Antibiotic prophylaxis with 2 g of cefazolin was performed. After preloading with isotonic NaCl solution, the patient underwent unilateral spinal anesthesia, which was subsequently assessed as inadequate. As a result, it was necessary to supplement the anesthesia plan with an additional femoral nerve blockade. 5 minutes after the femoral nerve blockade, the patient developed a clinical picture of shock. Intensive therapy included the use of vasopressors (adrenaline) and infusion therapy. As a result of the therapy, the patient's condition was stabilized and he was discharged from the hospital after 24 hours of observation in the intensive care unit. During the case analysis, it was found that the patient had concealed an episode of a mild anaphylactic reaction to cefazolin in the past. Preventive measures should include the availability of detailed medical documentation of drug allergies, including anaphylaxis. Thus, anesthe­siologists should be familiar with the epidemiology, mechanisms of development, clinical cases and treatment of patients with anaphylaxis during anesthesia. The result of the study is a recommendation to practicing anesthesiologists to carefully approach the collection of allergic history, including the possible use of preoperative questionnaires for patients for this purpose, which contributes to a significant reduction in the risks of adverse events during anesthesia care.

Key words: anaphylaxis, anesthesia, antibiotics

1. Rahimo M, Jerzyńska J, Brzozowska A, Pod­lecka D. When toothache results in asthma diagnosis. Int J Occup Med Environ Health. 2022;35(1):107-10. doi: https://doi.org/10.13075/ijomeh.1896.01810
2. Cardona V, Ansotegui IJ, Ebisawa M, El-Ga­mal Y, Rivas MF, Fineman S, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organ J. 2020;13:100472. doi: https://doi.org/10.1016/j.waojou.2020.100472
3. Mi JH, Shen TT, Wang HW. A case report of anaphylactic shock caused by lidocaine. Medicine (Baltimore).2025;104(4):e41325. doi: https://doi.org/10.1097/MD.0000000000041325
4. Liu K, Bao JF, Wang T, Yang H, Xu BP. Camre­lizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature. World J Clin Cases. 2022;10(18):6198-204. doi: https://doi.org/10.12998/wjcc.v10.i18.6198
5. Liu X, Gong R, Xin X, Zhao J. Clinical charac­teristics and allergen detection of perioperative ana­phylaxis: a 12-year retrospective analysis from an anesthesia clinic  in China. Perioper Med (Lond). 2022;11(1):5. doi: https://doi.org/10.1186/s13741-021-00234-z
6. Bina B, Hersh EV, Hilario M, Alvarez K, McLaugh­lin B. True Allergy to Amide Local Anesthetics: A Review and Case Presentation. Anesth Prog. 2018;65(2):119-23. doi: https://doi.org/10.2344/anpr-65-03-06
7. Dumitru M, Berghi ON, Taciuc IA, Vrinceanu D, Manole F, Costache A. Could Artificial Intelligence Prevent Intraoperative Anaphylaxis? Reference Review and Proof of Concept. Medicina (Kaunas). 2022;58(11):1530. doi: https://doi.org/10.3390/medicina58111530
8. Cherobin ACFP, Tavares GT. Safety of local anesthetics. An Bras Dermatol. 2020;95(1):82-90. doi: https://doi.org/10.1016/j.abd.2019.09.025
9. Khan DA, Banerji A, Bernstein JA, et al. Cepha­losporin Allergy: Current Understanding and Future Chal­lenges. J Allergy Clin Immunol Pract. 2019;7(7):2105-2 114. doi: https://doi.org/10.1016/j.jaip.2019.06.001
10. Gouel-Cheron A, Neukirch C, Kantor E, et al. Cli­nical reasoning in anaphylactic shock: addressing the challenges faced by anaesthesiologists in real time: A clinical review and management algorithms. Eur J Anaesthesiol.2021;38(11):1158-67. doi: https://doi.org/10.1097/EJA.0000000000001536
11. Lisiecka MZ. Antibiotic Hypersensitivity: Classi­fication, Mechanisms, Signs, and Diagnostic Approaches: A Critical Review. Ther Drug Monit. 2025 Aug 21. Epub ahead of print. doi: https://doi.org/10.1097/FTD.0000000000001376

Look through:

Tutunnyk A.G. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0003-0594-0889

Mynka N.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0001-5024-911X

Kobelyatskyy Yu.Yu. Dnipro State Medical University, Dnipro, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-8504-6125

Tutunnyk A.G., Mynka N.V., Kobelyatskyy Yu.Yu. Anaphylaxis during anesthesia: a clinical case. Medicni perspektivi. 2025;30(3):126-131.
doi: https://doi.org/10.26641/2307-0404.2025.3.340752

Altruistic values among students of Nursing, Midwifery, Physiotherapy, and Health Psychology: a cross-sectional study

The aim of this study was to analyze anxiety, depression, aggression, cognitive impairments, and quality of life in patients receiving methadone maintenance therapy. The study was conducted in 2024 at one of the methadone maintenance therapy sites of the Municipal Enterprise «Dnipropetrovsk multidisciplinary clinical hospital for the provision of psychiatric care» Dnipropetrovsk Regional Council». A total of 150 patients aged 26 to 64 years par­ticipated in the study, including 117 (78.0%) men and 33 (22.0%) women. The participants were divided into the main group (101 individuals) and the comparison group (49 individuals). The study employed clinical-anamnestic, clinical-psycho­pathological, and psychodiagnostic methods, including the Symptom Checklist-90-Revised (SCL-90-R), the Hamilton An­xiety Rating Scale (HAM-A), the Hamilton Depression Rating Scale (HAM-D), the Buss-Durkee Hostility Inventory, the Montreal Cognitive Assessment (MoCA), and the World Health Organization Quality of Life Brief Questionnaire (WHOQOL-BREF). The results indicated that the median levels of depression 13,0 [7,0; 19,0] and anxiety 15,0 [8,0; 22,0] in the total sample and both groups corresponded to a mild severity. Most patients exhibited mild anxiety (60,7%). Depression assessment revealed that the majority of patients either had no depression (28,7%) or presented with mild symptoms (24,0%). The majority of participants had no cognitive impairment (45,3%) or only mild deficits (54,7%). Patients demonstrated normal levels of aggression 19,0 [16,0; 24,0] but exhibited an increased level of hostility 10,0 [8,0; 12,0]. At baseline, mild anxiety and depressive symptoms predominated among patients receiving methadone therapy. Elevated hostility was observed, whereas overall aggression remained within the normative range. Cognitive impairment was absent or mild. These baseline findings may inform the development of differentiated treatment strategies for this cohort.

Key words: methadone, substitution maintenance therapy, opioid agonists, mental and behavioral disorders in addicts, comorbidity of disorders in addicts, anxiety, depression, quality of life

1. Volkow ND, Blanco C. The Changing Opioid Crisis: development, challenges and opportunities. Mol Psychiatry.2021;26:218-33. doi: https://doi.org/10.1038/s41380-020-0661-4
2. Hornberger J, Chhatwal J. Opioid Misuse: A Global Crisis. Value Health. 2021;24:145-6. doi: https://doi.org/10.1016/j.jval.2020.12.003
3. Humphreys K, Shover CL, Andrews CM, Boh­nert ASB, Brandeau ML, Caulkins JP, et al. Responding to the Opioid Crisis in North America and Beyond: Recom­mendations of the Stanford-Lancet Commission. Lancet Lond 2022;399:555-604. doi: https://doi.org/10.1016/S0140-6736(21)02252-2.
4. Fipps DC, Oesterle TS, Kolla BP. Opioid Main­tenance Therapy: A Review of Methadone, Bupreno­rphine, and Naltrexone Treatments for Opioid Use Disorder. Semin Neurol. 2024 Aug;44(4):441-51. doi: https://doi.org/10.1055/s-0044-1787571
5. Pilarinos A, Kwa Y, Joe R, Dong H, Grant C, Fast D, et al. Methadone Maintenance Treatment Discon­tinuation Among Young People who use Opioids in Vancouver, Canada. Can J Psychiatry. 2023 Feb;68(2):89-100. doi: https://doi.org/10.1177/07067437221136468
6. Santo T, Clark B, Hickman M, Grebely J, Camp­bell G, Sordo L, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78:979-93. doi: https://doi.org/10.1001/jamapsychiatry.2021.0976
7. Pilarinos A, Kwa Y, Joe R, Thulien M, Buxton JA, DeBeck K, et al. Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada. Int J Drug Policy. 2022;107:103773. doi: https://doi.org/10.1016/j.drugpo.2022.103773
8. Stuikyte R, Varentsov I, Cook C, Dvoriak S. Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund support. HarmReduct  2024;21:7. doi: https://doi.org/10.1186/s12954-024-00931-0
9. Cao P, Zhang Z, Zhong J, Xu S, Huang Q, Fan N. Effects of treatment status and life quality on anxiety in MMT patients. Subst Abuse Treat Prev Policy. 2021 Jan 13;16(1):9. doi: https://doi.org/10.1186/s13011-021-00343-4
10. Chang HM, Huang MC, Fang SC, Lin SK. Quality of life and associated factors of heroin-dependent patients receiving methadone and buprenorphine maintenance treatment. Neuropsychopharmacol Rep. 2023 Dec;43(4):607-15. doi: https://doi.org/10.1002/npr2.12402
11. Kelly LM, Alessi SM, Rash CJ, Zajac K. Predic­tors of Suicidal Ideation and Continued Substance Use Problems Among Patients Receiving Methadone Main­tenance Treatment Who Have Co-Occurring Cocaine Use Disorder. Subst Use Misuse. 2024;59(5):752-62. doi: https://doi.org/10.1080/10826084.2024.2302131
12. The Universal Declaration on Bioethics and Human Rights. Int Soc Sci J. 2005;57:745-53. doi: https://doi.org/10.1111/j.1468-2451.2005.00592.x
13. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-4. doi: https://doi.org/10.1001/jama.2013.281053
14. Dembitskyi S, Sereda Yu. [Leonard Derogatis Symptom Questionnaire (SCL-90-R): validation in Uk­raine]. Sotsiolohiia: teoriia, metody, marketynh. [Internet]. [cited 2025 Apr 29]. 2015;4:40-71. Ukrainian. Avai­lable from: http://jnas.nbuv.gov.ua/j-pdf/stmm_2015_4_5.pdf
15. Chaban OS, Khaustova OO. [Practical psychoso­matics: diagnostic scales]. 2025. p. 49-54, 76-78, 184-91. Ukrainian.
16. Stepaniuk O, Melnychenko O. [Methodological guide for professionals implementing a typical program for offenders: A collection of practical materials]. Kyiv; 2020. p. 14-20. Ukrainian.
17. Development of the World Health Organization WHOQOL-BREF quality of life assessment [Internet]. [cited 2025 Apr 29]. Available from: https://www.who.int/tools/whoqol/whoqol-bref/docs/default-source/publishing-policies/whoqol-bref/ukrainian-whoqol-bref
18. Torres D, Normando D. Biostatistics: essential con­cepts for the clinician. Dent Press J Orthod. 2021;26:e21spe1. doi: https://doi.org/10.1590/2177-6709.26.1.e21spe1
19. Chang TG, Yen TT, Hsu WY, Chang SM. Frontal Lobe Functions, Demoralization, Depression and Craving as Prognostic Factors and Positive Outcomes of Patients with Heroin Use Disorder Receiving 6 Months of Methadone Maintenance Treatment. Int J Environ Res Public Health. 2022 Mar 20;19(6):3703. doi: https://doi.org/10.3390/ijerph19063703
20. Bahji A, Bastien G, Bach P, Choi J, Le Foll B, Lim R, Jutras-Aswad D, Socias ME. The Association Bet­ween Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial. CanJ  2024 Mar;69(3):172-82. doi: https://doi.org/10.1177/07067437231194385
21. Zhao W, Duan F, Li X, Li J, Xia L, Ren Z, et al. Cognitive control in individuals with heroin use disorder after prolonged methadone maintenance treatment. BMC Psychiatry. 2025;25:78. doi: https://doi.org/10.1186/s12888-025-06523-x

Look through:

Halytska-Pasichnyk N.R. Municipal Enterprise "Dnipropetrovsk multidisciplinary clinical hospital for the provision of psychiatric care" Dnipropetrovsk Regional Council", Dnipro, Ukraine, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0004-8512-9993

Halytska-Pasichnyk N.R. Psychiatric and behavioral disorders in patients undergoing opioid agonist maintenance therapy. Medicni perspektivi. 2025;30(3):132-139.
doi: https://doi.org/10.26641/2307-0404.2025.3.340755

Assessment of adolescent physical development using body mass index and body self-perception

The study was aimed at evaluating the effectiveness of using a modified removable purse-string suture with polyurethane tubing to reduce complications after transvesical adenomectomy in patients with benign prostatic hyperplasia. A total of 60 pa­tients participated in the study. They were distributed into two groups: 30 patients in the main group, where the improved method using a polyurethane tube was used, and 30 patients in the control group, where the standard technique without removable suture was used. The comparison showed that in the main group, the average volume of blood loss in the first 48 hours was 240 [200-280] ml, which was significantly less than in the control group, where it reached 385 [320-450] ml (p<0.05). Furthermore, in patients of the main group, the haemoglobin level on the first day after surgery was higher – 112.3 [103.9-120.7] g/l compared to 104.5 [96.9-112.1] g/l in the control group (p<0.05). This indicated better control of blood loss. The incidence of complications such as bleeding and inflammation was lower in the main group, 6% versus 20% in the control group (p<0.05). Additionally, the level of C-reactive protein on the third day after surgery in the main group was 12.3 [10.1-14.5] mg/l, while in the control group, it was significantly higher – 17.6 [14.1-21.1] mg/l (p<0.05). Thus, the use of removable purse-string suture with polyurethane tube demonstrated its effectiveness in reducing blood loss and complication rate, providing better recovery after surgery in patients with benign prostatic hyperplasia. The findings demonstrate that the use of a modified removable purse-string suture with polyurethane tubing effectively reduces blood loss, enhances haemostasis, and lowers the incidence of postoperative complications in patients undergoing transvesical adenomectomy for benign prostatic hyperplasia. Additionally, this technique contributes to a shorter recovery period and improved haemoglobin levels, indicating better overall postoperative outcomes.

Key words: open adenomectomy, blood loss, complications, modified removable sutures, benign prostatic hyperplasia

1. Wang H, Tang R, Luo S, Hou H, Liu J, Liu M, et al. Association of life’s crucial 9 score with benign prostatic hyperplasia: A cross-sectional study. J Health Popul Nutr. 2025;44(163):1-11. doi: https://doi.org/10.1186/s41043-025-00925-z
2. Pérez MLF, Becerra AJM, Delgado MGR. Post­operative complications in patients with benign prostatic hyperplasia according to surgical technique. Rev Cub Med Mil. [Internet]. 2021 [cited 2025 Jun 7];50(4):e02101615. Available from: https://www.medigraphic.com/pdfs/revcubmedmil/cmm-2021/cmm214j.pdf
3. Baktybek Uulu A, Usupbaev A, Ismatov B, Abi­billaev D, Konurbaev B. Comparative outcomes of retro­pubic versus transvesical open adenomectomy in benign prostatic hyperplasia: A retrospective cohort study. Heart Vessel 2025;9. doi: https://doi.org/10.24969/hvt.2025.580
4. Sfredo LR, de Oliveira IC, Novakoski GK, Dig­ner IS, Silva IVM, Lacerda DAM, et al. Comparative analysis between open transvesical and laparoscopic ade­nomectomy in the treatment of benigne prostatic hyperplasia in a tertiary hospital in Curitiba-PR: a retrospective study. Rev Col Bras Cir. 2023;50:e20233450. doi: https://doi.org/10.1590/0100-6991e-20233450-en
5. Akassimadou N, Avion KP, Aguia B, Zouan F, Alloka V, Kamara BS, et al. Post-operative complications of transvesical prostatic adenomectomy at Bouake Teaching Hospital: Epidemiological, diagnostic and therapeutic aspects. Open J Urol. 2023;13(9):345-52. doi: https://doi.org/10.4236/oju.2023.139039
6. Fariñas Martínez JA, Laffita Estévez S, Téllez Pé­rez R, Ortega Rodríguez D. Complications of adeno­mec­tomy in the elderly. Rev Electron Zoilo. 2013;38(5):1-10.
7. Berthe A, Ballo B, Drago AA, Togola A, Sis­soko I, Ouattara AD, et al. Postoperative complications of trans­vesical adenomectomy of the prostate in the urology department of the centre Hospitalier Universitaire GABRIEL TOURE in Bamako. East Afr Sch J Med Sci. 2024;7(2):78-82. doi: https://doi.org/10.36349/easms.2024.v07i02.008
8. van der Sanden WMH, Fossion LMCL, de Laet K. Endoscopic transvesical adenomectomy of the prostate, a new minimal invasive approach for large benign prostate hyperplasia. A description of the technique and the results  of the first 40 patients. Urology. 2019;125:174-8. doi: https://doi.org/10.1016/j.urology.2018.12.031
9. Noguera RS, Rodríguez RC. Open adenomec­tomy: past, present and future. Curr Opin Urol. 2008;18(1):34-40. doi: https://doi.org/10.1097/mou.0b013e3282f0d625
10. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biom. 1965;52(3-4):591-611. doi: https://doi.org/10.1093/biomet/52.3-4.591
11. Cochran WG. The χ² Test of Goodness of Fit. Ann Math Statist. 1952;23(3):315-45. doi: https://doi.org/10.1214%2Faoms%2F1177729380
12. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: https://doi.org/10.1001/jama.2013.281053
13. The Clavien-Dindo Classification [Internet]. 2025 [cited 2025 Jun 7]. Available from: https://www.assessurgery.com/clavien-dindo-classification/
14. Gorety M, Winarto E, Utama JEP. The ‘Maria screening instrument’ for post-open prostatectomy bleeding risk: A qualitative study. Hearty J Public Health. 2024;12(3):604-10. doi: https://doi.org/10.32832/hearty.v12i3.16719
15. Borkowski T, Michalec J, Kuzaka B, Borkows­ki A, Radziszewski P. Internal optical urethrotomy is the treatment of choice in stenosis of the bladder neck after open prostate adenectomy. Wideochir Inne Tech Maloinwazyjne.2019;14(3):427-32. doi: https://doi.org/10.5114/wiitm.2019.82686
16. El Alaoui A, El Boté H. Giant prostatic adenoma. Pan Afr Med J. 2018;30:256. doi: https://doi.org/10.11604/pamj.2018.30.256.12142
17. Dell'Atti L, Galeotti R. Pseudoaneurysm secon­dary to transvesical prostatectomy. Indian J Urol. 2016;32(2):164-5. doi: https://doi.org/10.4103/0970-1591.174783
18. Bove AM, Altobelli E, Sergi F, Buscarini M. Robot-assisted laparoscopic radical prostatectomy after previous open transvesical adenomectomy. J Robot Surg. 2014;8(1):85-8.
    doi: https://doi.org/10.1007/s11701-013-0392-5
19. Mdivnishvili M, Khuskivadze N, Khuskivadze A. Giant benign prostatic hyperplasia: A case report. Cureus. 2024;16(5):e61295. doi: https://doi.org/10.1016/j.eucr.2019.101051
20. Cornejo-Dávila V, Mayorga-Gómez E, Palmeros-Rodríguez MA, Uberetagoyena-Tello de Meneses I, Gar­za-Sáinz G, Osornio-Sánchez V, et al. Role of transvesical adenomectomy in treatment of prostate hyperplasia: 7 years of experience at a single center in Mexico City. Rev Mex 2015;75(1):14-9. doi: https://doi.org/10.1016/j.uromx.2014.11.002
21. Vale L, Fossion L. Endoscopic transvesical adeno­mectomy of the prostate, a new minimally invasive approach for large benign prostatic hyperplasia. What has our experience taught us? Cent European J Urol. 2020;73(4):482-9. doi: https://doi.org/10.5173/ceju.2020.0053.R3
22. Horovyi VI, Shaprynskyi VO, Kapshuk OM, Sos­nin MD, Tsekrovnyuk RG, Moraru-Burlesku RP, et al. Transcervical transvesical prostatectomy in patients with benign prostate hyperplasia. Health Man. 2024;3:56-62. doi: https://doi.org/10.30841/2786-7323.3.2024.316663
23. Gnammi LR, Cissé D, Gamamou VA, Kanté D, Diawo Bah M, Akinocho EM, et al. Comparative study of transvesical and retropubic prostatic adenomectomies in the Urology-Andrology Department of Ignace Deen University Hospital Center. Open J Urol. 2024;14(4):227-43. doi: https://doi.org/10.4236/oju.2024.144023
24. Coulibaly N, Ackoundou-N'guessan C, Ngues­san Y, Aye Y, Guei M, Toure D, et al. Morbidity and mortality after transvesical prostatic adenomectomy at the University Hospital of Libreville. A report of 68 cases. Uro-Andro. [Internet]. 2017[cited 2025 Jun 7];1(8):362-6. Available from: https://revue-uroandro.org/index.php/uro-andro/article/view/113
25. Botcho G, Kpatcha TM, Tengue K, Dossouvi T, Sewa EV, Simlawo K, et al. Morbidity and mortality after open prostatectomy for benign prostatic hyperplasia by transvesical approach at the Teaching Hospital of Kara, Togo. Afr J Urol. 2018;24(4):353-8. doi: https://doi.org/10.1016/j.afju.2018.01.008

Look through:

Botalaev B. Kyrgyz State Medical Academy named after I.K. Akhunbaev, Bishkek, Kyrgyz Republic
https://orcid.org/0009-0009-2442-2674

Usupbaev A. Kyrgyz State Medical Academy named after I.K. Akhunbaev, Bishkek, Kyrgyz Republic
https://orcid.org/0009-0000-3521-8913

Abdykalykov M. Kyrgyz State Medical Institute for Retraining and Advanced Training named after S.B. Daniyarova, Bishkek, Kyrgyz Republic, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0008-5292-7250

Zhumagaziev T. Kyrgyz State Medical Institute for Retraining and Advanced Training named after S.B. Daniyarova, Bishkek, Kyrgyz Republic
https://orcid.org/0009-0005-9110-647X

Mailubashev M. Kyrgyz State Medical Institute for Retraining and Advanced Training named after S.B. Daniyarova, Bishkek, Kyrgyz Republic
https://orcid.org/0009-0002-6309-7260

Botalaev B., Usupbaev A., Abdykalykov M, Zhumagaziev T., Mailubashev M. Ways to reduce complications during open adenomectomy in patients with BPH using modified removable sutures. Medicni perspektivi. 2025;30(3):140-151.
doi: https://doi.org/10.26641/2307-0404.2025.3.340756

Health and school difficulties of children in foster care in the experience of their foster parents

The aim of the study was to analyse the effect of a long-acting muscarinic antagonist and an inhaled corticosteroid on the circadian profile, blood pressure (BP) variability, and circadian rhythm disturbances in patients with chronic obstructive pulmonary disease (COPD) and concomitant arterial hypertension, based on ambulatory blood pressure monitoring (ABPM) data during long-term use of these therapies. A total of 86 patients with COPD of GOLD stage II and III (Global Initiative for Chronic Obstructive Lung Disease) and stage II hypertension (men – 67 (77.9%), women – 19 (22.1%), mean age – 62 (56; 74) years) in a stable phase of the disease were examined. All patients received continuous combined antihypertensive therapy, which remained un­changed for at least 6 months. Depending on the degree of bronchial obstruction and the type of inhalation therapy, patients were divided into three subgroups: subgroup 1 included 34 patients with GOLD stage II airflow limitation who received only a bronchodilator (tiotropium bromide 18 μg per day); subgroup 2 included 23 patients with GOLD stage III airflow limitation who received both a bronchodilator (tiotropium bromide 18 μg/day) and an inhaled corticosteroid (ICS) (beclometasone dipropionate 250 μg twice daily); subgroup 3 included 29 patients with GOLD stage III airflow limitation who received only a bronchodilator (tiotropium bromide 18 μg/day), despite indications for combined therapy. All patients achieved target office blood pressure levels (<140/90 mmHg); however, ABPM revealed elevated mean daily blood pressure (>130/80 mmHg) in 60 out of 86 patients (69.8%), predominantly in subgroup 2 (p<0.05). At night, mean diastolic blood pressure in subgroup 2 was 67 (57; 79) mmHg, higher than in subgroup 1 (60 (51; 69) mmHg; p<0.05). Blood pressure variability also increased with severe bronchial obstruction: in subgroup 3, night-time systolic BP variability reached 14 (13; 17) mmHg (p<0.05 vs. other groups). A normal circadian profile (“dipper”) was observed in 25 patients (41.7%), whereas pathological types were recorded in 35 patients (58.3%) – “non-dipper” and “night-peaker” in 33 cases (94.3%) and “over-dipper” in 2 cases (5.7%). Disturbances in nocturnal blood pressure reduction were most frequent in subgroup 2 (p<0.05). Thus, patients with COPD and clinically stable (medically compensated) concomitant hypertension generally exhibit normal office blood pressure values. However, nearly 70% of such patients show elevated night-time blood pressure according to ABPM. Patients receiving ICS for COPD therapy predominantly demonstrate pathological circadian BP patterns (“non-dipper” and “night-peaker”), whereas a normal circadian BP pattern (“dipper”) is more frequent in patients treated with a long-acting muscarinic antagonist as baseline COPD therapy (p<0.05). In patients with COPD and concomitant hypertension, blood pressure should be monitored not only by office measurements but also using ABPM; in cases of ABPM abnormalities, patients require dynamic follow-up by a cardiologist.

Key words: chronic obstructive pulmonary disease, arterial hypertension, spirometry, bronchial obstruction, blood pressure, ambulatory blood pressure monitoring, inhalation therapy, inhaled corticosteroid, long-acting muscarinic antagonist, antihypertensive therapy

1. Santos NCD, Miravitlles M, Camelier AA, Al­meida VDC, Maciel RRBT, Camelier FWR. Prevalence and impact of comorbidities in individuals with chronic obstructive pulmonary disease: a systematic review. Tuberc Respir Dis (Seoul). 2022;85(3):205-20. doi: http://doi.org/10.4046/trd.2021.0179
2. López Campo I, Barreales Castillo M, Izquierdo Alonso JL, et al. Impact of comorbidities on COPD clinical control criteria. The CLAVE study. BMC Pulm Med. 2023;23(1):258.
   doi: http://doi.org/10.1186/s12890-023-02758-0
3. Finks SW, Rumbak MJ, Self TH. Treating hyper­tension in chronic obstructive pulmonary disease. N Engl J Med.2020;382(4):353-63. doi: http://doi.org/10.1056/NEJMra1805377
4. Hu WP, Lhamo T, Zhang FY, Hang JQ, Zuo YH, Hua JL, et al. Predictors of acute cardiovascular events following acute exacerbation period for patients with COPD: a nested case-control study. BMC Cardiovasc Disord.2020;20(1):518. doi: http://doi.org/10.1186/s12872-020-01803-8
5. Ji J, Zhao Q, Yuan J, Yuan Z, Gao N. Causal asso­ciations between chronic obstructive pulmonary disease and common comorbidities: evidence from comprehensive genetic methods. Int J Chron Obstruct Pulmon Dis. 2025;20:601-10. doi: http://doi.org/10.2147/COPD.S498513
6. Ambrosino P, Bachetti T, D'Anna SE, Gallo­way B, Bianco A, D'Agnano V, et al. Mechanisms and clinical implications of endothelial dysfunction in arterial hypertension. J Cardiovasc Dev Dis. 2022;9(5):136. doi: http://doi.org/10.3390/jcdd9050136
7. Faraci FM, Scheer FAJL. Hypertension: causes and consequences of circadian rhythms in blood pressure. Circ 2024;134(6):810-32. doi: http://doi.org/10.1161/CIRCRESAHA.124.323515
8. Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review. AmJ  2015;128(1):14-20. doi: http://doi.org/10.1016/j.amjmed.2014.07.021
9. [Unified clinical protocol for primary and spe­cialized medical care Hypertensive disease (Arterial hypertension). Order of the Ministry of Health of Ukraine No. 1581 dated 2024 Sept 12]. [Internet]. 2024 [cited 2025 Jun 16]. 58 р. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2024/09/ykpmd_1581_12092024_dod.pdf
10. Yang WY, Melgarejo JD, Thijs L, et al. Asso­cia­tion of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322(5):409-20. doi: http://doi.org/10.1001/jama.2019.9811
11. Wu YK, Huang CY, Yang MC, et al. Effect of tiotropium on heart rate variability in stable chronic obstructive pulmonary disease patients. J Aerosol Med Pulm Drug Deliv. 2015;28(2):100-5. doi: http://doi.org/10.1089/jamp.2014.1125
12. Miravitlles M, Auladell-Rispau A, Monteagu­do M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. EurRespir  2021;30(160):210075. doi: http://doi.org/10.1183/16000617.0075-2021
13. Calverley PM, Anderson JA, Celli B, et al. Salme­terol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-89. doi: http://doi.org/10.1056/NEJMoa063070
14. Wedzicha JA, Calverley PMA, Seemungal TA, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374(23):2222-34. doi: http://doi.org/10.1056/NEJMoa1516385
15. Vestbo J, Anderson JA, Brook RD, et al. Fluti­casone furoate and vilanterol and survival in COPD with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817-26. doi: http://doi.org/10.1016/S0140-6736(16)30069-1
16. Brook RD, Anderson JA, Calverley PM, et al. Car­diovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103:1536-42. doi: http://doi.org/10.1136/heartjnl-2016-310897
17. Salpeter SR, Ormiston TM, Salpeter EE. Cardio­vascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-21. doi: http://doi.org/10.1378/chest.125.6.2309
18. Divo M, Casanova C, Pinto-Plata V. Cardiovas­cular risk assessment in patients with COPD: reduce, reuse and recycle. Eur Respir J. 2025;65(2):2402103. doi: http://doi.org/10.1183/13993003.02103-2024
19. Matera MG, Page CP, Calzetta L, Rogliani P, Caz­zola M. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol 2020;72(1):218-52. doi: http://doi.org/10.1124/pr.119.018150
20. Li C, Cheng W, Guo J, Guan W. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Int J Chron Obstruct Pulmon Dis. 2019;14:799-808. doi: http://doi.org/10.2147/COPD.S198288
21. Venkatesan P. GOLD COPD report: 2024 update. Lancet Respir Med. 2024;12(1):15-6. doi: http://doi.org/10.1016/S2213-2600(23)00461-7
22. [Unified clinical protocol of primary, specialized and emergency medical care for chronic obstructive lung disease. Order of the Ministry of Health of Ukraine No. 1610 dated 2024 Sept 20]. 2024 [cited 2025 May 23]. 72 p. Ukrainian. Available from: https://moz.gov.ua/storage/uploads/bade03ef-2dbf-4d85-8a67-3040fe8b5db8/2024_06_20_%D0%A3%D0%9A%D0%9F%D0%9C%D0%94_%D0%A5%D0%9E%D0%97%D0%9B-%D0%B1%D0%B5%D0%B7-%D1%88%D0%BA-(1).pdf
23. Graham BL, Steenbruggen I, Miller MR, et al. Stan­dardization of spirometry 2019 update: an official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88. doi: http://doi.org/10.1164/rccm.201908-1590ST
24. Mostovoi YuM, Konstantynovych TV, Moroz LV, et al. [Modern instrumental diagnostic methods for respira­tory organs: a textbook]. Lviv: Vydavets MarchenkoTV;  308 p. Ukrainian. ISBN: 978-617-574-232-7
25. Sullivan LM. Biostatistics for Population Health: A Primer. Burlington, MA: Jones & Bartlett Learning; 2021. 432 p. ISBN: 9781284194265
26. Dolzhenko MN. [Pulmonary Hypertension Revi­sited: Myth or Reality?]. Novyny medytsyny ta farmatsii. [Internet]. Kardyolohiia. 2008 [cited 2025 May 23];241:7-9. Ukrainian. Available from: http://www.mif-ua.com/archive/article/5007

Look through:

Konopkina L.I. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0002-2238-6501

Dziublyk Ya.O. State organization "National sceintific center of phthisiology, pulmonology and allergology named after F. G. Yanovsky NAMS of Ukraine", Kyiv, Ukraine
https://orcid.org/0000-0002-6497-5267

Babets A.A. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0009-0009-2577-3302

Shchudro O.O. Dnipro State Medical University, Dnipro, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-7575-2651

Konopkina L.I., Dziublyk Ya.O., Babets A.A., Shchudro O.O. Circadian blood pressure profile in patients with chronic obstructive pulmonary disease and arterial hypertension on baseline therapy. Medicni perspektivi. 2025;30(3):152-161.
doi: https://doi.org/10.26641/2307-0404.2025.3.340759

Diagnostic value of the gingival cytogram in school-age children suffering from chronic gastritis and duodenitis

Autoimmune liver diseases in children, particularly autoimmune hepatitis and autoimmune sclerosing cholangitis, represent a challenging clinical issue due to their variable clinical course, diagnostic complexity, and suboptimal therapeutic efficacy. Despite common pathogenetic mechanisms, including impaired immune regulation, association with class II major histocompatibility complex molecules, chronic inflammation, and fibrosis, these conditions differ significantly in clinical presentation, treatment response, and prognosis. The incidence of autoimmune hepatitis in children is 3-6 cases per 100,000, whereas autoimmune sclerosing cholangitis is rarer, diagnosed in 0.2-1.5 cases per 100,000 children. The primary therapeutic goal is achieving biochemical remission and preventing fibrosis progression. A lack of biochemical improvement within the first 6–12 months of treatment is associated with poorer outcomes; however, clear algorithms for intensifying therapy have not yet been established. Standardizing biochemical markers for assessing treatment effectiveness remains a relevant issue. The aim of this study was to perform a comparative analysis of immunosuppressive therapy effectiveness in children with autoimmune hepatitis and autoimmune sclerosing cholangitis based on the evaluation of biochemical response rates. We conducted a retrospective analysis of immunosuppressive therapy effectiveness during the first 12 months in children and adolescents with autoimmune liver diseases treated in the pediatric hepatology department for 2016 to 2024. Two groups were formed: group 1 – autoimmune hepatitis (n=84), and group 2 – autoimmune sclerosing cholangitis (n=38). At disease onset, children in group 2 exhibited higher gamma-glutamyltransferase levels (p=0.003) and more frequently had inflam­matory bowel disease (68% vs. 9.5%, p<0.0001). Early biochemical response was achieved in 4 weeks of therapy in 86% of group 1 and 82% of group 2, respectively (p>0.05). In 6 months, complete biochemical response was observed in 50% of group 1 and 32% of group 2 (p=0.07). In 12 months, complete response rates were 73% and 47%, respectively (p=0.007). Elastography indicated a significant decrease in liver stiffness in both groups (p<0.0001 and p=0.002, respectively). Thus, children with autoimmune sclerosing cholangitis demonstrate significantly lower efficacy of immunosuppressive therapy within the first 12 months compared to autoimmune hepatitis. Liver stiffness measurement by elastography may serve as an additional objective criterion for evaluating treatment effectiveness.

Key words: autoimmune hepatitis, autoimmune sclerosing cholangitis, treatment, biochemical response, shear wave elastography

1. Kemme S, Mack CL. Pediatric autoimmune liver diseases: autoimmune hepatitis and primary sclerosing cholangitis. Pediatr Clin North Am. 2021;68(6):1293-307. doi: https://doi.org/10.1016/j.pcl.2021.07.006
2. Nastasio S, Mosca A, Alterio T, Sciveres M, Mag­giore G. Juvenile autoimmune hepatitis: Recent advances in diagnosis, management and long-term outcome. Diagnostics.2023;13:2753. doi: https://doi.org/10.3390/diagnostics13172753
3. Di Giorgio A, Vergani D, Mieli-Vergani G. Cut­ting edge issues in juvenile sclerosing cholangitis. Dig Liver 2022;54:417-27. doi: https://doi.org/10.1016/j.dld.2021.06.028
4. Ricciuto A, Kamath BM, Hirschfield GM, Tri­vedi PJ. Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem?J  2023;79(2):567-75. doi: https://doi.org/10.1016/j.jhep.2023.02.030
5. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the mana­gement of autoimmune hepatitis. J Hepatol. 2025;83(2):453-501. doi: https://doi.org/10.1016/j.jhep.2025.03.017
6. Ramonet M, Ramirez-Rodriguez N, Chávez FÁ, Ar­regui MC, Boldrini G, Osorio VB, et al. Autoimmune hepa­titis in pediatrics: A review by the Working Group of the Latin American Society for Pediatric Gastroenterology, Hepato­logy, and Nutrition. Arch Argent Pediatr. 2022;120:281-7. doi: https://doi.org/10.5546/aap.2022.eng.281
7. Ludz C, Stirnimann G, Semela D, Mertens J, Kremer AE, Sinnreich MF, et al. Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: A retrospective and prospective cohort study. SwissMed  2023;153:40102. doi: https://doi.org/10.57187/smw.2023.40102
8. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. doi: https://doi.org/10.1002/hep.31065
9. Wang P, Yuksel M, Gabeta S, Graham J, Hus­sain M, Blackmore LJ, et al. HLA alleles predisposing to autoimmunity are linked to impaired immunoregulation in patients with juvenile autoimmune liver disease and in their first-degree relatives. J Autoimmun. 2025;154:103436. doi: https://doi.org/10.1016/j.jaut.2025.103436
10. Sutton H, Tayler R, Chalmers I, Cowieson J, Fra­ser K, Henderson P, et al. The epidemiology of pediatric autoimmune hepatitis in Scotland. JPGN Rep. 2022;3:e223. doi: https://doi.org/10.1097/pg9.0000000000000223
11. Warner S, Rajanayagam J, Russell E, Lloyd C, Ferguson J, Kelly DA, et al. Biliary disease progression in childhood-onset autoimmune liver disease: A 30-year follow-up into adulthood. JHEP Rep. 2024;6:100901. doi: https://doi.org/10.1016/j.jhepr.2023.100901
12. Anderson CM, Welle CL, Ludwig DR, An­derson MA, Khot R, Itani M, et al. Autoimmune disorders of the liver and biliary tract. Radiographics. 2025;45:e240126. doi: https://doi.org/10.1148/rg.240126
13. Mieli‐Vergani G, Vergani D, Baumann U, Czub­kowski P, Debray D, Dezsofi A, et al. Diagnosis and management of pediatric autoimmune liver disease. J PediatrGastroenterol  2018;66:345-60. doi: https://doi.org/10.1097/MPG.0000000000001801
14. Ricciuto A, Kamath BM, Hirschfield GM, Tri­vedi PJ. Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem? J Hepatol. 2023;79:567-7 doi: https://doi.org/10.1016/j.jhep.2023.02.030
15. Stevens JP, Gupta NA. Recent insights into pediatric primary sclerosing cholangitis. Clin Liver Dis. 2022;26:489-519. doi: https://doi.org/10.1016/j.cld.2022.03.009
16. Di Giorgio A, Hadzic N, Dhawan A, Dehera­goda M, Heneghan MA, Vergani D, et al. Seamless management of juvenile autoimmune liver disease: Long-term medical and social outcome. J Pediatr. 2020;218:121-129.e3. doi: https://doi.org/10.1016/j.jpeds.2019.11.028
17. Pape S, Snijders RJALM, Gevers TJG, Cha­zouilleres O, Dalekos GN, Hirschfield GM, et al. Syste­matic review of response criteria and endpoints in autoimmune hepatitis by the International Autoim­muneHepatitis Group. J Hepatol. 2022;76:841-9. doi: https://doi.org/10.1016/j.jhep.2021.12.041
18. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: https://doi.org/10.1001/jama.2013.281053
19. Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: Review of histologic features included in the simplified criteria proposed by the International Autoimmune Hepatitis Group and proposal for new histologic criteria. Mod Pathol.2017;30:773-83. doi: https://doi.org/10.1038/modpathol.2016.267
20. Lohse AW, Sebode M, Bhathal PS, Clouston AD, Dienes HP, Jain D, et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology.Liver  2022;42(7):1375-89. doi: https://doi.org/10.1111/liv.15230
21. Riffenburgh RH. Statistics in Medicine. 4th ed. Amsterdam: Academic Press, Elsevier; 2020. ISBN: 978-0-12-820297-5
22. Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2018;68:754-63. doi: https://doi.org/10.1016/j.jhep.2017.11.020
23. Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: Epidemiology and natural history. Hepatology. 2013;58:1392-400. doi: https://doi.org/10.1002/hep.26454
24. Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G. A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis. 2021;53(11):1381-93. doi: https://doi.org/10.1016/j.dld.2021.05.03
25. Plagiannakos CG, Hirschfield GM, Lytvyak E, Roberts SB, Ismail M, Gulamhusein AF, et al. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. J Hepatol. 2024;81:227-37. https://doi.org/10.1016/j.jhep.2024.03.021
26. Deneau MR, El‐Matary W, Valentino PL, Ab­dou R, Alqoaer K, Amin M, et al. The natural history of primary sclerosing cholangitis in 781 children: A multi­center, international collaboration. Hepatology. 2017;66:518-27. doi: https://doi.org/10.1002/hep.29204
27. Maggiore G, Riva S, Sciveres M. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood. Minerva Gastroenterol Dietol. 2009;55:53-70. PMID: 19212308
28. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et Autoimmune hepati­tis/sclerosing cholangitis overlap syndrome in childhood: A 16‐year prospective study. Hepatology. 2001;33:544-53. doi: https://doi.org/10.1053/jhep.2001.22131
29. Pape S, Gevers TJG, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B, et al. Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2019;17:2068-2075.e2. doi: https://doi.org/10.1016/j.cgh.2018.12.035
30. Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, et al. Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months. Clin Gastroenterol Hepatol. 2020;18:1609-1617.e4. doi: https://doi.org/10.1016/j.cgh.2019.11.013
31. Dyba MB, Berezenko VS. [Possibilities of shear wave elastography in the diagnosis of liver fibrosis and monitoring of autoimmune liver diseases in children]. Modern Pediatr. 2023;8(136):34-41. Ukrainian. doi: https://doi.org/10.15574/SP.2023.136.34

Look through:

Dyba M.B. SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children, Kyiv, Ukraine, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-9463-7867

Berezenko V.S. SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children; Bogomolets National Medical University, Kyiv, Ukraine, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-3777-5251

Tkalyk O.M. SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children, Kyiv, Ukraine, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-5449-8399

Dmytrenko Kh.Z. SI “Ukrainian Center of Maternity and Childhood of the National Academy of Medical Sciences of Ukraine”, Department of Hepatology and Comorbidities in Children, Kyiv, Ukraine, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-6720-6674

Dyba M.B., Berezenko V.S., Tkalyk O.M., Dmytrenko Kh.Z. Effectiveness of immunosuppressive therapy in children with autoimmune hepatitis and autoimmune sclerosing cholangitis. Medicni perspektivi. 2025;30(3):162-170.
doi: https://doi.org/10.26641/2307-0404.2025.3.340760

Indicative features of tissue and microbial sensitization in the pathogenesis of generalized parodontitis associated with rheumatoid arthritis

The present study focuses on the assessment of health-promoting behaviors and the manner in which the curriculum of teaching programs affects students in the bache­lor's degree programs in Nursing and Midwifery, as well as the professional master's degree program in Health Psy­chology. The study used a descriptive correlational design. The data were collected between 15th of February and 15th of March, 2024 from undergraduate students enrolled in nursing and midwifery programmes, as well as postgraduate students pursuing a professional master's degree in Health Psychology at the Faculty of Natural Sciences, University of Shkodra "Luigj Gurakuqi", Shkodër, Albania. The data were collected using an online questionnaire comprising three sections. The first section incorporated socio-demographic variables. The second section incorporated the Health-Promoting Lifestyle Profile II (HPLP II) questionnaire, developed by Walker et al., 1995, to assess health-promoting behaviours. The third section of the study focused on curricular formation and included three questions designed to assess students' perceptions of health promotion in their academic programmes. The mean overall Health-Promoting Lifestyle Profile II (HPLP II) score was 2.60±0.40, indicating that, on average, students follow health-promoting behaviours from "sometimes" to "often". Among the six subscales, spiritual growth (2.99±0.50) and interpersonal relations (2.89±0.47) had the highest mean scores, suggesting that students more frequently follow behaviours related to personal development and social support. The findings of the study indicated that students enrolled in both bachelor's degree programmes in Nursing and Midwifery and master's degree programmes in Health Psychology, despite being presumed to possess a substantial body of knowledge on health-promoting behaviours, do not consistently implement these practices in their daily lives. Given their role as role models for others, health personnel have a dual responsibility for the promotion of healthy behaviours. This finding suggests a deficiency in the incorporation of health-promoting behaviours as a core value within the curricula of bachelor's degree programmes in nursing and midwifery.

Key words: health-promoting behaviours, students, nurse, midwifery

1. Okab AA. Assessment of Nurse's Health Promo­tion of Their Lifestyles at Al-Kut City Hospitals, Iraq. Evidence-Based Nursing Research. 2020;2(4):8. doi: https://doi.org/10.47104/ebnrojs3.v%vi%i.155
2. Karimian Z, Moradi M, Zarifsanaiey N. Exploring the relationship between contextual factors and health-pro­moting lifestyle profile (HPLP) among medical stu­dents: A cross-sectional study. Health Sci Rep. 2024;7(4):e2040. doi: https://doi.org/10.1002/hsr2.2040
3. Amiri M, Raei M, Sadeghi E, Keikavoosi-Ara­ni L, Khosravi A. Health-promoting lifestyle and its deter­mining factors among students of public and private universities in Iran. J Educ Health Promot. 2023 Jul 29;12:239. doi: https://doi.org/10.4103/jehp.jehp_963_22
4. Diana MPLJ, Cercado FG, Chiu PZ, De Justo PA, De Silva AR, Oducado RMF. Filipino Nursing Students’ Health Promoting Behaviors during Pandemic. Nurse Media Journal of Nursing. 2023 Apr;13(1):1-11. doi: https://doi.org/10.14710/nmjn.v13i1.49896
5. Temiz G, Harmankaya G. Evaluation of health promoting behaviors and affecting factors in high school students. Gevher nesibe journal of medical and health sciences. 2022 Aug 11;7(19):94-102. doi: https://doi.org/10.5281/zenodo.6976429
6. Hwang Y, Oh J. Factors Affecting Health-Promoting Behaviors among Nursing Students. Int J Environ Res Public Health. 2020 Aug 28;17(17):6291. doi: https://doi.org/10.3390/ijerph17176291
7. Yıldırım Şişman N, Karaca A, Cangür S. Factors affecti̇ng health-promoting behavi̇ors i̇n nursi̇ng students: A structural equation modeling approach. Nurse Educ Pract. 2020 Oct;48:102880. doi: https://doi.org/10.1016/j.nepr.2020.102880. Erratum in: Nurse Educ Pract. 2023 Jan;66:103513. doi: https://doi.org/10.1016/j.nepr.2022.103513
8. Mak YW, Kao AHF, Tam LWY, Tse VWC, Tse DTH, Leung DYP. Health-promoting lifestyle and quality of life among Chinese nursing students. Prim Health Care Res Dev. 2018 Nov;19(6):629-36. doi: https://doi.org/10.1017/S1463423618000208
9. Paudel S, GC KB, Bhandari L, Arjyal A. Health related lifestyle behaviors among undergraduate medical students in Patan Academy of Health Sciences in Nepal. Journal of Biosciences and Medicines. 2017 Aug 23;5(9):43-53. doi: https://doi.org/10.4236/jbm.2017.59005
10. Kurt AS. The relationship between healthy life­style behaviors and health locus of control among nursing and midwifery students. American Journal of Nursing Research. 2015;3(2):36-40. doi: https://doi.org/10.12691/ajnr-3-2-2
11. Wei CN, Harada K, Ueda K, Fukumoto K, Mina­moto K, Ueda A. Assessment of health-promoting lifestyle profile in Japanese university students. Environ Health Prev Med. 2012 May;17(3):222-7. doi: https://doi.org/10.1007/s12199-011-0244-8
12. Baransel ES, Barut S. Exploration of the mid­wifery students' health-promoting lifestyle behaviors ac­cording to their body mass indexes and body per­ceptions. Medicine Science. 2023 Sep 1;12(3):987-93. doi: https://doi.org/10.5455/medscience.2023.07.107
13. Alzahrani SH, Malik AA, Bashawri J, Sha­heen SA, Shaheen MM, Alsaib AA, et al. Health-promo­ting lifestyle profile and associated factors among medical students in a Saudi university. SAGE Open Med. 2019 Mar 25;7:2050312119838426. doi: https://doi.org/10.1177/2050312119838426
14. Müller C, El-Ansari K, El Ansari W. Health-Pro­moting Behavior and Lifestyle Characteristics of Students as a Function of Sex and Academic Level. Int J Environ Res Public Health. 2022 Jun 20;19(12):7539. doi: https://doi.org/10.3390/ijerph19127539
15. Fashafsheh I, Al-Ghabeesh SH, Ayed A, Sala­ma B, Batran A, Bawadi H. Health-Promoting Behaviors among Nursing Students: Palestinian Perspective. Inquiry. 2021 Jan-Dec;58:469580211018790. doi: https://doi.org/10.1177/00469580211018790
16. Almutairi KM, Alonazi WB, Vinluan JM, Almig­bal TH, Batais MA, Alodhayani AA, et al. Health promo­ting lifestyle of university students in Saudi Arabia: a cross-sec­ti­onal assessment. BMC Public Health. 2018 Sep 5;18(1):1093. doi: https://doi.org/10.1186/s12889-018-5999-z
17. TemizG, Harmankaya G. Evaluation of health pro­moting behaviors and affecting factors in high school stu­dents. GNJ [Internet]. 2022 [cited 2025 Mar 18];7(19):94-102. Available from: https:gevhernesibedergisi.com/index.php/gnj/article/view/213
18. Chao Health-promoting lifestyle and its pre­dictors among health-related and non-health-related uni­versity students in Taiwan: a cross-sectional quantitative study. BMCPublic Health. 2013;23:827. doi: https://doi.org/10.1186/s12889-023-15760-2
19. Cameron DM, Muratore F, Tower M, Eades CE, Evans JM. Exploration of health and health behaviours of undergraduate nursing students: a multi-methods study in two countries. Contemporary Nurse. 2022 Nov 2;58(5-6):473-83. doi: https://doi.org/10.1080/10376178.2022.2085128
20. Abuadas F. Assessment of Health-promoting Be­haviors and Influential Factors in Undergraduate Students in Saudi Arabian Governmental Universities. Open Public Health 2023;16:e18749445271320. doi https://doi.org/10.2174/0118749445271320230922102204
21. Walker SN, Sechrist KR, Pender NJ. Health pro­motion model-instruments to measure health promoting lifestyle: Health-promoting lifestyle profile [HPLP II] (Adult version). University of Michigan Library. Deep Blue Documents [Internet]. 1995 [cited 2025 Apr 29]. Avialablefrom: https://deepblue.lib.umich.edu/handle/2027.42/85349
22. Gosset WS. The probable error of a mean. Bio­metrika. 1908;6(1):1-25. doi: https://doi.org/10.1093/biomet/6.1.1
23. Fisher RA. Statistical methods for research workers. Oliver and Boyd; 1928.
24. Pearson K. VII. Note on regression and inheri­tance in the case of two parents. Proceedings of the royal society of London. 1895 Dec 31;58(347-352):240-2. doi: https://doi.org/10.1098/rspl.1895.0041
25. Anh TT, Kang M, Kim N. Factors Affecting Health-Promoting Behaviors among Vietnamese Students in Korea. Korean J Adult Nurs. 2021 Aug;33(4):349-59. doi: https://doi.org/10.7475/kjan.2021.33.4.349
26. Kraja J, Fresku E, Xhakollari L. Altruistic values among students of Nursing, Midwifery, Physiotherapy, and Health Psychology: a crosssectional study. Medicni perspektivi. 2024;2:123-32. doi: https://doi.org/10.26641/2307-0404.2024.2.307603

Look through:

Xhakollari L. University of Shkodra “Luigj Gurakuqi”, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-6552-4364

Kraja J. University of Shkodra “Luigj Gurakuqi”, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-6694-394X

Marku M. University of Shkodra “Luigj Gurakuqi”, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0007-0251-8283

Fresku E. University of Shkodra “Luigj Gurakuqi”, Shkoder, Albania
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-1333-8986

Xhakollari L., Kraja J., Marku M., Fresku E. Nursing, midwifery and health psychology students' attitude towards health-promoting behaviours: a cross-sectional study. Medicni perspektivi. 2025;30(3):171-181.
doi: https://doi.org/10.26641/2307-0404.2025.3.340761

Indicative features of tissue and microbial sensitization in the pathogenesis of generalized parodontitis associated with rheumatoid arthritis

The human body during physical exercise triggers various molecular reactions, one of which is the activation of hypoxia-inducible factor-1 alpha (HIF-1α), a transcription factor that plays a role in cellular responses to hypoxic conditions. Hypoxia is a condition in which the body experiences a lack of oxygen. Although it is known that physical exercise can increase HIF-1α expression, until now there is still inconsistency in the results of studies related to the impact of physical exercise on HIF-1α expression.In addition, the underlying mechanism of increased HIF-1α during physical exercise is not fully understood. The lack of a deep understanding of the causal relationship between physical exercise and HIF-1α expression is a challenge in efforts to unravel the underlying mechanisms. Therefore, more systematic studies are needed to evaluate the specific effects of physical exercise on HIF-1α regulation and its impact on physiological adaptation. The aim of this study was to investigate and measure the mechanism of physical exercise on increasing the expression of hypoxia-inducible factor 1-alpha (HIF-1α). Several journal databases, including Embase, Pubmed, Web of Science, and Scopus, were searched for this study. The study considered several criteria, including studies published in the last five years and those related to erythropoietin, physical activity, and HIF-1α. The only papers excluded from inclusion in this analysis were those published in non-reputable journals.Using databases from Embase, Web of Science, Pubmed, and Scopus, a total of 1578 publications were identified. Ten carefully screened and peer-reviewed papers addressed what is needed for this systemic change. The current standard operating procedure for investigations was established using Systematic and Meta-Analysis Preferred Reporting Items (PRISMA). The results of this systemic analysis show that physical exercise has been shown to increase HIF-1α expression. Increased HIF-1α causes the hormone erythropoietin to be secreted and an increase in erythrocytes count which then affects hemoglobin and VO₂max and ultimately increases the athlete's physical performance.

Key words: physicalexercise, hipoxia, HIF-1α

1. Li J, Li Y, Atakan MM, Kuang J, Hu Y, Bi­shop DJ, et al. The Molecular Adaptive Responses of Skeletal Muscle to High-Intensity Exercise/Training and Hypoxia. Antioxidants (Basel). 2020 Jul 24;9(8):656. doi: https://doi.org/10.3390/antiox908065
2. Soo J, Raman A, Lawler NG, Goods PSR, Deldi­cque L, Girard O, et al. The role of exercise and hypoxia on glucose transport and regulation. Eur J Appl Physiol. 2023 Jun;123(6):1147-65. doi: https://doi.org/10.1007/s00421-023-05135-1
3. Herrmann SD, Willis EA, Ainsworth BE, Bar­reira TV, Hastert M, Kracht CL, et al. 2024 Adult Com­pendium of Physical Activities: A third update of the energy costs of human activities. J Sport Health Sci. 2024 Jan;13(1):6-12. doi: https://doi.org/10.1016/j.jshs.2023.10.010
4. Kammerer T, Faihs V, Hulde N, Stangl M, Bret­tner F, Rehm M, et al. Hypoxic-inflammatory responses under acute hypoxia: In Vitro experiments and prospective observational expedition trial. Int J Mol Sci. 2020;21(3):1034. doi: https://doi.org/10.3390/ijms21031034
5. Nell HJ, Castelli LM, Bertani D, et al. The effects of hypoxia on muscle deoxygenation and recruitment in the flexor digitorum superficialis during submaximal inter­mittent handgrip exercise. BMC Sports Sci Med Rehabil. 2020;12:16.
   doi: https://doi.org/10.1186/s13102-020-00163-2
6. Khalafi M, Symonds ME. The impact of high-intensity interval training on inflammatory markers in metabolic disorders: A meta-analysis. Scand J Med Sci Sports. 2020 Nov;30(11):2020-36. doi: https://doi.org/10.1111/sms.13754
7. Khalafi M, Sakhaei MH, Symonds ME, Noori Mof­rad SR, Liu Y, Korivi M. Impact of Exercise in Hypoxia on Inflammatory Cytokines in Adults: A Systematic Review and Meta-analysis. Sports Med Open. 2023 Jun 29;9(1):50.
   doi: https://doi.org/10.1186/s40798-023-00584-6
8. Kierans SJ, Taylor CT. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J Physiol. 2021 Jan;599(1):23-37. doi: https://doi.org/10.1113/JP280572
9. Torabimehr F, Kazemi N, Hosseini SA. Effects of Resistance and Endurance Training on HIF-1α and VEGF in Heart Tissues of Pregnant Rats with Cadmium Toxicity. Gene Cell Tissue. 2019;6(1):e88363. doi: https://doi.org/10.5812/gct.88363
10. Soori R, Zadeh M, Ghram A, Choobineh S, Mir­zaei MR, Voltarelli AF. Effects of Hypoxic and Normoxic Training in Altitude on HIF-1α and PGC-1α Levels in Elite Endurance Runners. Sport Sciences and Health Research, 2020;11(1): 61-70. doi: https://doi.org/10.32598/jesm.11.1.6
11. Flood D, Lee ES, Taylor CT. Intracellular energy production and distribution in hypoxia. J Biol Chem. 2023 Sep;299(9):105103. doi: https://doi.org/10.1016/j.jbc.2023.105103
12. Burtscher J, Hohenauer E, Burtscher M, Mil­let GP, Egg M. Environmental and behavioral regulation of HIF-mitochondria crosstalk. Free Radic Biol Med. 2023 Sep;206:63-73. doi: https://doi.org/10.1016/j.freeradbiomed.2023.06.015
13. Wibawa JC, Arifin MZ, Herawati L. Ascorbic Acid Drink after Submaximal Physical Activity can Maintain the Superoxide Dismutase Levels in East Java Student Regiment. Indian J Forensic Med Toxicol. 2021 May 17;15(3):3383-92. doi: https://doi.org/10.37506/ijfmt.v15i3.15824
14. Donnelly C, Schmitt S, Cecatto C, Cardoso LHD, Komlódi T, Place N, et al. The ABC of hypoxia – what is the norm. Bioenerg Commun. 2022;12:v2. doi: https://doi.org/10.26124/bec:2022-0012.v2
15. Burtscher J, Duderstadt Y, Gatterer H, Burt­scher M, Vozdek R, Millet GP, et al. Hypoxia Sensing and Responses in Parkinson's Disease. Int J Mol Sci. 2024 Feb 1;25(3):1759. doi: https://doi.org/10.3390/ijms25031759
16. Burtscher J, Romani M, Bernardo G, Popa T, Zi­viani E, Hummel FC, et al. Boosting mitochondrial health to counteract neurodegeneration. Prog Neurobiol. 2022 Aug;215:102289. doi: https://doi.org/10.1016/j.pneurobio.2022.102289
17. Chong MC, Shah AD, Schittenhelm RB, Silva A, James PF, Wu SSX, et al. Acute exercise-induced release of innate immune proteins via small extracellular vesicles changes with aerobic fitness and age. Acta Physiol (Oxf). 2024 Mar;240(3):e14095. doi: https://doi.org/10.1111/apha.14095
18. Ayubi N, Wibawa JC, Callixte С. The mechanism of physical exercises increases heat shock protein 70 (HSP70) (a systematic review). Medicni perspektivi. 29(4):14-22.
    doi: https://doi.org/10.26641/2307-0404.2024.4.319168
19. Song W, Liang Q, Cai M, Tian Z. HIF-1α-indu­ced up-regulation of microRNA-126 contributes to the effectiveness of exercise training on myocardial angio­genesis in myocardial infarction rats. J Cell Mol Med. 2020 Nov;24(22):12970-9. doi: https://doi.org/10.1111/jcmm.15892
20. Baygutalp F, Buzdağlı Y, Ozan M, Koz M, Kılıç Baygutalp N, Atasever G. Impacts of different intensities of exercise on inflammation and hypoxia markers in low al­ti­tude. BMC Sports Sci Med Rehabil. 2021 Nov 22;13(1):145. doi: https://doi.org/10.1186/s13102-021-00375-0
21. Tian X, Zhou N, Yuan J, et al. Heat shock trans­cription factor 1 regulates exercise-induced myocardial angiogenesis after pressure overload via HIF-1α/VEGF pathway. J Cell Mol Med. 2020;24(3):2178-88. doi: https://doi.org/10.1111/jcmm.14872
22. Wu D, Cao W, Xiang D, Hu YP, Luo B, Chen P. Exercise induces tissue hypoxia and HIF-1α redistribution in the small intestine. J Sport Health Sci. 2020 Jan;9(1):82-9. doi: https://doi.org/10.1016/j.jshs.2019.05.002
23. Tryfonos A, Tzanis G, Pitsolis T, Karatzanos E, Koutsilieris M, Nanas S, et al. Exercise Training Enhances Angiogenesis-Related Gene Responses in Skeletal Muscle of Patients with Chronic Heart Failure. Cells. 2021 Jul 28;10(8):1915. doi: https://doi.org/10.3390/cells10081915
24. Płoszczyca K, Chalimoniuk M, Przybylska I, Czu­ba M. Effects of Short-Term Phosphate Loading on Aero­bic Capacity under Acute Hypoxia in Cyclists: A Ran­domized, Placebo-Controlled, Crossover Study. Nutrients. 2022 Jan 6;14(2):236. doi: https://doi.org/10.3390/nu14020236
25. Kamada Y, Arai Y, Toyama S, Inoue A, Naka­gawa S, Fujii Y, et al. Hypoxia with or without Treadmill Exercises Affects Slow-Twitch Muscle Atrophy and Joint Destruction in a Rat Model of Rheumatoid Arthritis. Int J Mol Sci. 2023 Jun 5;24(11):9761. doi: https://doi.org/10.3390/ijms24119761
26. Volga Fernandes R, Tricoli V, Garcia Soares A, Haruka Miyabara E, Saldanha Aoki M, Laurentino G. Low-Load Resistance Exercise with Blood Flow Restriction Increases Hypoxia-Induced Angiogenic Genes Expression. J Hum Kinet. 2022 Nov 8;84:82-91. doi: https://doi.org/10.2478/hukin-2022-0101
27. Wibawa JC, Febrianto N, Fudin MS, Ockta Y, Festiawan R. El mecanismo del ejercicio físico aumenta la glutatión peroxidasa como antioxidante endógeno: una revisión sistemática. Retos.2025;63:610-9. doi: https://doi.org/10.47197/retos.v63.108856
28. Mukund K, Subramaniam S. Skeletal muscle: A review of molecular structure and function, in health and disease. Wiley Interdiscip Rev Syst Biol Med. 2020 Jan;12(1):e1462. doi: https://doi.org/10.1002/wsbm.1462
29. Yu Y, Ma L, Zhang H, Sun W, Zheng L, Liu C, et al. EPO could be regulated by HIF-1 and promote osteogenesis and accelerate bone repair. Artif Cells Nanomed 2020 Dec;48(1):206-17. doi: https://doi.org/10.1080/21691401.2019.1699827
30. Xu Z, Chen Y, Yu D, Mao D, Wang T, Feng D, et al. The effects of exercise on COVID-19 therapeutics: A protocol for systematic review and meta-analysis. Medi­cine(Baltimore). 2020 Sep 18;99(38):e22345. doi: 10.1097/MD.0000000000022345
31. Singh RB, Tappia PS, Fedacko J, et al. Repeated episodes of physical training induced hypoxia, may be associated with improved exercise tolerance in COVID-19. MOJPublic  2022;11(2):50-2. doi: https://doi.org/10.15406/mojph.2022.11.00374
32. Macarlupu JL, Marchant D, Jeton F, Villafuerte F, Richalet JP, Voituron N. Effect of exercise training in rats exposed to chronic hypoxia: Application for Monge's disease. Physiol 2021 Apr;9(7):e14750. doi: https://doi.org/10.14814/phy2.14750
33. Uzun AB, Iliescu MG, Stanciu LE, Ionescu EV, Un­gur RA, Ciortea VM, et al. Effectiveness of Intermittent Hy­poxia-Hyperoxia Therapy in Different Pathologies with Pos­sible Metabolic Implications. Metabolites. 2023;13(2):181. doi: https://doi.org/10.3390/metabo13020181
34. Zhao Y, Xing C, Deng Y, Ye C, Peng H. HIF-1α signaling: Essential roles in tumorigenesis and impli­cations in targeted therapies. Genes Dis. 2023;11(1):234-51. doi: https://doi.org/10.1016/j.gendis.2023.02.039
35. Liu Z, Wu Z, Fan Y, Fang Y. An overview of biological research on hypoxia-inducible factors (HIFs). Endokrynol 2020;71(5):432-40. doi: https://doi.org/10.5603/EP.A2020.0064
36. Korbecki J, Simińska D, Gąssowska-Dobrowols­ka M, Listos J, Gutowska I, Chlubek D, et al. Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Mo­lecular Mechanisms. Int J Mol Sci. 2021 Oct 2;22(19):10701. doi: https://doi.org/10.3390/ijms221910701
37. Daniela M, Catalina L, Ilie O, Paula M, Daniel-Andrei I, Ioana B. Effects of Exercise Training on the Autonomic Nervous System with a Focus on Anti-Inflammatory and Antioxidants Effects. Antioxidants (Basel).2022 Feb 10;11(2):350. doi: https://doi.org/10.3390/antiox11020350
38. McKenna MJ, Renaud JM, Ørtenblad N, Over­gaard K. A century of exercise physiology: effects of muscle contraction and exercise on skeletal muscle Na+,K+-ATPase, Na+ and K+ ions, and on plasma K+ concentration-historical developments. Eur J Appl Physiol. 2024 Mar;124(3):681-751. doi: https://doi.org/10.1007/s00421-023-05335-9
39. Liepinsh E, Makarova E, Plakane L, Konrade I, Liepins K, Videja M, et al. Low-intensity exercise stimu­lates bioenergetics and increases fat oxidation in mitochondria of blood mononuclear cells from sedentary adults. Physiol 2020 Jun;8(12):e14489. doi: https://doi.org/10.14814/phy2.14489
40. Drouin PJ, Liu T, Lew LA, McGarity-Shipley E, Tschakovsky ME. The 'normal' adjustment of oxygen deli­very to small muscle mass exercise is not optimized for muscle contractile function. J Physiol. 2023 Feb;601(4):783-99. doi: https://doi.org/10.1113/JP283933
41. Ayubi N, Wibawa JC, Lesmana HS, et al. Physical exercise induces increased translocation of type 4 glucose transporters (GLUT4): a systematic review. 2024;59:1003-8. doi: https://doi.org/10.47197/retos.v59.104078
42. Wu G, Cao B, Zhai H, Liu B, Huang Y, Chen X, et al. EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3. Ann Rheum Dis. 2024 Apr 11;83(5):564-75. doi: https://doi.org/10.1136/ard-2023-224852
43. Bhoopalan SV, Huang LJ, Weiss MJ. Erythro­poietin regulation of red blood cell production: from bench to bedside and back. F1000Res. 2020 Sep 18;9:F1000 Faculty Rev-1153. doi: https://doi.org/10.12688/f1000research.26648.1
44. Wang X, Zhu N, Zeng W, Wang P. Hemoglobin variability in patients receiving EPO and roxadustat during maintenance hemodialysis: a self-control study. Eur Rev Med Pharmacol Sci. 2024 Jan;28(1):303-9. doi: https://doi.org/10.26355/eurrev_202401_34917
45. Yunus M. Effect of 6 Weeks of Circuit Training on Increased Vo₂Max. J Heal Sains. 2023;4(7):26-33. doi: https://doi.org/10.46799/jhs.v4i7.1001

Look through:

Yulfadinata A. Universitas Negeri Surabaya, Surabaya, Jawa Timur, Indonesia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0004-1281-0518

Ayubi N. Universitas Negeri Surabaya, Surabaya, Jawa Timur, Indonesia
https://orcid.org/0000-0002-5196-6636

Wibawa J.C. STKIP PGRI Trenggalek, Trenggalek, Jawa Timur, Indonesia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0009-2597-5350

Rizki A.Z. Universitas Negeri Surabaya, Surabaya, Jawa Timur, Indonesia
https://orcid.org/0009-0006-7025-7209

Afandi A. Universitas Negeri Surabaya, Surabaya, Jawa Timur, Indonesia
https://orcid.org/0009-0009-7161-3852

Jr P.B.D. Mariano Marcos State University, Batac, Ilocos Norte, Philippines, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-4249-6126

Yulfadinata A., Ayubi N., Wibawa J.C., Rizki A.Z., Afandi A., Jr P.B.D. The effect of physical exercise in increasing hypoxia-inducible factor-1 alpha: a systematic review. Medicni perspektivi. 2025;30(3):182-192.
doi: https://doi.org/10.26641/2307-0404.2025.3.340762

On the issue of creating an algorithm for assessing safety culture in modern healthcare institutions

Despite the successes of modern rehabilitation in acute stroke, the effectiveness of existing methods remains limited in patients with visuospatial neglect (VSN). This encourages the search for new methods of occupational therapy interventions, in particular, taking into account the available interactive devices. The aim of this study was to evaluate the impact of the interactive and cognitive rehabilitation device Myro on the state of cognitive functions, visuospatial perception, fine motor skills, gross upper limb functions and limitations of daily activity in patients with neglect due to stroke during the post-acute rehabilitation period. In the study 46 patients were included, 12 women and 34 men, aged 32 to 86 years (mean age was 62.8(12.8) years). All patients were assessed for their visuospatial perception, cognitive function, motor and sensory functions, and activity limitations at the beginning and the end of rehabilitation. In the first stage, during 2023-2024, 18 patients were included in the control group, who were assigned a standardized rehabilitation program. In the second stage, during 2024-2025, 28 patients participated in the main group, who were assigned an author's occupational therapy program using the Myro interactive and cognitive rehabilitation device. All patients received 3 hours of rehabilitation interventions per day for 14 days. The use of the program with an interactive device showed greater effectiveness in restoring gross motor functions of the upper limb, in particular 2.1 times better according to the results of the “Box and Blocks” test (p<0.05), to significantly greater dynamics according to the Barthel Index level (3.3 times, p<0.05). In addition, in the main group, signs of VSN were 27.1% less common at the end of therapy (p<0.05). However, after completing the rehabilitation course there weren’t the advantages of the author's program in terms of the effectiveness of improving cognitive function according to the Montreal Cognitive Test, functioning of the upper limb according to the Fugl-Meyer scale, as well as in terms of restoring fine motor skills of the upper limb according to the “9 pegs” test (p>0.05). Thus, the use of the interactive and cognitive rehabilitation device Myro has shown its effectiveness for the treatment of symptoms of VSN, recovery of gross motor functions and limitations of daily functioning in patients with the consequences of cerebral stroke. However, there is no convincing data on the superior effectiveness of this technique in patients with impaired fine motor skills of the upper limb and cognitive impairment compared to the standard program. 

Key words: stroke, visuospatial neglect, rehabilitation, occupational therapy, interactive sensor device Myro, cognitive function, functioning, disability

1. Esposito E, Shekhtman G, Chen P. Prevalence of spatial neglect poststroke: a systematic review. Ann Phys Rehabil Med. 2021;64:101459. doi: https://doi.org/10.1016/j.rehab.2020.10.010
2. Rowe FJ, Hepworth LR, Begoña Coco-Mar­tin M, Gillebert CR, Leal-Vega L, Palmowski-Wolfe A, et al. European Stroke Organisation (ESO) guideline on visual impairment in stroke. Eur Stroke J. 2025 May 22:23969873251314693. doi: https://doi.org/10.1177/23969873251314693
3. Chen P, Chen CC, Hreha K, Goedert KM, Bar­rett AM. Kessler Foundation Neglect Assessment Process uniquely measures spatial neglect during activities of daily living. Arch Phys Med Rehabil. 2015 May;96(5):869-876.e1. doi: https://doi.org/10.1016/j.apmr.2014.10.023
4. Totska A, Nekhanevych O, Korota Y, Mokhna V, Kharchenko V. [The effectiveness of compensatory stra­tegies in the rehabilitation of patients with visuospatial neglect during the post-acute period of stroke rehabi­litation]. Medicni perspektivi.2025;30(1):127-34. Ukrainian. doi: https://doi.org/10.26641/2307-0404.2025.1.325373 
5. Moore MJ, Vancleef K, Riddoch MJ, Gille­bert CR, Demeyere N. Recovery of visuospatial neglect subtypes and relationship to functional outcome six months after stroke. Neurorehabil Neural Repair. 2021;35:823-35. doi: https://doi.org/10.1177/15459683211032977
6. Overman MJ, Binns E, Milosevich ET, De­meyere N. Recovery of Visuospatial Neglect With Stan­dard Treatment: A Systematic Review and Meta-Analysis. Stroke.2024 Sep;55(9):2325-39. doi: https://doi.org/10.1161/STROKEAHA.124.046760
7. National clinical guideline for stroke. Fifth Edi­tion. [Internet]. UK: Royal college of Physycians; 2016. [cited 2025 Apr 29].151 p. Available from: https://www.strokeguideline.org/app/uploads/2023/03/2016-National-Clinical-Guideline-for-Stroke-5th-edition.pdf
8. Clinical Guidelines for Stroke Management 2017. Summary – Occupational Therapy. Prevent. Treat. Beat [Internet]. [cited 2025 Apr 29]. Available from: https://informme.org.au/en/Guidelines/Clinical-Guidelines-for-Stroke-Management-2017
9. Bai Z, Zhang J, Zhang Z, Shu T, Niu W. Compa­rison Between Movement-Based and Task-Based Mirror Therapies on Improving Upper Limb Functions in Patients With Stroke: A Pilot Randomized Controlled Trial. Front Neurol.2019 Mar 26;10:288. doi: https://doi.org/10.3389/fneur.2019.00288 
10. Dido YuM, Dulo OA. Dynamic of upper limb sensorimotor recovery assessed on the fugl-meyer scale in post-stroke patients with neglect syndrome re-ceiving combined physical therapy and ergotherapy. Wiadomości Lekarskie.2021;74(4):849-55. doi: https://doi.org/10.36740/WLek202104107
11. Kwakkel G, Kollen BJ. Predicting activities after stroke: what is clinically relevant? Int J Stroke. 2013;8:25-32.
    doi: https://doi.org/10.1111/j.1747-4949.2012.00967.x
12. Carlsson H, Rosén B, Björkman A, Pessah-Ras­mussen H, Brogårdh C. SENSory re-learning of the UPPer limb (SENSUPP) after stroke: development and descrip­tion of a novel intervention using the TIDieR checklist. Trials.2021 Jul 5;22(1):430. doi: https://doi.org/10.1186/s13063-021-05375-6 
13. Tutak JS, Mucha J. A Prototype Mechatronic De­vice for Upper Limb Rehabilitation and Analysis of Its Functionality. Applied Sciences. 2025;15(12):6613. doi: https://doi.org/10.3390/app15126613
14. Gibson E, Koh CL, Eames S, Bennett S, Scott AM, Hoffmann TC. Occupational therapy for cogni­tive impairment in stroke patients. Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: https://doi.org/10.1002/14651858.CD006430.pub3
15. Nekhanevych O, Griban G, Sekretnyi V, Baku­ridze-Manina V, Kaniuka Ye, Kovalenko T, et al. Pre­dicting the Effectiveness of Physical Therapy in Hockey Players after Cerebral Concussion. International Journal of Human Movement and Sports Sciences. 2023;11(2):316-25. doi: https://doi.org/10.13189/saj.2023.110208
16. [Standard of medical care for ischemic stroke. Order of the Ministry of Health of Ukraine dated 2024 Jun 20 No 1070]. [Internet]. 2024 [cited 2025 Apr 29]. Available from: https://moz.gov.ua/uk/decrees/nakaz-moz-ukrayini-vid-20-06-2024-1070-pro-zatverdzhennya-standartu-medichnoyi-dopomogi-ishemichnij-insult
17. Vratsistas-Curto A, Downie A, McCluskey A, Sherrington C. Trajectories of arm recovery early after stroke: an exploratory study using latent class growth analysis. Ann 2023 Dec;55(1):253-65. doi: https://doi.org/10.1080/07853890.2022.2159062
18. Ahmed Hassanin M, Aly MG, Atef H, Marques-Sule E, Ahmed GM. Task-oriented training for upper limb functions in patients with multiple sclerosis: Systematic review and meta-analysis. Mult Scler Relat Disord. 2023 May;73:104625. doi: https://doi.org/10.1016/j.msard.2023.104625
19. Huang YD, Li W, Chou YL, Hung ES, Kang JH. Pendulum test in chronic hemiplegic stroke population: additional ambulatory information beyond spasticity. Sci Rep.2021;11(1):14769. doi: https://doi.org/10.1038/s41598-021-94108-5
20. Stroke rehabilitation in adults. NICE guideline [Internet]. 2023 Oct 18 [cited 2025 Apr 29]. Available from: https://www.nice.org.uk/guidance/ng236
21. Pyrozhkov SI, Riazantseva VV, Motoryn RM, et al. [Statistics]. Kyiv National University of Trade and Economics; 2020. 328 p. doi: http://doi.org/10.31617/p.knute.2020-164 
22. Husain M, Rorden C. Non-spatially lateralized me­chanisms in hemispatial neglect. Nat Rev Neurosci. 2003;4:26-36. doi: https://doi.org/10.1038/nrn1005
23. Demeyere N, Gillebert CR. Ego- and allocentric visuospatial neglect: dissociations, prevalence, and la­terality in acute stroke. Neuropsychology. 2019;33:490-8. doi: https://doi.org/10.1037/neu0000527
24. Saj A, Verdon V, Vocat R, et al. ‘The anatomy un­derlying acute versus chronic spatial neglect’ also depends on clinical tests. Brain. 2012;135(Pt 2):e207; author reply e08. doi: https://doi.org/10.1093/brain/awr227

Look through:

Totska A.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0009-0001-7169-3022

Nekhanevych O.B. Dnipro State Medical University, Dnipro, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-0307-784X

Korota Yu.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0009-0000-7536-7673

Mokhna V.S. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0001-6009-6110

Logvynenko V.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0001-5576-1681

Totska A.V., Nekhanevych O.B., Korota Yu.V., Mokhna V.S., Logvynenko V.V. Effectiveness of device for using interactive and cognitive therapy in the rehabilitation of patients with visuospatial neglect due to cerebral stroke during the post-acute rehabilitation period. Medicni perspektivi. 2025;30(3):192-199.
doi: https://doi.org/10.26641/2307-0404.2025.3.340763

On the issue of creating an algorithm for assessing safety culture in modern healthcare institutions

Infantile hemangiomas are the most common benign vascular tumors in infants, with a detection rate of 2-5% in newborns, while among premature infants their incidence reaches 23%. These tumors can vary greatly in size and location, sometimes causing serious complications such as visual, respiratory or bleeding disorders, which significantly impair the quality of life of patients and can lead to long-term consequences. Propranolol in the form of an oral solution has been approved as a first-line treatment for infantile hemangiomas, it has vasoconstrictor and antiangiogenic effects and promotes the induction of apoptosis of tumor endothelial cells, resulting in a significant reduction in hemangioma size and improvement in patient condition. Despite the high incidence of the disease, there are no standardized propranolol medicines for pediatric patients in Ukraine, which greatly complicates treatment and forces doctors to use off-label drugs. This creates risks associated with improper dosage, variability in the concentration of the active ingredient, and possible side effects. The purpose of the study is to analyze the scientific literature on the efficacy and safety of propranolol in the treatment of infantile hemangiomas, as well as to justify the need to develop new dosage forms for pediatrics. To achieve this goal, we analyzed scientific articles, clinical trial data, and the legislative framework, including international guidelines and treatment protocols. The study used methods of analysis, information systematization and genera­lization.The results of the study show that propranolol is highly effective in the treatment of hemangiomas. Its therapeutic effect is explained by vasoconstrictor, antiangiogenic effects and induction of apoptosis of tumor endothelial cells. According to clinical trials, the standard treatment regimen involves the use of propranolol at a dose of 2-3 mg/kg of body weight per day for six months, which helps to reduce tumor size, low the possibility of complications and improve the quality of life of patients. The development of new, standardized pharmaceutical products for children with propranolol will increase the effectiveness of treatment and minimize side effects, making this issue relevant for both clinical practice and the pharmaceutical industry.

Key words: off-label use, propranolol, infantile hemangioma, children, neonates, pediatrics, safety, prescription, legislation

1. Meng M, Zhou Q, Lei W, et al. Recommendations on Off-Label Drug Use in Pediatric Guidelines. Front Pharmacol.2022;9(13):892574. doi: https://doi.org/10.3389/fphar.2022.892574 
2. Petkova V, Georgieva D, Dimitrov M, Nikolova I. Off-Label Prescribing in Pediatric Population - Literature Review for 2012-2022. Pharmaceutics. 2023;15(12):2652. doi: https://doi.org/10.3390/pharmaceutics15122652
3. Yuan X, Gao J, Yang L, Tan Y, Bajinka O. Off‑la­bel and unapproved pediatric drug utilization: A meta‑analysis. ExpTher  2024;28:412. doi: https://doi.org/10.3892/etm.2024.12701
4. Kaley VR, Aregullin EO, Samuel BP, Vettu­kat­til JJ. Trends in the off-label use of β-blockers in pediatric patients. Pediatr 2019;61:1071-80. doi: https://doi.org/10.1111/ped.14015
5. Walton M, Wagner JB. Pediatric Beta Blocker The­rapy: A Comprehensive Review of Development and Ge­netic Variation to Guide Precision-Based The­rapy in Child­ren, Adolescents, and Young Adults. Genes. 2024;15(3):379. doi: https://doi.org/10.3390/genes15030379
6. Attebäck M, Hedin B, Mattsson S. Formulation Optimization of Extemporaneous Oral Liquids Containing Naloxone and Propranolol for Pediatric Use. Scientia Pharmaceutica.2022;90:15. doi: https://doi.org/10.3390/scipharm90010015
7. Guideline on Pharmaceutical Development of Medicines for Paediatric Use. European Medicines Agency [Internet]. 2014 [cited 2024 Oct 29]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf
8. Seebauer CT, Graus MS, Huang L, et al. Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. J Clin Invest. 2022;132(3):e151109. doi: https://doi.org/10.1172/jci151109
9. Holm A, Mulliken JB, Bischoff J. Infantile he­mangioma: the common and enigmatic vascular tumor. J Clin 2024;134(8):e172836. doi: https://doi.org/10.1172/jci172836
10. Dankhara N, Kalikkot Thekkeveedu R, Patel J, Desai J. Association of Infantile Hemangiomas and Reti­nopathy of Prematurity: Analysis of the Multicenter KID. Biomed 2022;7(1):24-30. doi: https://doi.org/10.1159/000521413
11. Tan JMC, Lim HW, Koh MJ. Oral propranolol for the treatment of infantile haemangiomas in Singapore. SingaporeMed  2021;62(3):139-42. doi: https://doi.org/10.11622/smedj.2020008
12. Classification ISSVA [Internet]. [cited 2024 Dec 26]. Available from: https://www.issva.org/classification
13. Kowalska M, Dębek W, Matuszczak E. Infantile Hemangiomas: An Update on Pathogenesis and Treatment. JClin  2021;10(20):4631. doi: https://doi.org/10.3390/jcm10204631
14. Rodríguez Bandera AI, Sebaratnam DF, War­gon O, Wong LF. Infantile hemangioma. Part 1: Epide­miology, pathogenesis, clinical presentation and asses­sment. J Am Acad Dermatol. 2021;85(6):1379-92. doi: https://doi.org/10.1016/j.jaad.2021.08.019
15. Hamada H, Iwama N, Tomita H, et al. The Japan Environment And Children's Study Group. Association between Maternal Birth Weight and Prevalence of Congenital Malformations in Offspring: The Japanese En­vironment and Children's Study. Nutrients.2024;16(4):531. doi: https://doi.org/10.3390/nu16040531
16. Sandru F, Petca A, Radu A-M, et al. Infantile Hemangioma: Risk Factors and Management in a Preterm Patient – A Case Report. Reports. 2024;7(1):3. doi: https://doi.org/10.3390/reports7010003
17. Foust AM, Krishnasarma R, Robson C, et al. Con­genital and Infantile Masses of the Head and Neck. Radiographics.2024;44(12):e240059. doi: https://doi.org/10.1148/rg.240059
18. Sandru F, Turenschi A, Constantin AT, Dinu­lescu A, Radu AM, Rosca I. Infantile Hemangioma: A Cross-Sectio­nal Observational Study. Life (Basel). 2023;13(9):1868. doi: https://doi.org/10.3390/life13091868
19. Börjesson C, Malloizel-Delaunay J, Onnis G, Ma­zereeuw-Hautier J, Dreyfus I. Value of Doppler ultrasound scans in deciding whether to treat infantile haemangioma with oral propranolol. Annales de Dermatologie et de Vénéréologie. 2021;148(4):233-7. doi: https://doi.org/10.1016/j.annder.2021.03.004
20. Daruwalla SB, Khunger N, Kumar A, Dhurat RS. Should all Infantile Hemangiomas be Treated? − Time to Learn, Unlearn, and Relearn. Indian Journal of Paediatric Dermatology. 2022;23(1):28-32. doi: https://doi.org/10.4103/ijpd.ijpd_168_20
21. Gomez-Acevedo H, Dai Y, Strub G, et al. Identi­fication of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration. Sci Rep. 2020;10:3261.
    doi: https://doi.org/10.1038/s41598-020-60025-2
22. Meyer A, Mortensen L, Miller KA, et al. Use of modified human hemangioma tissue cultures and human umbilical vein endothelial cell cultures to gain mechanistic insights into imiquimod treatment for infantile heman­gioma. In Vitro Cell Dev Biol Anim. 2025 Jan;61(1):36-45. doi: https://doi.org/10.1007/s11626-024-00978-0
23. Gözdaşoğlu S. Infantile Hemangioma. In: Pu­revjav E, Storgion S, Dean Minniear T, editors. Common Childhood Diseases – Diagnosis, Prevention and Mana­gement [Internet]. IntechOpen; 2024 [cited 2024 Dec 26]. Available from: https://www.intechopen.com/chapters/1175355 doi: https://doi.org/10.5772/intechopen.1005634
24. Sun Y, Qiu F, Hu C, Guo Y, Lei S. Hemangioma Endothelial Cells and Hemangioma Stem Cells in Infantile Hemangioma. AnnPlast  2022;88(2):244-9. doi: https://doi.org/10.1097/SAP.0000000000002835
25. Jung HL. Update on infantile hemangioma. Clin Exp Pediatr. 2021;64(11):559-72. doi: https://doi.org/10.3345/cep.2020.02061
26. Rešić A, Barčot Z, Habek D, Pogorelić Z, Baš­ković M. The Evaluation, Diagnosis, and Management of Infantile Hemangiomas – A Comprehensive Review. J Clin 2025;14(2):425. doi: https://doi.org/10.3390/jcm14020425
27. Bellinato F, Marocchi M, Pecoraro L, et al. Diag­nosis and Treatment of Infantile Hemangioma from the Primary Care Paediatricians to the Specialist: A Narrative Review. Children(Basel). 2024;11(11):1397. doi: https://doi.org/10.3390/children11111397
28. Chang R, Qiu Y, Lin X. Intralesional corticos­teroid injections for infantile hemangioma. Chinese Jour­nal of Plastic and Reconstructive Surgery. 2023;5(2):80-5. doi: https://doi.org/10.1016/j.cjprs.2023.03.006
29. Yuan SM, Zhang M, Guo Y, et al. Intralesional injection of diprospan is effective for infantile heman­gioma. J Craniofac 2015;26(2):422-4. doi: https://doi.org/10.1097/SCS.0000000000001274   
30. Gałązka P, Bereźnicka W, Leis K, et al. Treatment of haemangiomas using propranolol in paediatric patients: a retrospective cohort study. Postepy Dermatol Alergol. 2020;37(4):603-7. doi: https://doi.org/10.5114/ada.2020.98282
31. Wu Y, Zhao P, Song W, Lu W, Dai T, Wang L. Our experience with propranolol for infantile hemangioma. SkinRes  2023;29:1-4. doi: https://doi.org/10.1111/srt.13310
32. Serreau R, Amirouche A, Benyamina A, Ber­teina-Raboin S. Propranolol Hydrochloride Psychiatric Effectiveness and Oxidative Stress: An Update. Oxygen.2024;4(2):139-49. doi: https://doi.org/10.3390/oxygen4020009
33. Bogatyryova R, Baula O, Nagorna O, et al. [Gui­deline ST-N of the Ministry of Health of Ukraine 42-3.15:2014. Medicinal products. Pharmaceutical develop­ment of medicinal products for pediatric use]. Kyiv: State Committee for Consumer Protection of Ukraine; 2003. 51 p. Ukrainian.
34. European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP), Pae­diatric Committee (PDCO), Guideline on Pharmaceutical Development of Medicines for Paediatric Use; EMA/CHMP/QWP/805880/2012 Rev. 2, 2013 [Internet]. EMA: Amsterdam, The Netherlands; 2013 [cited 2024 Oct 13]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf
35. Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Gras­si G, Esler M. Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comor­bidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension.2022 Jun;79(6):1153-66. doi: https://doi.org/10.1161/HYPERTENSIONAHA.122.19020
36. Peixoto R, Pereira MdL, Oliveira M. Beta-Bloc­kers and Cancer: Where Are We? Pharmaceuticals. 2020;13(6):105. doi: https://doi.org/10.3390/ph13060105
37. Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Hemangiol. Interna­tional non-proprietary name: propranolol. Procedure No: EMEA/H/C/002621/0000 [Internet]. London: Euro­pean Medicines Agency; 2014 [cited 2024 Sept 4]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/hemangiol-epar-public-assessment-report_en.pdf
38. [Vascular abnormalities in children. Order of the Ministry of Health of Ukraine 2016 Aug8 No. 813. Uni­fied clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care]. [Internet]. 2016 [cited 2024 Sept 4]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2019/11/2016_813_ykpmd_sa.pdf
39. Tiemann L, Hein S. Infantile Hemangioma: A Re­view of Current Pharmacotherapy Treatment and Practice Pearls. J Pediatr Pharmacol Ther. 2020;25(7):586-99. doi: https://doi.org/10.5863/1551-6776-25.7.586
40. Mauguen C, Maruani A, Barbarot S, et al. Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral pro­pranolol: A case-control study using the 2014-2021. French Ouest DataHub. Annales de Dermatologie et de Vénéréologie. 2023;150(3):189-94. doi: https://doi.org/10.1016/j.annder.2023.03.007
41. Colmant C, Powell J. Medical Management of Infan­tile Hemangiomas: An Update. Pediatr Drugs. 2022;24:29-43. doi: https://doi.org/10.1007/s40272-021-00477-9
42. Colmenero-Sendra M, Del Boz-González J, Grau-Pérez M, et al. Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas. JAMA Dermatol.2025;161(2):203-7. doi: https://doi.org/10.1001/jamadermatol.2024.5125
43. Vivcharuk V, Davydenko V. Influence of age and morphological features on the clinical manifestations and treatment efficacy of hemangiomas in children. Inter Collegas.2021;8(1):22-9. doi: https://doi.org/10.35339/ic.8.1.22–29
44. Frost S, Saddi V, Teng A, et al. Propranolol's effects on the sleep of infants with hemangiomas: A prospective pilot study. Pediatr Dermatol. 2021;38(2):371-7. doi: https://doi.org/10.1111/pde.14484
45. Mimura H, Akita S, Fujino A, et al. Japanese Cli­nical Practice Guidelines for Vascular Anomalies 2017. Pediatrics 2020;62(3):260-307. doi: https://doi.org/10.1111/ped.14077
46. Park M, Jung HL, Shim YJ, et al. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential bio­markers predicting clinical outcomes. Pediatr Res. 2020;88(5):749-55. doi: https://doi.org/10.1038/s41390-020-0862-1
47. Gupta R. Propranolol for Vascular Anomalies: Efficacy and Complications in Pediatric Patients. J Indian Assoc Pediatr Surg. 2023;28(3):194-205. doi: https://doi.org/10.4103/jiaps.jiaps_117_22
48. Kwak JH, Yang A, Jung HL, et al. Cardiac Eva­luation before and after Oral Propranolol Treatment for Infantile Hemangiomas. Journal of Clinical Medicine. 2024;13(11):3332. doi: https://doi.org/10.3390/jcm13113332
49. HEMANGEOL (propranolol hydrochloride) La­bel. U.S. Food and Drug Administration [Internet]. 2020 [cited 2024 Nov 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205410s005lbl.pdf
50. Léauté-Labrèze C, Frieden I, Delarue A. Early ini­tiation of treatment with oral propranolol for infantile hemangioma improves success rate. Pediatr Dermatol. 2023;40(2):261-4. doi: https://doi.org/10.1111/pde.15198
51. Yi J, Kaiying Y, Jiangyuan Z, et al. Propranolol for the treatment of ulcerated infantile hemangiomas: A prospective study. Journal of the American Academy of Dermatology. 2022;86(5):1149-51 doi: https://doi.org/10.1016/j.jaad.2021.04.055
52. Duell K, McNab S. Propranolol and topical timo­lol for infantile haemangiomas of the skin. J Paediatr Child Health.2020;56(3):480-2. doi: https://doi.org/10.1111/jpc.14730
53. Ţarcă E. Treatment of Children Hemangiomas. Chirurgia (Bucur). 2020;115(5):643-9. doi: https://doi.org/10.21614/chirurgia.115.5.643
54. Abruzzo A, Crispini A, Prata C, et al. Freeze-Dried Matrices for Buccal Administration of Propranolol in Children: Physico-Chemical and Functional Charac­terization. JPharm  2021;110(4):1676-86. doi: https://doi.org/10.1016/j.xphs.2020.10.033
55. Mohamad SA, Salem H, Yassin HA, Mansour HF. Bucco-Adhesive Film as a Pediatric Proper Dosage Form for Systemic Delivery of Propranolol Hydrochloride: In-vitro and in-vivo Evaluation. Drug Des Devel Ther. 2020;14:4277-89. doi: https://doi.org/10.2147/dddt.s267317
56. Kashiwagura Y, Hakamata A, Shirai M, et al. Topical Formulations of Propranolol for Infantile He­mangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. Chem Pharm Bull (Tokyo). 2022;70(4):277-82. doi: https://doi.org/10.1248/cpb.c21-00997
57. Fadda HM, Weiler H, Carvalho M, et al. Pediatric oral extemporaneous preparations and practices: Inter­national Pharmaceutical Federation (FIP) global study. Eur J Pharm Biopharm. 2024;204:114483. doi: https://doi.org/10.1016/j.ejpb.2024.114483
58. Walton M, Wagner JB. Pediatric Beta Blocker The­rapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults. Genes. 2024;15(3):379. doi: https://doi.org/10.3390/genes15030379
59. Belayneh A, Tessema Z. A Systematic Review of the Stability of Extemporaneous Pediatric Oral Formu­lations. Scientific World Journal. 2021;2021:8523091. doi: https://doi.org/10.1155/2021/8523091
60. Ensom MH, Kendrick J, Rudolph S, Decarie D. Stability of propranolol in extemporaneously compounded suspensions. Can J Hosp Pharm. 2013;66(2):118-24. doi: https://doi.org/10.4212/cjhp.v66i2.1234
61. Kalam MN, Rasool MF, Rehman AU, Ahmed N. Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review. Curr Drug Metab. 2020;21(2):89-105. doi: https://doi.org/10.2174/1389200221666200414094644
62. Karunarathna I, Lakmali W, Hapuarachchi T, Dis­sanayake DD. The clinical use of propranolol: Mechanism, adverse effects, and interprofessional care. Uva Clinical Anaesthesia and Intensive Care; 2024. 7 p.
63. Pr HEMANGIOL Propranolol oral solution 3.75 mg/mL propranolol (as propranolol hydrochloride). Product monograph including patient medication information. Canada: Pierre-Fabre Dermo-Cosmétique; 2018. 40 p.
64. Mortlock R, Smith V, Nesci I, et al. A Com­parative Evaluation of Propranolol Pharmacokinetics in Obese versus Ideal Weight Individuals: A Blueprint towards a Personalised Chem Biol Interact. 2023;371:110351. doi: https://doi.org/10.1016/j.cbi.2023.110351
65. Del Frari L, Léauté‐Labrèze C, Guibaud L, et al. Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Mo­deling and dosing regimen recommendations. Pharmacol Res Perspect. 2018 Apr 30;6(3):e00399. doi: https://doi.org/10.1002/prp2.399
66. Takechi T, Kumokawa T, Kato R, Higuchi T, Ka­neko T, Ieiri I. Population Pharmacokinetics and Pharma­codynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma. J Clin Pharmacol. 2018;58(10):1361-70. doi: https://doi.org/10.1002/jcph.1149
67. Li L, Yu L, He H, et al. Plasma Drug Concen­tration of Propranolol and Genetic Study in Chinese Han Patients With Infantile Haemangioma. Front Pediatr. 2022;10:849496. doi: https://doi.org/10.3389/fped.2022.849496
68. Ţarcă E. Treatment of Children Hemangiomas. Chirurgia (Bucur). 2020;115(5):643-9. doi: https://doi.org/10.21614/chirurgia.115.5.643
69. Cuesta AM, Gallardo-Vara E, Casado-Vela J, et al. The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases. International Journal of Molecular Sciences. 2022;23(8):4217. doi: https://doi.org/10.3390/ijms23084217
70. Zhou C, Chen X, Zeng W, et al. Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget.2016;7:68314-27. doi: https://doi.org/10.18632/oncotarget.11599
71. Product Monograph. HEMANGIOL (propranolol hydrochloride) [Internet]. [cited 2024 Dec 06]. Available from: https://pdf.hres.ca/dpd_pm/00061838.PDF
72. Şen HS, Yalçın B, Canpınar H, Ocak S, Akyüz C. Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol. The Turkish Journal of Pediatrics. 2020;62(6):979-85. doi: https://doi.org/10.24953/turkjped.2020.06.009
73. Huang CY, Perman MJ, Yan AC. Regimen for accelerated propranolol initial dosing (RAPID). Pediatr Dermatol.2024;41(4):621-7. doi: https://doi.org/10.1111/pde.15623
74. Wu Z, Zou Y, Yuan H, Fu R, Jin P. Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China. Sci 2025;15(1):459. doi: https://doi.org/10.1038/s41598-024-84653-0
75. Fu R, Zou Y, Wu Z, et al. Safety of oral pro­pranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. Sci Rep. 2023;13(1):5956. doi: https://doi.org/10.1038/s41598-023-33105-2
76. Jacks SK, Kertesz NJ, Witman PM, Fernandez Faith E. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas. J Am Acad Dermatol. 2015;73(2):255-7. doi: https://doi.org/10.1016/j.jaad.2015.05.015
77. Petrovic J, Trifunovic B, Vukomanovic G, Topa­lovic M, Trajkovic G, Parezanović V. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. JDermatolog  2017;28(6):554-8. doi: https://doi.org/10.1080/09546634.2016.1277177
78. William M, Bhusal A, Umar SM, Jamal A, Anjum AS, Habib M. PHACE syndrome: a case report and a comprehensive review. Ann Med Surg (Lond). 2024;86(4):2286-91. doi: https://doi.org/10.1097/MS9.0000000000001759
79. Phillips JD, Merrill T, Gardner JR, Collins TR 2nd, Sanchez J, Johnson AB, et al. Clinical Significance of Screening Electrocardiograms for the Administration of Propranolol for Problematic Infantile Hemangiomas. Int J Pediatr.2021;2021:6657796. doi: https://doi.org/10.1155/2021/6657796
80. González-Llorente N, Del Olmo-Benito I, Muñoz-Ollero N, Descalzo MA, García-Doval I, Torrelo A. Study of Cognitive Function in Children Treated with Pro­pranolol for Infantile Hemangioma. Pediatr Dermatol. 2017;34(5):554-8. doi: https://doi.org/10.1111/pde.13229
81. Roth B, Becker N, Romeyke S, Schäfer S, Dom­nick F, Spinath FM. Intelligence and school grades: a meta-analysis. Intelligence.2015;53:118-37. doi: https://doi.org/10.1016/j.intell.2015.09.002
82. Hermans MM, Rietman AB, Schappin R, et al. Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Eur J 2022;182(2):757-67. doi: https://doi.org/10.1007/s00431-022-04674-7
83. Hasan I, Zinn Z. Safety of Prior Propranolol The­rapy for Infantile Hemangioma. Pediatric Dermatology. 2024;41:1057-62. doi: https://doi.org/10.1111/pde.15753
84. Gatts JE, Rush MC, Check JF, Samelak DM, McLean TW. Safety of propranolol for infantile heman­gioma in infants less than five weeks corrected age. Pediatr Dermatol. 2022;39:389-93. doi: https://doi.org/10.1111/pde.14966
85. Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treat­ment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013;131(3):601-13. doi: https://doi.org/10.1097/PRS.0b013e31827c6fab
86. Khamaysi Z, Jiryis B, Zoabi R, Avitan-Hersh E. Laser treatment of infantile hemangioma. J Cosmet Dermatol.2023;22(Suppl 2):1-7. doi: https://doi.org/10.1111/jocd.16344
87. European Medicines Agency [Inter­net]. [cited 2025 May 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol
88. Root C. FDA Approves Pierre Fabre's Hemangeol For Infantile Hemangioma. Clinical Leader [Internet]. 2014 [cited 2025 May 20]. Available from: https://www.clinicalleader.com/doc/fda-approves-pierre-fabre-s-hemangeol-for-infantile-hemangioma-0001

Look through:

Surzhykov I.O. National University of Pharmacy, Kharkiv, Ukraine
https://orcid.org/0009-0007-6080-8211

Bevz O.V. BERKANA+ LTD, Kharkiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-7695-3612

Goncharuk V.A. PE “Infusion”, Cherkasy, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0009-0003-4510-9819

Kryvanych O.V. Administration of the state institution of higher education "Uzhhorod National University", Uzhhorod, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
 https://orcid.org/0000-0001-7311-1543

Bevz N.Y. National University of Pharmacy, Kharkiv, Ukraine
https://orcid.org/0000-0002-7259-8908

Georgiyants V.A. National University of Pharmacy, Kharkiv, Ukraine
https://orcid.org/0000-0001-8794-8010

Surzhykov I.O., Bevz O.V., Goncharuk V.A., Kryvanych O.V., Bevz N.Y., Georgiyants V.A. Prospects for off-label use of propranolol for the treatment of infantile hemangioma in children. Medicni perspektivi. 2025;30(3):200-210.
doi: https://doi.org/10.26641/2307-0404.2025.3.340764

On the issue of creating an algorithm for assessing safety culture in modern healthcare institutions

Computer modeling and in silico prediction of molecular properties are rational approaches in early Drug Development, facilitating the targeted synthesis. One of the promising scaffold for the Drug Design is the rhodanine cycle due to the possibility of introducing substituents in positions 3 and 5. The aim of the work is to study the spectrum of biological activity of a series of 5-arylidene derivatives of 3-(benzo[d]thiazol-2-ylamino)-2-thioxothiazolidin-4-one, predict the affinity for therapeutic targets and establish their possible affiliation to certain codes according to the Anatomical Therapeutic Chemical Classification System of drugs, and predict possible toxicity of hit compounds via the online services. The investigated series of compounds consists of 21 derivatives. In silico prediction was carried out with the use of the web resources SuperPred 3.0, ProTox 3.0. A wide spectrum of biological activity of the derivatives of the series with a predominant antitumour effect is demonstrated. The group structural similarity of compounds to antineoplastic and immunomodulating agents was established. A high probability of group-level efficacy is predicted for the antitumor therapy targets: Krüppel-like factor 5, Nuclear factor erythroid 2-related factor 2, and DNA-(apurinic/apyrimidinic site) lyase. Compounds 3 ((ethyl (E)-4-(2-(2-((3-(benzo[d]thiazol-2-ylamino)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-4-chlorophenoxy)acetamido)benzoate)), 4 ((E)-2-(2-((3-(benzo[d]thiazol-2-yla­mino)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-4-chlorophenoxy)-N-(4-sulfamoylphenyl)acetamide) and 9 ((E)-2-(2-((3-(benzo[d]thiazol-2-ylamino)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-4,6-dimethylphenoxy)acetamide) can be conside­red as hit compounds. With high predictive model accuracy, their potential impact on the specified targets is 99.43%, 95.88%, and 96.92%, respectively. Compound 3 is a potential multi-hitter. The obtained results confirmed the viability of further in vitro, in vivo research.

Key words: rhodanine, benzothiazole, 5-arylidene substituents, biological activity, drug development, in silico prediction, antineoplastic agents, SAR analysis

1. Akash S, Arefin F, Aovi FI. In silico investigation of potential therapeutic medication for the inhibition of dengue virus (DENV NS2B/NS3 and NS1) by modi­fication of polycyclic quaternary alkaloid (sanguinarine derivatives) with different computational approaches. Biointerface Res Appl Chem. 2023;13(5):403. doi: https://doi.org/10.33263/BRIAC135.403
2. Mosula L, Zimenkovsky B, Havrylyuk D, Mis­sir A-V, Chirita IC, Lesyk R. Synthesis and antitumor acti­vity of novel 2-thioxo-4-thiazolidinones with benzo­thiazole moieties. [Internet]. Farmacia. 2009 [cited 2025 Jun 29];57(3):321-30. Available from: https://farmaciajournal.com/arhiva/20093/issue32009art08.pdf
3. Mosula LM, Kolodych IO, Mosula VS. [Virtual screening of the properties of a series of 5-arylidene deri­vatives of 3-(benzo[d]thiazol-2-ylamino)-2-thioxothiazo­lidin-4-one]. Annaly Mechnykovskoho Instytutu. 2025;1:73-80. doi: https://doi.org/10.5281/zenodo.15011532
4. SuperPred 3.0 [Internet]. [cited 2025 Jun 29]. Available from: https://prediction.charite.de/index.php/
5. Kopak NA. Searching of biological activity of S-esters 4- acetylaminobenzenethiosulfoacid using methods of chemoinformatics. Chem Technol Appl Subst. 2023;6(2):76-86. doi: https://doi.org/10.23939/ctas2023.02.076
6. Gallo K, Goede A, Preissner R, Gohlke BO. Su­perPred 3.0: drug classification and target prediction-a machine learning approach. Nucleic Acids Res. 2022;50(W1):W726-W31. doi: https://doi.org/10.1093/nar/gkac297
7. ProTox 3.0 [Internet]. [cited 2025 Jun 29]. Avai­lable from: https://tox.charite.de
8. Gao Y, Ding Y, Haiying C, Haijun C, Zhou J. Targeting Krüppel-Like Factor 5 (KLF5) for Cancer Therapy. Curr Top Med Chem. 2015;15(8):699-13. doi: https://doi.org/10.2174/1568026615666150302105052
9. Siraj AK, Pratheeshkumar P, Divya SP, et al. Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer. Front Pharmacol. 2020;11:598880. doi: https://doi.org/10.3389/fphar.2020.598880
10. Paramasivan P, Kankia IH, Langdon SP, Deeni YY. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies. CancerDrug  2019;2:490-15. doi: http://dx.doi.org/10.20517/cdr.2019.57
11. He F, Antonucci L, Karin M. NRF2 as a regulator of cell metabolism and inflammation in cancer. Car­cinogenesis.2020;41(4):405-16. doi: https://doi.org/10.1093/carcin/bgaa039
12. Lin Y, McMahon A, Driscoll G, Bullock S, Zhao J, Yan S. Function and molecular mechanisms of APE2 in genome and epigenome integrity. Mutat Res Rev Mutat Res. 2021;787:108347. doi: https://doi.org/10.1016/j.mrrev.2020.108347
13. Hans F, Senarisoy M, Bhaskar Naidu C, Tim­mins J. Focus on DNA Glycosylases-A Set of Tightly Regulated Enzymes with a High Potential as Anticancer Drug Targets. Int J Mol Sci. 2020;21(23):9226. doi: https://doi.org/10.3390/ijms21239226
14. Zhang A, Fan T, Liu Y, Yu G, Li C, Jiang Z. Re­gulatory T cells in immune checkpoint blockade antitumor therapy. Mol 2024;23(1):251. doi: https://doi.org/10.1186/s12943-024-02156-y
15. Dembic Z. Antitumor Drugs and Their Targets. Molecules. 2020;25(23):5776. doi: https://doi.org/10.3390/molecules25235776
16. Albarran V, San Roman M, Pozas J, et al. Adoptive T cell therapy for solid tumors: current land­scape and future challenges. Front Immunol. 2024;15:1352805. doi: https://doi.org/10.3389/fimmu.2024.1352805
17. Shen X, Zhang Y, Xu Z, et al. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colo­rectal cancer organoids by restoring apoptotic response. CellDeath  2022;13:303. doi: https://doi.org/10.1038/s41419-022-04773-1
18. SinghA, Venkannagari S, Oh KH, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes The­rapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chemical Biology. 2016;11(11):3214-25. doi: https://doi.org/10.1021/acschembio.6b00651
19. Madhusudan S, Smart F, Shrimpton P, et al. Isola­tion of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Research. 2005;33(15):4711-24. doi: https://doi.org/10.1093/nar/gki781
20. Pidugu LS, Servius HW, Sevdalis SE, et al. Cha­racterizing inhibitors of human AP endonuclease 1. PloS ONE. 2023;18(1):e0280526. doi: https://doi.org/10.1371/journal.pone.0280526

Look through:

Mosula L.M. I. Horbachevsky Ternopil National Medical University of Ministry of Health of Ukraine, Ternopil, Ukraine, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0003-3339-0562

Zhmura I.O. I. Horbachevsky Ternopil National Medical University of Ministry of Health of Ukraine, Ternopil, Ukraine
https://orcid.org/0009-0007-0919-3346

Mosula V.S. I. Horbachevsky Ternopil National Medical University of Ministry of Health of Ukraine, Ternopil, Ukraine
https://orcid.org/0009-0000-6918-3229

Mosula L.M., Zhmura I.O., Mosula V.S. 5-Аrylidene derivatives of 3-(benzo[d]thiazol-2-ylamino)-2-thioxothiazolidin-4-one as potential antineoplastic agents – in silico evaluation. Medicni perspektivi. 2025;30(3):211-219.
doi: https://doi.org/10.26641/2307-0404.2025.3.340765

Optimization and standardization of the work of a health care facility during a chemical accident

Over the past decades, medical cannabis has received official recognition in more than 40 countries around the world, including Germany, Canada, Italy, and Israel. Medical cannabis is considered a potentially effective remedy for incurable conditions accompanied by pain, spasms, or nausea. Despite its relative safety compared to opioids, the issue of side effects remains relevant. The aim of the study was to systematize information on the main pharmacological properties of medical cannabis and its bioactive components, available dosage forms and medically approved cannabis-based drugs, as well as analyze the evidence base for assessing the effectiveness of medical cannabis in various pathological conditions, taking into account potential risks and safety of use in clinical practice. To achieve the aim of the study, a search for scientific publications was carried out using the queries: medical marijuana, cannabis, cannabinoids, names of medical cannabis drugs, names of cannabinoids in the PubMed, Scopus and Google Scholar databases (2005-2025). 8254 results were obtained for the query. The exclusion criteria were: publications that did not meet the purpose of the review; language of publications (except Ukrainian, English); annotations that did not contain complete information about the results of the studies; publications with closed access. 44 publications were selected for analysis. The article analyzed clinical conditions in which the use of cannabis may be potentially beneficial (mental disorders (post-traumatic stress disorder, anxiety, depression), pain, drug addiction, diseases of the central nervous system and gastrointestinal tract). The safety of medical cannabis is highlighted: risks of addiction, neuro- and cardiotoxicity, psychotic reactions, side effects and features of using by vulnerable groups. Despite the growth of therapeutic use, the evidence base for clinical benefit remains incomplete, and undesirable effects limit its use. The choice of form and route of administration should be adapted to the individual needs of the patient. Thus, the analysis of the literature confirms the significant potential of medical cannabis in the treatment of various diseases, but the safety of its use requires further research.

Key words: Δ9-tetrahydrocannabinol, cannabidiol, medical marijuana, cannabis, cannabinoids, Cannabis sativa L., endocannabinoid system

1. Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-49. doi: https://doi.org/10.1159/000521683
2. Bruni N, Della Pepa C, Oliaro-Bosso S, Pes­sione E, Gastaldi D, Dosio F. Cannabinoid Delivery Sys­tems for Pain and Inflammation Treatment. Molecules. 2018;23(10):2478. doi: https://doi.org/10.3390/molecules23102478
3. Shirah BH, Ahmed MM. The Use of Cannabis for Medical Purposes in the Arab World. Med Cannabis Cannabinoids.2020 Dec 7;4(1):72-4. doi: https://doi.org/10.1159/000510824
4. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Canna­binoids. [Internet]. The Current State of Evidence and Recommendations for Research. Washington, D.C., Natio­nal Academies Press; 2017 [cited 2025 Apr 29]. ISBN-13 978-0-309-45304-2. Available from: https://nap.nationalacademies.org/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state
5. Narcotic Drugs annual report [Internet]. 2017 [ci­ted 2025 Apr 29]. Available from: https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2017/7_Part_2_comments_E.pdf
6. Osakwe O. Pharmaceutical regulation: the role of Government in the business of drug discovery. Chapter 1. In: Social Aspects of Drug Discovery, Development and Commercialization. Osakwe O, Rizvi SAA, eds. London, Elsevier; 2016. ISBN 978-0-12-802220-7. doi: https://doi.org/10.1016/C2014-0-02679-2
7. Tkach SM. [The role of cannabis and its deriva­tives in gastroenterological pathology]. [Internet]. Hastro­enterolohiia. Hepatolohiia. Koloproktolohiia. 2020[ci­ted 2025 Apr 21];3(57):28-30. Ukrainian. Available from: https://health-ua.com/gastroenterology/funkcionalni-zaxvoriuvannia-skt/62041-rol-kannabisa-iego-proizvodnyh-prigastroenterologicheskoj-patologii
8. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. International Journal of Molecular Sciences. 2021;22(17):9472. doi: https://doi.org/10.3390/ijms22179472
9. MARINOL (dronabinol) capsules, for oral use, CIII. Full prescribing information [Internet]. 2023 [cited 2025 Apr 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018651s033lbl.pdf
10. Bajtel Á, Kiss T, Tóth B, Kiss S, Hegyi P, Vörhen­di N, et al. The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials. Pharmaceuticals(Basel). 2022 Jan 14;15(1):100. doi: https://doi.org/10.3390/ph15010100
11. Cesamet® (nabilone) Capsules. Full prescribing information [Internet]. 2022 [cited 2025 Apr 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018677Orig1s017lbl.pdf
12. EPIDIOLEX® (cannabidiol) oral solution. Full Prescribing Information [Internet]. 2021 [ci­ted 2025 Apr 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210365Orig1s011lbl.pdf
13. Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, et al. Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial. Age Ageing. 2025 May 31;54(6):afaf149. doi: https://doi.org/10.1093/ageing/afaf149
14. Bajaj S, Jain S, Vyas P, Bawa S, Vohora D. The role of endocannabinoid pathway in the neuropathology of Alzheimer’s disease: can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer’s di­sease?  Brain Res Bull. 2021 Sep;174:305-22. doi: https://doi.org/10.1016/j.brainresbull.2021.06.022
15. Schlag AK, O'Sullivan SE, Zafar RR, Nutt DJ. Current controversies in medical cannabis: Recent deve­lopments in human clinical applications and potential therapeutics. Neuropharmacology. 2021 Jun 15;191:108586. doi: https://doi.org/10.1016/j.neuropharm.2021.108586
16. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456-73. doi: https://doi.org/10.1001/jama.2015.6358. Erratum in: JAMA. 2015 Aug 4;314(5):520. doi: https://doi.org/10.1001/jama.2015.8253. Erratum in: JAMA. 2015 Aug 25;314(8):837. doi: https://doi.org/10.1001/jama.2015.9010. Erratum in: JAMA. 2015 Dec 1;314(21):2308. doi: https://doi.org/10.1001/jama.2015.15929. Erratum in: JAMA.2016 Apr 12;315(14):1522. doi: https://doi.org/10.1001/jama.2016.3470
17. Crippa JA, Guimarães FS, Campos AC, Zuar­di AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol.2018 Sep 21;9:2009. doi: https://doi.org/10.3389/fimmu.2018.02009
18. Jetly R, Heber A, Fraser G, Boisvert D. The ef­ficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A pre­liminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinol. 2015 Jan;51:585-8. doi: https://doi.org/10.1016/j.psyneuen.2014.11.002.
19. Graczyk M, Łukowicz M, Dzierzanowski T. Pros­pects for the Use of Cannabinoids in Psychiatric Disorders. Front 2021;12:620073. doi: https://doi.org/10.3389/fpsyt.2021.620073
20. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Canna­bidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology.2011 May;36(6):1219-26. doi: https://doi.org/10.1038/npp.2011.6
21. Kaul M, Zee PC, Sahni AS. Effects of cannabi­noids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics. 2021 Jan;18(1):217-27. doi: https://doi.org/10.1007/s13311-021-01013-w.
22. Kudrich C, Hurd YL, Salsitz E, Wang AL. Adjun­ctive Management of Opioid Withdrawal with the Nono­pioid Medication Cannabidiol. Cannabis Cannabinoid Res. 2022 Oct;7(5):569-81. doi: https://doi.org/10.1089/can.2021.0089
23. Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. Anesth­Analg.2017 Nov;125(5):1638-52. doi: https://doi.org/10.1213/ANE.0000000000002110
24. Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: Findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3:e341-e350. doi: https://doi.org/10.1016/S2468-2667(18)30110-5
25. Kienzl M, Storr M, Schicho R. Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clin Transl Gastroenterol. 2020 Jan;11(1):e00120. doi: https://doi.org/10.14309/ctg.0000000000000120
26. Bilbao A, Spanagel R. Medical cannabinoids: a phar­macology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259. doi: https://doi.org/10.1186/s12916-022-02459-1
27. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. NatRev  2020;16:9-29. doi: https://doi.org/10.1038/s41582-019-0284-z
28. Chan A, Silván CV. Evidence-based management of multiple sclerosis spasticity with nabiximolsoromucosal spray in clinical practice: a 10-year recap. Neurodegener Dis 2022 Jun;12(3):141-54. doi: https://doi.org/10.2217/nmt-2022-0002
29. Farrelly AM, Vlachou S, Grintzalis K. Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Ap­proaches and Recent Advances. Int J Environ Res Public Health. 2021 Apr 10;18(8):3993. doi: https://doi.org/10.3390/ijerph18083993
30. Galan FN, Miller I. Cannabinoids for the Treat­ment of Epilepsy: a Review. Curr Treat Options Neurol. 2020;22:14.
    doi: https://doi.org/10.1007/s11940-020-00621-9
31. Jakubovski E, Pisarenko A, Fremer C, Haas M, May M, Schumacher C, et al. The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Pla­cebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders. Front Psychiatry. 2020 Nov 26;11:575826. doi: https://doi.org/10.3389/fpsyt.2020.575826
32. Bogale K, Raup-Konsavage W, Dalessio S, Vra­na K, Coates MD. Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease. Med Cannabis Cannabinoids. 2021 Jun 21;4(2):97-106. doi: https://doi.org/10.1159/000517425
33. Comparison of Safety, Tolerability and Phar­macokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult Volunteers [Internet]. [cited 2025 Apr 29]. Available from: https://clinicaltrials.gov/study/NCT03936907?term=medical%20marijuana%20nabiximols%20intestines&rank=1
34. Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015 Nov;45(15):3181-9. doi: https://doi.org/10.1017/S0033291715001178
35. Meier MH, Caspi A, Ambler A, Harrington HR, Houts RSE, Keefe K, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci. 2012;109(40):E2657-E2664. doi: https://doi.org/10.1073/pnas.1206820109
36. Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scrano L. Cannabis: A Toxin-Producing Plant with Potential The­rapeutic Uses. Toxins (Basel). 2021 Feb 5;13(2):117. doi: https://doi.org/10.3390/toxins13020117
37. Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020 Apr;7(4):344-53. doi: https://doi.org/10.1016/S2215-0366(20)30074-2
38. Ganesh S, Cortes-Briones J, Ranganathan M, Rad­hakrishnan R, Skosnik PD, D'Souza DC. Psychosis-Rele­vant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. Int J Neuropsychopharmacol. 2020 Dec 3;23(9):559-70. doi: https://doi.org/10.1093/ijnp/pyaa031
39. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem. 2013 Mar;59(3):478-92. doi: https://doi.org/10.1373/clinchem.2012.194381
40. Dabiri AE, Kassab GS. Effects of Cannabis on Car­diovascular System: The Good, the Bad, and the Many Unk­nowns. Med Cannabis Cannabinoids. 2021 Nov 12;4(2):75-85. doi: https://doi.org/10.1159/000519775
41. Martinez Naya N, Kelly J, Corna G, Golino M, Polizio AH, Abbate A, et al. An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects. Molecules.2024 Jan 18;29(2):473. doi: https://doi.org/10.3390/molecules29020473
42. Urits I, Charipova K, Gress K, Li N, Berger AA, Cornett EM, et al. Adverse Effects of Recreational and Medi­cal Cannabis. Psychopharmacol Bull. 2021 Jan 12;51(1):94-109. PMID: 33897066. PMCID: PMC8063125.
43. Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):281-92. doi: https://doi.org/10.1007/s00406-024-01880-2
44. Smith SA, Le GH, Teopiz KM, Kwan ATH, Rhee TG, Ho RC, et al. Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. Drug Metab Rev. 2024 Feb-May;56(2):164-74. doi: https://doi.org/10.1080/03602532.2024.2346767. Erratum in: Drug Metab Rev. 2025 Jul 30:1. doi: https://doi.org/10.1080/03602532.2025.2541147 

Look through:

Kaidash S.P. Dnipro State Medical University, Dnipro, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-3210-3560

Sliesarchuk V.Yu. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0001-8777-1243

Sokolova K.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0001-5022-3227

Potapova T.M. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0003-0184-3571

Kaidash S.P., Sliesarchuk V.Yu., Sokolova K.V., Potapova T.M. Global experience with medical cannabis use: indications and safety profile (literature review). Medicni perspektivi. 2025;30(3):220-230.
doi: https://doi.org/10.26641/2307-0404.2025.3.340767

Optimization and standardization of the work of a health care facility during a chemical accident

Cardiac glycoside digoxin may be an effective adjuvant to classical antiepileptic drugs (AEDs) in the drug-resistant epilepsy treatment. However, the mechanisms of digoxin’s anticonvulsant effect, in particular ability of digoxin itself and its combination with classical AED sodium valproate to influence neuroinflammation as well as counteracting neuronal damage, remains unexplored. Thus, the aim of the study is to elucidate the role of individual markers of neuroinflammation and neuronal apoptosis, in particular interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), interleukin-4 (IL-4), Fas ligand (FasL), heat shock protein 70 (HSP₇₀), 5-lipoxygenase (5-LOX) and nitric oxide synthase (NOS) in the realization of the anticonvulsant potential of digoxin and sodium valproate under experimental epileptogenesis. The model of chronic epileptogenesis, kindling induced pentylenetetrazole (PTZ) in mice, has been used. 40 animals were divided into 5 groups of 8 mice each: vehicle control (receiving solvent – water), positive control (receiving only PTZ), sodium valproate (150 mg/kg intragastrically), digoxin (0.8 mg/kg subcutaneously), and valproate+digoxin combination. Medicines – both per se and in combination – were administered 30 min before PTZ (30 mg/kg intraperitoneally). After 16 days, IL-6, TNF-α, IL-4, FasL, HSP₇₀, 5-LOX and NOS have been identified in the whole brain. It was confirmed that the combination of digoxin with sodium valproate more effectively prevents the development of seizures than monotherapy. It was proven that sodium valproate and digoxin exhibit pronounced anti-inflammatory properties, restoring the content of TNF-α (but not IL-6) and increasing the expression of IL-4, and in combination they also normalize the level of 5-LOX in the brain. Also, digoxin more clearly than sodium valproate counteracts neuroapoptosis and neurodegeneration by affecting FasL and HSP₇₀. Cerebral NOS, however, is not involved in the development of experimental seizures, nor in the anticonvulsant effect of sodium valproate and digoxin. The obtained results expand the understanding of the mechanisms of anticonvulsant action of digoxin and sodium valproate and may be important in the development of new strategies for drug-resistant epilepsy treatment.

Key words: pentylenetetrazole-induced kindling, digoxin, valproate, neuroinflammation, neuroapoptosis

1. Sultana B, Panzini MA, Veilleux Carpentier A, Comtois J, Rioux B, Gore G, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805-17. doi: https://doi.org/10.1212/WNL.0000000000011839
2. Auvin S, Galanopoulou AS, Moshé SL, Po­tschka H, Rocha L, Walker MC, et al. Revisiting the concept of drug-resistant epilepsy: a TASK1 report of the ILAE/AES Joint Translational Task Force. Epilepsia. 2023;64(11):2891-908. doi: https://doi.org/10.1111/epi.17751
3. Guery D, Rheims S. Clinical management of drug resistant epilepsy: a review on current strategies. Neuro­psychiatrDis  2021;17:2229-42. doi: https://doi.org/10.2147/NDT.S256699
4. Elkommos S, Mula M. Current and future phar­macotherapy options for drug-resistant epilepsy. Expert Opin 2022;23:2023-34. doi: https://doi.org/10.1080/14656566.2022.2128670
5. Mesraoua B, Brigo F, Lattanzi S, Abou-Khalil B, Al Hail H, Asadi-Pooya AA. Drug-resistant epilepsy: defi­nition, pathophysiology, and management. J Neurol Sci. 2023;452:120766. doi: https://doi.org/10.1016/j.jns.2023.120766
6. Tsyvunin V, Shtrygol’ S, Shtrygol’ D. Digoxin enhances the effect of antiepileptic drugs with different mechanism of action in the pentylenetetrazole-induced seizures in mice. Epilepsy Res. 2020;167:106465. doi: https://doi.org/10.1016/j.eplepsyres.2020.106465
7. Tsyvunin V, Shtrygol S, Mishchenko M, Shtry­gol D. Digoxin at sub-cardiotonic dose modulates the anticonvulsive potential of valproate, levetiracetam and topiramate in experimental primary generalized seizures. CeskaSlov  2022;71:78-88. doi: https://doi.org/10.5817/CSF2022-2-76 
8. Tsyvunin V, Shtrygol S, Mishchenko M, et al. Effect of digoxin, sodium valproate, and celecoxib on the cerebral cyclooxygenase pathway and neuron-specific enolase under the pentylenetetrazole-induced kindling in mice. CeskaSlov  2023;72:172-83. doi: https://doi.org/10.5817/CSF2023-4-172
9. Bishara AJ, Li J, Conley C. Informal versus formal judgment of statistical models: The case of normality assumptions. Psychon Bull Rev. 2021;28(4):1164-82. doi: https://doi.org/10.3758/s13423-021-01879-z
10. Housing and husbandry: Mouse [Internet]. London: National Centre for the Replacement, Refinement and Reduction of Animals in Research; 2024 [ci­ted 2025 Aug 13]. Available from: https://nc3rs.org.uk/3rs-resources/housing-and-husbandry-mouse
11. Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S. Sodium valproate inhibits pro­duction of TNF-α and IL-6 and activation of NF-κB. Brain Res.2000;857(1-2):246-51. doi: https://doi.org/10.1016/S0006-8993(99)02439-7
12. Mairuae N, Cheepsunthorn P. Valproic acid atte­nuates nitric oxide and interleukin-1β production in lipopolysaccharide-stimulated iron-rich microglia. Biomed Rep.2018;8(4):359-64. doi: https://doi.org/10.3892/br.2018.1062
13. Ximenes JC, de Oliveira Gonçalves D, Si­queira RM, et al. Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory pro­per­ties. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(7):575-87. doi: https://doi.org/10.1007/s00210-013-0853-4
14. Crowley T, Cryan JF, Downer EJ, O’Leary OF. Inhibiting neuroinflammation: the role and therapeutic potential of GABA in neuro-immune interactions. Brain Behav 2016;54:260-77. doi: https://doi.org/10.1016/j.bbi.2016.02.001
15. Ihenetu K, Espinosa R, de Leon R, et al. Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines. Inflamm Res. 2008;57:519-23.
    doi: https://doi.org/10.1007/s00011-008-7249-9
16. Meng Q, Liu K, Liu Z, et al. Digoxin protects against intervertebral disc degeneration via TNF/NF-κB and LRP4 signaling. Front Immunol. 2023;14:1251517. doi: https://doi.org/10.3389/fimmu.2023.1251517
17. El-Mahdy NA, Tadros MG, El-Masry TA, et al. Efficacy of the cardiac glycoside digoxin as an adjunct to csDMARDs in rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2024;15:1445708. doi: https://doi.org/10.3389/fphar.2024.1445708
18. Chen L, Zhu L, Lu D, et al. Interleukin 4 affects epilepsy by regulating glial cells: potential and possible mechanism. Front Mol Neurosci. 2020;13:554547. doi: https://doi.org/10.3389/fnmol.2020.554547
19. El-Hodhod MA, Tomoum HY, Abd Al-Aziz MM, Samaan SM. Serum Fas and Bcl-2 in patients with epilepsy. Acta Neurol Scand. 2006;113(5):315-21. doi: https://doi.org/10.1111/j.1600-0404.2006.00592.x
20. Zummo L, Vitale AM, Caruso Bavisotto C, et al. Molecular chaperones and miRNAs in epilepsy: pathogenic implications and therapeutic prospects. Int J Mol 2021;22(16):8601. doi: https://doi.org/10.3390/ijms22168601
21. Hu F, Zhou J, Lu Y, et al. Inhibition of Hsp70 suppresses neuronal hyperexcitability and attenuates epilepsy by enhancing A-type potassium current. Cell Rep. 2019;26(1):168-81.e4. doi: https://doi.org/10.1016/j.celrep.2018.12.032
22. Kamel MM, Mounir SM, Okaily NI, Abdel­zaher MH, Hassan MH. Possible role of heat shock protein 70 in childhood seizures. Int J Epilepsy. 2018;5(2):87-91. doi: https://doi.org/10.1055/s-0038-1676907
23. Zeng M, Xu W. A narrative review of the pub­lished pre-clinical evaluations: multiple effects of arachidonic acid, its metabolic enzymes and metabolites in epilepsy. Mol 2025;62:28-303. doi: https://doi.org/10.1007/s12035-024-04274-6
24. Zhu X, Dong J, Han B, et al. Neuronal nitric oxide synthase contributes to PTZ kindling epilepsy-induced hippocampal endoplasmic reticulum stress and oxidative damage. Front Cell Neurosci. 2017;11:377. doi: https://doi.org/10.3389/fncel.2017.00377

Look through:

Tsyvunin V.V. National University of Pharmacy, Kharkiv, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-2980-5035

Shtrygol’ S.Yu. National University of Pharmacy, Kharkiv, Ukraine
https://orcid.org/0000-0001-6832-5643

Lytkin D.V. National University of Pharmacy, Kharkiv, Ukraine
https://orcid.org/0000-0002-4173-3046

Shtrygol’ D.V. V.N. Karazin Kharkiv National University, Kharkiv, Ukraine
https://orcid.org/0000-0003-3112-4703

Tsyvunin V.V., Shtrygol’ S.Yu., Lytkin D.V., Shtrygol’ D.V. Impact of digoxin and sodium valproate on the mechanisms of neuroinflammation and neuroapoptosis under experimental epileptogenesis. Medicni perspektivi. 2025;30(3):230-238.
doi: https://doi.org/10.26641/2307-0404.2025.3.340812

Optimization and standardization of the work of a health care facility during a chemical accident

The main objective was to determine whether it is always appropriate, according to the lipid hypothesis, to reduce low-density lipoprotein fractions in primary prevention, particularly through the use of statins. Another aim was to update information on the mechanisms of the adverse effects of statins on various physiological systems of the human body. The study analyzed current scientific evidence on the causal relationships between hypercholesterolemia and the risk of cardio­vascular diseases (including their impact on patients’ lifespan and quality of life), as well as the consequences of using the most common treatment for this condition – statins. Statins are a group of hypolipidemic drugs whose mechanism of action involves inhibition of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), which catalyzes the initial and intermediate stages of cholesterol biosynthesis in the liver. These cholesterol-lowering agents, widely known as statins, are heavily promoted not only for secondary but also for primary prevention of cardiovascular disease (CVD), despite their proven side effects, and in some cases, the risks of their use may outweigh the benefits. The analysis showed that the widespread belief that “elevated cholesterol is the primary cause of cardiovascular disease” is limited, while low cholesterol levels may sometimes pose even greater risks to the body. It is known that statins cause mitochondrial dysfunction and act as mevalonate blockers, promote coronary artery calcification, and inhibit the synthesis of vitamin K2. Statins also interfere with the cardioprotective effects of omega-3 fatty acids and contribute to the development of insulin resistance, while their adverse effects can negatively impact various physiological systems. In conclusion, our findings suggest that in certain patient groups (especially those with low or moderate risk), statin prescription remains debatable. Therefore, we believe that the lipid hypothesis has limitations and requires reconsideration, particularly in the context of primary prevention. 

Key words: atherosclerosis, cardiovascular diseases, low-density lipoproteins, statins, mitochondrial dysfunction, coenzyme Q10, side effect

1. Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA.2022 Aug 23;328(8):754-71. doi: https://doi.org/10.1001/jama.2022.12138
2. Lahoz R, Seshagiri D, Electricwala B, Achouba A, Ding Y, Heo JH, et Clinical characteristics and treat­ment patterns in patients with atherosclerotic cardio­vascular disease with hypercholesterolemia: a ret­rospective analysis of a large US real-world database cohort. Curr Med Res Opin. 2023;40(1):15-25. doi: https://doi.org/10.1080/03007995.2023.2270901 
3. BurnettH, Fahrbach K, Cichewicz A, Jindal R, Tarpey J, Durand A, et  Comparative efficacy of non-statin lipid-lowering therapies in patients with hyper­cholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022 May;38(5):777-84. doi: https://doi.org/10.1080/03007995.2022.2049164
4. Murto MO, Simolin N, Arponen O, Siltari A, Ar­tama M, et al. Statin use, cholesterol level, and mortality among females with breast cancer. JAMA Netw Open. 2023 Nov 1;6(11):e2343861. doi: https://doi.org/10.1001/jamanetworkopen.2023.43861
5. Ravnskov U, de Lorgeril M, Diamond DM, Ha­ma R, Hamazaki T, Hammarskjöld B, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert Rev Clin Pharmacol. 2018 Oct;11(10):959-70. doi: https://doi.org/10.1080/17512433.2018.1519391
6. Liu Y, Liu F, Zhang L, Li J, Kang W, Song F, et al. Association between low-density lipoprotein choles­terol and all-cause mortality: results from the NHANES 1999-Sci Rep. 2021;11:22111. doi: https://doi.org/0.1038/s41598-021-01738-w
7. Zhou L, Wu Y, Yu S, Shen Y, Ke C. Low-density lipoprotein cholesterol and all-cause mortality: Findings from the China health and retirement longitudinal study. BMJ 2020;10:e036976. doi: https://doi.org/10.1136/bmjopen-2020-036976
8. Kip KE, Diamond D, Mulukutla S, Marr­oquin OC. LDL cholesterol associated with long-term mortality among primary prevention adults? A retrospective cohort study from a large healthcare system. BMJ Open. 2024;14(3):e077949. doi: https://doi.org/10.1136/bmjopen-2023-077949
9. Ennezat PV, Guerbaai RA, Maréchaux S, Le Jem­tel TH, François P. Extent of low-density lipoprotein cholesterol reduction and all-cause and cardiovascular mortality benefit: A systematic review and meta-analysis.J Cardiovasc Pharmacol. 2023 Jan 1;81(1):35-44. doi: https://doi.org/10.1097/FJC.0000000000001345
10. Koskinas KC, Siontis GC, Piccolo R, Mavridis D, Räber L, Mach F, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.Eur Heart  2018;39(14):1172-80. doi: https://doi.org/10.1093/eurheartj/ehx566
11. Gupta R, Wielgosz A, AlHabib KF, Dans A, Lo­pez-Jaramillo P, Avezum A, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155722 indi­viduals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395(10226):795-808. doi: https://doi.org/10.1016/S0140-6736(19)32008-2
12. Arnett DK, Blumenthal RS, Albert MA, Buro­ker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Di­sease: Executive Summary. Circulation. 2019;140(11):e563-95. doi: https://doi.org/10.1161/CIR.0000000000000677
13. De Backer G, Jankowski P, Kotseva K, Mir­rakhimov E, Reiner Ž, Rydén L, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019 Jun;285:135-46. doi: https://doi.org/10.1016/j.atherosclerosis.2019.03.014
14. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross-Sectional Obser­vational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev 2021 Sep 20;28(11):1279-89. doi: https://doi.org/10.1093/eurjpc/zwaa047
15. Kosmas CE, Muñoz Estrella A, Sourlas A, Sil­verio D, Hilario E, Montan PD, et al. Inclisiran: a new pro­mising agent in the management of hypercholesterolemia. Diseases.2018 Jul 13;6(3):63. doi: https://doi.org/10.3390/diseases6030063
16. Okuyama H, Langsjoen PH, Hamazaki T, Ogu­shi Y, Hama R, Kobayashi T, et al. Statins stimulate athe­rosclerosis and heart failure: pharmacological mecha­nisms. Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99. doi: https://doi.org/10.1586/17512433.2015.1011125
17. Diamond DM, Ravnskov U. How statistical de­cep­tion created the appearance that statins are safe and effective in primary and secondary prevention of car­diovascular disease. Expert Rev Clin Pharmacol. 2015;8(2):201-10. doi: https://doi.org/10.1586/17512433.2015.1012494
18. Chaulin A. Cardiotoxicity as a Possible Side Effectof Statins. Rev Cardiovasc Med. 2023;24(1):22. doi: https://doi.org/10.31083/j.rcm2401022
19. Zoungas S, Curtis A, Spark S, McNeil JJ, Beilin L, Chong TTJ, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13:e069915.
    doi: https://doi.org/10.1136/bmjopen-2022-069915
20. Ward NC, Watts GF, Eckel RH. Statin Toxicity: Mechanistic Insights and Clinical Implications. Circulation Research.2019;124(2):328-50. doi: https://doi.org/10.1161/CIRCRESAHA.118.312782
21. Grunwald SA, Popp O, Haafke S, Jedraszczak N, Grieben U, SaarK, et  Statin-induced myopathic chan­ges in primary human muscle cells and reversal by a prosta­glandin F2 alpha analogue. Sci Rep. 2020;10(1):2158. doi: https://doi.org/10.1038/s41598-020-58668-2
22. Zhu Y, Zhang C, Chen B, Chen R, Guo A, Hong J, et al. Cholesterol is required for maintaining T-tubule integrity and intercellular connections at intercalated discs in cardiomyocytes. J Mol Cell Cardiol. 2016;97:204-12. doi: https://doi.org/10.1016/j.yjmcc.2016.05.013
23. Ünlü S, Nurkoç SG, Sezenöz B, Cingirt M, Gül­bahar Ö, Abacı A. Impact of statin use on high sensitive troponin T levels with moderate exercise. Acta Cardiol. 2019;74(5):380-5. doi: https://doi.org/10.1080/00015385.2018.1510801
24. Zhelyazkova-SavovaMD, Yotov YT, Nikolo­va MN, Nazifova-Tasinova NF, Vankova DG, Atanasov AA, et al. Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation? Kaohsiung J Med Sci. 2021 Jul;37(7):624-31. doi: https://doi.org/10.1002/kjm2.12373 
25. JacobsonTA, Cheeley MK, Jones PH, La For­ge R, Maki KC, López JAG, et  The STatin Adverse Treat­ment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-24. doi: https://doi.org/10.1016/j.jacl.2019.04.011
26. GrunwaldSA, Popp O, Haafke S, Jedraszczak N, Grieben U, Saar K, et  Statin-induced myopathic chan­ges in primary human muscle cells and reversal by a prosta­glandin F2 alpha analogue. Sci Rep. 2020;10(1):2158. doi: https://doi.org/10.1038/s41598-020-58668-2
27. GrunwaldSA, Popp O, Haafke S, Jed­ra­szczak N, Grieben U, Saar K, et al. Statin-induced myo­pathic chan­ges in primary human muscle cells and reversal by a prostaglandin F2 alpha analogue. Sci Rep. 2020;10(1):2158.
    doi: https://doi.org/10.1038/s41598-020-58668-2
28. HuangL, Zhang F, Xu P, Zhou Y, Liu Y, Zhang H, et  Effect of omega-3 polyunsaturated fatty acids on cardiovascular outcomes in patients with diabetes: a meta-analysis of randomized controlled trials. Adv Nutr Res. 2023;14(4):629-36. doi: https://doi.org/10.1016/j.advnut.2023.04.009
29. RodriguezD, Lavie CJ, Elagizi A, Milani  Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health. Nutrients. 2022;14(23):5146. doi: https://doi.org/10.3390/nu14235146 
30. LaaksoM, Fernandes Silva  Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne). 2023;14:1239335. doi: https://doi.org/10.3389/fendo.2023.1239335
31. GrunwaldSA, Haafke S, Grieben U, Kassner U, Steinhagen-Thiessen E, Spuler S. Statins aggravate the risk of insulin resistance in human muscle. Int J Mol Sci. 2022;23(4):2398. doi: https://doi.org/10.3390/ijms23042398
32. SridharanS, Kaptoge S, McKee M, Bagnall A, Collins R, Clarke R, et  Effect of statin therapy on mus­cle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022 Aug 29;400(10356):1007-16. doi: https://doi.org/10.1016/S0140-6736(22)01545-8
33. LiuJ, Wu YP, Qi JJ, Yue ZP, Hu  Effect of Statin Therapy on Diabetes Retinopathy in People With Type 2 Diabetes Mellitus: A Meta-Analysis. Clin Appl Thromb Hemost. 2021;27:10760296211040109. doi: https://doi.org/10.1177/10760296211040109
34. JiaoXF, Li HL, Jiao XY, et  Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System. Sci Rep. 2020;10:11955.
    doi: https://doi.org/10.1038/s41598-020-68906-2
35. BerekJS, Berek  Berek & Novak’s Gyne­cology. 16th ed. Alphen aan den Rijn: Wolters Kluwer; 2020. 1202 p.
36. Zoungas S, Curtis A, Spark S, McNeil JJ, Beilin L, Chong TTJ, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open [Internet]. 2023[cited 2025 Feb 6];13:e069915. doi: https://doi.org/10.1136/bmjopen-2022-069915
37. Diamond DM, Leaverton PE. Historical review of the use of relative risk statistics in the portrayal of the purported hazards of high LDL cholesterol and the benefits of lipid-lowering therapy. Cureus. 2023;15(5):e38391. doi: https://doi.org/10.7759/cureus.38391
38. Ravnskov U, de Lorgeril M, Kendrick M, Dia­mond DM. Serious flaws in targeting LDL-C reduction in the management of cardiovascular disease in familial hypercholesterolemia. Expert Review of Clinical Pharmacology.2021;14(3):405-6. doi: https://doi.org/10.1080/17512433.2021.1889368
39. Jones JE, TangKS, Barseghian A, Wong  Evolution of more aggressive LDL-cholesterol targets and therapies for cardiovascular disease prevention. Journal of Clinical Medicine. 2023;12(23):7432. doi: https://doi.org/10.3390/jcm12237432
40. Harcombe Z. Rebutting the cholesterol hypothesis. Zoë Harcombe [Internet]. 2021 [cited 2025 Mar 09]. Available from: https://www.zoeharcombe.com/2021/06/re­butting-the-cholesterol-hypothesis/ 
41. The truth about cholesterol: 12 things you need to know – from eggs to weight to statins. The Guardian [Internet]. 2025 [cited 2025 Mar 09]. Available from: https://www.theguardian.com/lifeandstyle/2025/mar/23/truth-cholesterol-12-things-you-need-to-know-eggs-weight-statins  
42. Feingold KR. Lipid and Lipoprotein Metabolism. Endocrinol Metab Clin North Am. 2022;51(3):437-58. doi: https://doi.org/10.1016/j.ecl.2022.02.008
43. Russell DW. Oxysterol biosynthetic enzymes. Biochimica et Biophysica Acta (BBA). Molecular and Cell Biology of Lipids. 2000;1529(1-3):126-35. doi: https://doi.org/10.1016/s1388-1981(00)00142-6
44. Xiang Y, Tang JJ, Tao W, Cao X, Song BL, Zhong J. Identifi cation of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C. Virus Infection J Virol. 2015;89(13):6805-16. doi: https://doi.org/10.1128/JVI.00587-15
45. Glitscher М, Heiler DM, Woytinek K, Schmidt B, Tabari D, et al. Targeting Cholesterol Metabolism as Efficient Antiviral Strategy Against the Hepatitis E Virus. Cell Mol Gastroenterol Hepatol. 2021;12(3):159-80. doi: https://doi.org/10.1016/j.jcmgh.2021.02.002
46. Feingold KR, Grunfeld C. The Effect of Inflam­mation and Infection on Lipids and Lipoproteins. In: Fein­gold KR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000 [cited 2025 Mar 02]. Available from: https://pubmed.ncbi.nlm.nih.gov/26561701
47. Balint B, Jeitner TM, Andrews D, et al. Mecha­nisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wall. Biochimie.2020;173:100-6. doi: https://doi.org/10.1016/j.biochi.2020.02.012
48. Lu J, Xie G, Xiong Q, et al. Mechanism of homo­cysteine-mediated endothelial injury and its consequences for atherosclerosis. Frontiers in Cardiovascular Medicine. 2023;9:1109445. doi: https://doi.org/10.3389/fcvm.2022.1109445
49. Zhao J, Li Z, Hou C, et‑al. Gender differences in risk factors for high plasma homocysteine levels based on a retrospective checkup cohort using a generalized estimating equation analysis. Lipids Health Dis. 2021 Apr 12;20(1):31. doi: https://doi.org/10.1186/s12944-021-01459-z
50. Jin P, Ma J, Wu P, et al. Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers. Lipids Health Dis. 2025 Jan 22;24(1):19. doi: https://doi.org/10.1186/s12944-025-02443-7
51. Pokushalov E, Ponomarenko A, Bayramova S, et al. Effect of Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin (SolowaysTM) Supplementation on Homocysteine and Low-Density Lipoprotein Cho­lesterol Levels in Patients with Methylenetetra­hyd­rofolate Reduc­tase, Methionine Synthase, and Methio­nine Synthase Reductase Polymorphisms: A Rando­mized Controlled Trial. Nutrients.2024;16(11):1550. doi: https://doi.org/10.3390/nu16111550  
52. Wang X, Ma X, Zeng Y. Hypermethylation of the  CTRP9 promoter region promotes Hcy induced VSMC  lipid deposition and foam cell formation via negatively  regulating ER stress. Sci Rep.2023;13:19438. doi: https://doi.org/10.1038/s41598-023-46981-5
53. Hornemann T. Lipidomics in Biomarker Re­search. In: Endotext [Internet]. MDText.com, Inc; 2021 [cited 2025 Mar 02]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK584293
54. Collins R, Reith C, Emberson J, et al. Inter­preta­tion of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61. doi: https://doi.org/10.1016/S0140-6736(16)31357-5
55. Newman CB, PreissD, Tobert JA, Jacobson TA, Page RL, et  Statin safety and associated adverse events. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81. doi: https://doi.org/10.1161/ATV.0000000000000073
56. Ruscica M, Ferri N, Banach M, Sirtori CR, Cor­sini A. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications Cardiovascular Research. 2022;118(17):3288-304. doi: https://doi.org/10.1093/cvr/cvac020

Look through:

Popova T.V. Dnipro State Medical University, Dnipro, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-9627-330X

Rodynskyi O.G. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0002-8011-6104

Skubytska L.D. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0002-4153-9446

Rolduhina M.O. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0009-0007-6673-1278

Mozgunov O.V. Dnipro State Medical University, Dnipro, Ukraine
https://orcid.org/0000-0002-4000-3420

Popova T.V., Rodynskyi O.G., Skubytska L.D., Rolduhina M.O., Mozgunov O.V. A modern view of the lipid hypothesis and the effect of statins on the physiological systems on the human body (literature review). Medicni perspektivi. 2025;30(3):239-251.
doi: https://doi.org/10.26641/2307-0404.2025.3.340813

Optimization and standardization of the work of a health care facility during a chemical accident

Aim of the study was to analyze the indicators of dental aid provided at the children's policlinic dental department in Poltava during the wartime in order to find ways of their optimization. Analytical and statistical methods of research are used. In 2024 there was a decrease in the number of working days of dentists by 6.17% and in the number of diagnostic visits by 23.02% (p<0.05); the number of applied fillings decreased by 13.85% (p<0.05); indicators of preventive, orthodontic and surgical work deteriorated, as well as the indicators of radiologic room. Also, some outpatient surgical procedures began to be performed in the children's hospital, as evidenced by a 1.39% increase in the number of hospitalizations and a 4.68% decrease in the proportion of patients undergoing surgery in the policlinic department (p<0.05). However, the number of preventive and primary visits increased, and the ratio of treated permanent teeth with uncomplicated to complicated caries increased from 17.1:1 in 2023 to 21.4:1 in 2024. In 2024, the number of visits per 1 remediation decreased by 16.67%, whereas the number of treatment courses for periodontal diseases doubled and the number of treatment courses for the diseases oral mucosa increased by 7.6%. In 2022-2024 years, an increase in the number of children examined during scheduled remediation is associated to the terms of the package of National service of health in Ukraine which includes mandatory checks-ups of children under 6 years of age. During wartime, the number of dental services provided by the department shifted due to the changes in the number of city residents, the decrease in the number of working days of dentists, and the transfer of some surgical services to the hospital. In order to optimize dental care for children in wartime, a state-owned medical institution has to promote its work on social media and television, focusing on preventive measures, and to introduce new diagnostic and treatment methods.

Key words: dental care, children, caries, treatment, prevention

1. Ukraine/Displacement Tracking Matrix [Internet]. 2024 [cited 2025 Feb 26]. Available from: https://dtm.iom.int/ukraine
2. Situation Ukraine Refugee Situation [Internet]. 2025 [cited 2025 Feb 26]. Available from: https://data.unhcr.org/en/situations/ukraine
3. Air-alarms.in.ua/statistic of air alarms [Internet]. 2024 [cited 2025 Feb 26]. Available from: https://air-alarms.in.ua/en/region/poltava
4. Tsuber V, Kadamov Y, Tarasenko L. Activation of antioxidant defenses in whole saliva by psychosocial stress is more manifested in young women than in young  men. PLoS One. 2014 Dec 19;9(12):e115048. doi: https://doi.org/10.1371/journal.pone.0115048
5. Boiko DI, Skrypnikov AM, Shkodina AD, Ha­san MM, Ashraf GM, et al. Circadian rhythm disorder and anxiety as mental health complications in post-COVID-19. Environ Sci Pollut Res Int. 2022;29(19):28062-9. doi: https://doi.org/10.1007/s11356-021-18384-4
6. Mazur IP, Lekhan VN, Rybachuk AV. [Transfor­mations of the dental industry during the period of independence of Ukraine and their impact on the availa­bi­lity of dental aid]. Medicni perspektivi. 2022;27(1):184-92.
   doi: https://doi.org/10.26641/2307-0404.2022.1.254470
7. Kaskova LF, Yanko NV, Tovma VV, Vashchen­ko IY, Ulasevich LP. [Analysis of dental aid indicators for children based on data from the pediatric dental clinic of Poltava city]. Actual Problems of the Modern Medicine: Bulletin of Ukrainian Medical Stomatological Academ. 2024;24(2):160-5. doi: https://doi.org/10.31718/2077-1096.24.2.160
8. Koval OI, Kaniura OA. Organization of dental aid for Ukrainian children during martial law. World of medicine and biology. 2024;1:79-83. doi: https://doi.org/10.26724/2079-8334-2024-1-87-79-83
9. Reyzvikh O, Ivanov V, Denga О, Sukhomeylo D, Shnaider S. [Analysis of the provision of dental aid to children under martial law]. Stomatological Bulletin. 2023;122(1):31-8. Ukrainian. doi: https://doi.org/10.35220/2078-8916-2023-47-1.6
10. Vukovic A, Schmutz KA, Borg-Bartolo R, Coc­co F, Rosianu RS, Jorda R, et al. Caries status in 12-year-old children, geographical location and socioeconomic conditions across European countries: A systematic review and meta-analysis. Int J Paediatr Dent. 2025;35(1):201-15. doi: https://doi.org/10.1111/ipd.13224
11. BhattacharyaPK, editor. Research Methodology in the Health Sciences: A Quick Reference Guide. New York: McGraw Hill; 2021. 192 p. Available from: https://accessmedicine.mhmedical.com/book.aspx?bookid=3018
12. Spiegelhalter D. The Art of Statistics: Learning from Data. London: Pelican; 2020. 426 p. Available from: https://cdn.penguin.co.uk/dam-assets/books/9780241258767/9780241258767-sample.pdf
13. Udod O, Dramaretska S. [Dynamics of some indicators of the provision of dental aid to the population of donetsk region in the pre-war years]. Stomatological Bulletin. 2023;123(2):170-4. Ukrainian. doi: https://doi.org/10.35220/2078-8916-2023-48-2.30
14. Luo H, Wu B, Wu Y, Moss ME. Dental caries and preventive dental visits among children in the U.S.: the impact of race/ethnicity and immigration. AJPM Focus. 2024;3(4):100230. doi: https://doi.org/10.1016/j.focus.2024.100230
15. Toh JR, Wooi N, Tan SN, Wong K, Lopez-Sil­va C, Zafar S. Association between lack of dental service utilisation and caregiver-reported caries in Australian Indigenous children: a national survey. J Paediatr Child Health. 2022;58(12):2218-24. doi: https://doi.org/10.1111/jpc.16192
16. Artemchuk L, Lytvynova L, Donik О, Orly­chen­ko K. [Provision of dental care to the population of ukraine: 15-year dynamics and current problems]. Ukrainian Dental Almanakh. 2025;(1):78-4. Ukrainian. doi: https://doi.org/10.31718/2409-0255.1.2025.13
17. Vandenplas Y, de Halleux V, Arciszewska M, Lach P, Pokhylko V, Klymenko V, et al. On Behalf of the voyage study group. A partly fermented infant formula with postbiotics including 3'-GL, specific oligosac­charides, 2'-FL, and milk fat supports adequate growth, is safe and well-tolerated in healthy term infants: a double-blind, randomised, controlled, multi-country tria Nutrients. 2020;12(11):3560. doi: https://doi.org/10.3390/nu12113560
18. Kaskova LF, Yanko NV, Sadovski MO, Pavlen­kova OS, Vashchenko IY, Novikova SC, et al. Assessment of attitudes and practices regarding oral healthcare among the parents during the war. JIDMR. 2024;1(17):203-8. Available from: https://repository.pdmu.edu.ua/server/api/core/bitstreams/56df650f-bd1c-416e-a8e1-e22f024bae8d/content

Look through:

Kaskova L.F. Poltava State Medical University, Poltava, Ukraine
https://orcid.org/0000-0003-0855-2865

Yanko N.V. Poltava State Medical University, Poltava, Ukraine
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0002-3752-4110

Tovma V.V. Community Establishment "Pediatric city clinical hospital of Poltava council", Pediatric policlinic dental department, Poltava, Ukraine, e-mail: mdksp@ukr.net
https://orcid.org/0009-0001-2797-2497

Vashchenko I.Yu. Poltava State Medical University, Poltava, Ukraine
https://orcid.org/0000-0002-5025-8005

Andriyanova O.Yu. Poltava State Medical University, Poltava, Ukraine
https://orcid.org/0000-0002-8332-7417

Novikova S.Ch. Poltava State Medical University, Poltava, Ukraine
https://orcid.org/0000-0002-7131-4512

Khmil O.V. Poltava State Medical University, Poltava, Ukraine
https://orcid.org/0000-0001-5390-9099

Kaskova L.F., Yanko N.V., Tovma V.V., Vashchenko I.Yu., Andriyanova O.Yu., Novikova S.Ch., Khmil O.V. Analysis of the provision of dental care to children in a state-owned medical institution in wartime conditions. Medicni perspektivi. 2025;30(3):252-259.
doi: https://doi.org/10.26641/2307-0404.2025.3.340814

Сlinical case of funicular myelosis in combination with a concomitant genetic predisposition to folate cycle disorder

The coronavirus pan­demic 2019 (COVID-19) has completed numerous global spreading waves. Several models categorized as compart­mental, growth, and distributional have been derived and are intended to determine the spread dynamics of the pandemic and behavioral patterns. However, it seems that a more generalized theoretical approach to this phenomenon can be derived via distributional models, especially the Gaussian distribution. For this reason, we aim to approach the problem as a stochastic phenomenon, considering that the spread and the related outcomes of the epidemic occur randomly and exhibit stochastic behavior. In this way, we can predict the course of the pandemic by detecting the spreading wave patterns using stochastic instruments and methods. The purpose of our study is to present a phenomenological model that helps us understand the general outbreak behaviors that determine the characteristic parameters of the pandemic and behavioral patterns in spreading waves. To achieve the goal, we have developed a theoretical approach that obtains a stochastic differential equation or a master equation called the Fokker-Planck equation by starting with a stochastic difference equation or a random walk model. Thus, as a solution to this master equation, we get a time-dependent Gaussian distribution with a shifted center, which is a good instrument to determine the characteristic spreading parameters of COVID-19 and the general behavior patterns for all pandemic diseases. The model uncovers thoughts on preventative mechanisms and sheds light on most criticisms about the importance of individual isolation, recovery treatments, remedies, and vaccine development.

Key words: biased Gaussian distribution, COVID-19 model, Markovian process, pandemic spreading model, stochastic model

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama.2020;323(13):1239-42. doi: https://doi.org/10.1001/jama.2020.2648
2. Prem K, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. The lancet public health. 2020;5(5):e261-e270. doi: https://doi.org/10.1016/S2468-2667(20)30073-6
3. Benitez D, et al. A phenomenological epidemic model based on the spatio-temporal evolution of a Gaus­sian probability density function. Mathematics. 2020;8(11):2000. doi: https://doi.org/10.3390/math8112000
4. Fan Y, Qiu D. On the evolution of COVID-19 virus based on the prediction model of deep learning and emotion analysis. [Internet]. Eng Lett. 2024 [cited 2024 Mar 16];32(2):412-28. Available from: https://www.engineeringletters.com/issues_v32/issue_2/EL_32_2_20.pdf
5. Derouich M, Boutayeb A. A SIAR model of COVID-19 with control. [Internet]. Eng Lett. 2022 [ci­ted 2024 Mar 16];30(1):98-107. Available from: https://www.engineeringletters.com/issues_v30/issue_1/EL_30_1_12.pdf
6. Kim A. Aaedm: Theoretical dynamic epidemic diffusion model and covid-19 Korea pandemic cases. medRxiv. 2020;2020(03):17.20037838. doi: https://doi.org/10.1101/2020.03.17.20037838
7. Wu K, et al. Generalized logistic growth modeling of the COVID-19 outbreak: comparing the dynamics in the 29 provinces in China and in the rest of the world. Non­linear 2020;101(3):1561-81. doi: https://doi.org/10.1007/s11071-020-05862-6
8. Bertozzi AL, et al. The challenges of modeling and forecasting the spread of COVID-19. PNAS. 2020;117(29):16732-8. doi: doi.org/10.1073/pnas.2006520117
9. Vasconcelos GL, et al. Modelling fatality curves of COVID-19 and the effectiveness of intervention strategies. Peer J. 2020;8:e9421. doi: https://doi.org/10.7717/peerj.9421
10. Tiwari V, Deyal N, Bisht NS. Mathematical mo­deling based study and prediction of COVID-19 epidemic dissemination under the impact of lockdown in India. Front Phys. 2020;8:586899. doi: https://doi.org/10.3389/fphy.2020.586899
11. Goto T, Nakai T. Steady distribution of cells in a one-dimensional biased random walk model of bacterial chemotaxis. J Biomech Sci Eng. 2016;11(2):15-00587. doi: https://doi.org/10.1299/jbse.15-00587
12. Painter KJ, Hillen T. From random walks to fully anisotropic diffusion models for cell and animal move­ment. In: Stolarska M, Tarfulea N, eds. Cell Movement. Modeling and Simulation in Science, Engineering and Technology. Birkhäuser, Cham; 2018. р. 103-41. doi: https://doi.org/10.1007/978-3-319-96842-1_5
13. Bressloff PC, Maclaurin JN. Stochastic hybrid syste­ms in cellular neuroscience. J Math Neurosci. 2018;8(1):12. doi: https://doi.org/10.1186/s13408-018-0067-7
14. Kim SJ, et al. Random walk with chaotically driven bias. Sci Rep. 2016;6(1):38634. doi: https://doi.org/10.1038/srep38634
15. Wang K, Crow ML. Fokker-Planck equation ap­plication to analysis of a simplified wind turbine model. In: 2012 North American Power Symposium (NAPS). IEEE; p. 1-5. doi: https://doi.org/10.1109/NAPS.2012.6336340
16. Kim M, Paini D, Jurdak R. Modeling stochastic processes in disease spread across a heterogeneous social system. PNAS. 2019;116(2):401-6. doi: https://doi.org/10.1073/pnas.1801429116
17. Ming RX, et al. Stochastic modelling of infec­tious diseases for heterogeneous populations. Infect Dis 2016;5:1-11. doi: https://doi.org/10.1186/s40249-016-0199-5
18. Denisov SI, Horsthemke W, Hänggi P. Genera­li­zed Fokker-Planck equation: Derivation and exact solutions. EPJ B. 2009;68:567-75. doi: https://doi.org/10.1140/epjb/e2009-00126-3

Look through:

Saglam Ugur Istanbul University, Faculty of Science, Department of Physics, Vezneciler, Istanbul, Turkey
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
https://orcid.org/0000-0001-5359-1447

Saglam Ugur. COVID-19 Pandemic: a novel theoretical approach to epidemics. Medicni perspektivi. 2025;30(3):260-267.
doi: https://doi.org/10.26641/2307-0404.2025.3.340816

Orthodontic and orthopedic rehabilitation of adult patients with congenital cleft lip and palate (clinical case)